   
   
 
CLINICAL STUDY PROTOCOL  
 
 
 
 
CONFIDENTIALITY STATEMENT 
The information in this document contains trade secrets and commercial information that are privileged or 
confidential and may not be disclosed unless such disclosure is required by [CONTACT_784]. In 
any event, persons to whom the information is disclosed must be informed that the information is privileged 
or confidential and may not be further disclosed without written authorization of Sponsor’s name. 
 
 
This study will be conduc ted in compliance with this protocol, 
the ICH Note for Guidance on Good Clinic al Practice (CMPM/ICH/135/95) 
and with the applic able regulatory requir ement(s)Phase 1b clinical study to investigate the safety and immunogenicity of 
the Bris10 (A/Brisbane/10/2007) M2SR and  
Sing2016 (A/Singapore/INFIMH -16-0019/2016)  
M2SR H3N2 monovalent influenza vaccines  
Products  Bris10  M2SR Vaccine  and 
 Sing2016 M2SR Vaccine  
Prot ocol Numbe r FLUGEN -H3N2 -V003 
 
IND N umber 016968  
 
Clinical Phase 1b 
 
Clinical Indication Not applicable (Healthy Volunteers)  
 
Initial Protocol Version 1.0, 30-Apr-[ADDRESS_958836] -2019  
Amendment 5 Version 6.0, 26-September -2019  
Amendment 6 Version 7.0, 28-October -2019  
Amendment 7 Version 8.0, 18 -May-2020  
 
 
Sponsor  FluGen  Corporation  
Sponsor Representative  Pamuk Bilsel  
Phone  [PHONE_14716]  
 Fax [PHONE_14717]  

FluGen, Inc.  CLINICAL STUDY PROTOCOL – FLUGEN -H3N2 -V003  
 18MAY2020 (v8.0)  
CONFIDENTIAL 2  
 
 SIGNATURES  
 
 
Signature [CONTACT_705662], Inc. Representative 
 
 
 
Study T itle: Phase 1b clinical study to investigate the safety and immunogenicity of the 
Bris10 (A/Brisbane/10/2007) M2SR and Sing2016 (A/Singapore/INFIMH -16-
0019/2016) M2SR H3N2 monovalent influenza vaccines  
Protocol Date: 30APR2019  
 
 
Name:   [CONTACT_705663], PhD  
Affiliation:   FluGen, Inc.  
Address:   [ADDRESS_958837], Madison, WI [LOCATION_003] [ZIP_CODE]  
 
 
This Clinical Study Protocol has been reviewed and approved by [CONTACT_705567]. 
 
 
 
 
Signature: 
[CONTACT_1782]: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FluGen, Inc.  CLINICAL STUDY PROTOCOL – FLUGEN -H3N2 -V003  
 18MAY2020 (v8.0)  
CONFIDENTIAL 3  
 
  
 
 
 
Signature [CONTACT_705662] , Inc.  Statistician 
 
 
 
Study T itle: Phase 1b clinical study to investigate the safety and immunogenicity of the 
Bris10 (A/Brisbane/10/2007) M2SR and Sing2016 (A/Singapore/INFIMH -16-
0019/2016) M2SR H3N2 monovalent influenza vaccines  
Protocol Date: 30APR2019  
 
 
Name:   [CONTACT_705664]:   North Rim Consulting  
Address:   [ADDRESS_958838], Longmont, Colorado [LOCATION_003]  [ZIP_CODE]  
 
 
 
This Clinical Study Protocol has been reviewed and approved by [CONTACT_705568], using technical terminolo gy as 
appropriate. 
 
 
 
 
Signature: 
 
[CONTACT_1782]: 
 
 
FluGen, Inc.   CLINICAL STUDY PROTOCOL - FLUGEN -H3N2 -V003   18May 2020 (v8.0) 
CONFIDENTIAL    4  
 
 
PROTOCOL HISTORY  
 
 
  
 
 
FluGen, Inc.  – FLUGEN -H3N2 -V003 
 
Document Issue Date Amendment Type Comments 
Initial Clinical Study Protocol 30APR2019  Not applicable  
Protocol V2.[ADDRESS_958839] udy is funded by [CONTACT_393795]  
2. New exclusion: Active military personnel not allowed to participate in the 
study  
3. Subject s are not allowed to use a  Legally Authorized Representative  
4. ICF must be administered individually to each subject and in a private 
setting  
5. Clarified duties and responsibilities of Medical Monitor  
6. Minor corrections and clarifications including word modification and 
administrative changes  
 Protocol V3.[ADDRESS_958840]’s 
microneutralization titer to Sing2016  
3. Clarified inclu sion and exclusion criteria  
4. Added a ± [ADDRESS_958841] modification and 
administrative changes  
  
FluGen, Inc.   CLINICAL STUDY PROTOCOL - FLUGEN -H3N2 -V003   18May 2020 (v8.0) 
CONFIDENTIAL    [ADDRESS_958842] a 
nasal  swab  if needed for lab confirmation of influenza infection.  
Protocol V8.0  18May2020  Non-substantial amendment  1. Section 9.8 was revised in protocol v4.0 08AUG2019 but the original 
language was inadvertently re -instated in v5.0 21AUG2019 and remained in 
later versions. The language from section 9.8 of protocol v4.0 is the intended 
language.  
2. Section [IP_ADDRESS], exclusio ns [ADDRESS_958843] modifications.  
 
 
  
CONFIDENTIAL 6 FluGen, Inc.  CLINICAL STUDY PROTOCOL - FLUGEN -H3N2 -V003  18May 2020 (v8.0)  
 
 
 
  
 
TABLE OF CONTENTS  
SIGNATURES  ................................ ................................ ................................ .........  [ADDRESS_958844] OF ABBREVIATIONS AND DEFINITIONS OF TERMS  ....................  26 
STUDY ADMINISTRATIVE STRUCTURE AND INVESTIGATORS  .........  29 
1. INTRODUCTION  ................................ ................................ .......................  31 
1.1. Overview  ................................ ................................ ................................ ... 31 
1.2. Background Info rmation  ................................ ................................ ...........  31 
1.2.1.  Influenza  ................................ ................................ ........................  31 
1.2.2.  Current Influenza Vaccines  ................................ ...........................  32 
1.2.3.  Live attenuated vaccines  ................................ ...............................  32 
1.2.4.  FluGen’s H3N2 (A/Brisbane/10/2007) M2SR vaccine  ................  33 
1.2.5.  FluGen’s H3N2 (A/Singapore/INFIMH -16-0019/2016) M2SR 
vaccine  ................................ ................................ .................  33 
1.3. Non-Clinical Studies of M2SR  ................................ ................................ . 34 
1.3.1.  Non-Clinical Safety  ................................ ................................ ....... 34 
1.3.2.  Non-Clinical Efficacy  ................................ ................................ ... 34 
1.4. Clinical Studies  ................................ ................................ .........................  35 
1.4.1.  Phase  1 Dose Escalation Study  ................................ .....................  35 
1.4.2.  Phase 1 Study in Adolescents  ................................ .......................  36 
1.4.3.  Phase 2a Challenge Study  ................................ .............................  36 
1.5. Overall Rationale for the Study  ................................ ................................ . 37 
1.6. Risk/Benefit Analysis  ................................ ................................ ................  [ADDRESS_958845] and Safety Reviews  ................................ ..........................  43 
CONFIDENTIAL 7 FluGen, Inc.  CLINICAL STUDY PROTOCOL - FLUGEN -H3N2 -V003  18May 2020 (v8.0)  
 
 
 
 3.3. Expected Duration of a Subject’s Participation in the Entire Study  .........  44 
3.4. Total Study Duration  ................................ ................................ .................  45 
3.5. Discussion of Study Design  ................................ ................................ ...... 45 
3.5.1.  Rationale for Use of Bris10 M2SR (H3N2) Vaccine and Route of 
Administration  ................................ ................................ ..... 45 
3.5.2.  Rationale for Dose Selection  ................................ .........................  45 
3.5.3.  Rationale for Placebo Control  ................................ .......................  45 
3.5.4.  Rationale for Randomization and Blinding  ................................ ... 45 
4. SELECTION OF STUDY POPULATION  ................................ ...............  46 
4.1. Inclusion Criteria  ................................ ................................ ......................  46 
4.2. Exclu sion Criteria  ................................ ................................ .....................  47 
4.3. Lifestyle Guidelines  ................................ ................................ ..................  49 
4.3.1.  Contraception  ................................ ................................ ................  50 
5. TREATMENTS  ................................ ................................ ............................  51 
5.1. Study Vaccines  ................................ ................................ ..........................  51 
5.2. Placebo Administered in the Study  ................................ ...........................  51 
5.3. Packaging and Labeling  ................................ ................................ ............  52 
5.3.1.  Vaccines  ................................ ................................ ........................  52 
5.3.2.  Placebo  ................................ ................................ ..........................  53 
5.4. Storage and Drug Accountability  ................................ ..............................  53 
5.4.1.  Vaccines  ................................ ................................ ........................  53 
5.4.2.  Placebo  ................................ ................................ ..........................  55 
5.5. Randomization  ................................ ................................ ..........................  55 
5.6. Blinding  ................................ ................................ ................................ ..... 55 
5.7. Dose and Administration  ................................ ................................ ...........  56 
5.7.1.  Vaccine  ................................ ................................ ..........................  56 
5.8. Treatment Com pliance  ................................ ................................ ..............  57 
5.9. PRIOR AND CONCOMITANT THERAPY ................................ ............  57 
5.9.1.  Permitted Concomitant Therapi[INVESTIGATOR_014]  ................................ .................  57 
5.9.2.  Prohibited Concomitant Therapi[INVESTIGATOR_014]  ................................ ................  58 
6. ASSESSMENTS ................................ ................................ ...........................  59 
6.1. Timi ng of Assessments ................................ ................................ .............  59 
6.1.1.  Screening Period 1 (Days -30 to Dosing)  ................................ ...... 62 
6.1.2.  Treatment P eriod (Day 1 to Day 57)  ................................ .............  63 
[IP_ADDRESS].  Day 1  63 
[IP_ADDRESS].  Day 4 ± 1  day ................................ ................................ ....... 63 
[IP_ADDRESS].  Day 8 ± 1 day  ................................ ................................ ....... 64 
[IP_ADDRESS].  Day 29 ± 7 days  ................................ ................................ ... 64 
[IP_ADDRESS].  Day 32 (3 days ± 1 day after second dose)  ..........................  65 
[IP_ADDRESS].  Day 36 (7 days -1/+7 day after second dose)  ......................  65 
[IP_ADDRESS].  Day 57 (28 days ± 7 days after second dose)  ......................  65 
[IP_ADDRESS].  Day 209 (180 days ± 14 days after sec ond dose) - on-site visit
 ................................ ................................ ...............  65 
6.1.3.  Testing for Influenza  ................................ ................................ ..... 66 
6.1.4.  Early Termination Visit  ................................ ................................ . 66 
6.1.5.  Unscheduled Visits ................................ ................................ ........  67 
6.2. Study Assessments  ................................ ................................ ....................  67 
CONFIDENTIAL 8 FluGen, Inc.  CLINICAL STUDY PROTOCOL - FLUGEN -H3N2 -V003  18May 2020 (v8.0)  
 
 
 
 6.2.1.  Clinical Evaluations  ................................ ................................ ...... 67 
[IP_ADDRESS].  Medical History  ................................ ................................ ... 67 
[IP_ADDRESS].  Concomitant Medications  ................................ ....................  67 
[IP_ADDRESS].  Demographics  ................................ ................................ ...... 67 
[IP_ADDRESS].  Physical Examination  ................................ ..........................  67 
[IP_ADDRESS]. Vital Signs  ................................ ................................ ...........  68 
[IP_ADDRESS].  Symptom Memory Aids  ................................ ......................  68 
[IP_ADDRESS].  Urine Samples ................................ ................................ ...... 69 
6.2.2.  Bioanalysis ................................ ................................ ....................  69 
6.2.3.  Adverse Eve nts ................................ ................................ ..............  70 
6.2.4.  Efficacy Evaluations  ................................ ................................ ..... 70 
[IP_ADDRESS].  Nasal Swabs  ................................ ................................ .........  70 
[IP_ADDRESS].  Delivery Device Weights  ................................ .....................  71 
[IP_ADDRESS].  Blood Collection for Influenza Antibody Testing  ...............  71 
[IP_ADDRESS].  PBMCs for Cell -mediated Immunity Testing  .....................  71 
[IP_ADDRESS].  Plasma for Gene Expression and Cytokine Testing  ............  71 
7. STUDY  TERM INATI ON/COMPLETI ON ................................ ...............  [ADDRESS_958846] Characteristics Data Set  ................................ ...................  76 
8.3.3.  Safety Analyses  ................................ ................................ .............  76 
8.3.4.  Additional Analyses  ................................ ................................ ...... 77 
8.4. Appropriateness of  Measurements  ................................ ............................  77 
9. ADV ERSE  EVENT REPORTING ................................ .............................  78 
9.1. Definitions  ................................ ................................ ................................ . 78 
9.2. Intens ity of Adverse Events  ................................ ................................ ...... 79 
9.3. Causal ity Assessment  ................................ ................................ ................  79 
9.4. Reactogenicity  ................................ ................................ ...........................  80 
9.5. Outcome ................................ ................................ ................................ .... 80 
9.6. Recording of Adverse Events  ................................ ................................ .... 81 
9.7. Reporting of Serious Adverse Even ts to the Sponsor for 
Pharmacovigilance  ................................ ................................ .............  81 
9.8. Pregn ancy ................................ ................................ ................................ .. 82 
9.9. Reporting of Serious Adverse Events to Competent Authorities/Ethics 
Committees  ................................ ................................ ........................  82 
9.10.  Medical Monitor  ................................ ................................ ...................  82 
9.11.  Safety Review Committee  ................................ ................................ .... 83 
10. ETHICAL  ASPECTS ................................ ................................ ..................  84 
10.1.  Study-Specific Des ign C onsiderat ions ................................ .................  84 
CONFIDENTIAL 9 FluGen, Inc.  CLINICAL STUDY PROTOCOL - FLUGEN -H3N2 -V003  18May 2020 (v8.0)  
 
 
 
 10.2.  Regulat ory Ethics Compliance ................................ .............................  [ADDRESS_958847] 
(IEC/IRB)  ................................ ................................ ............  [ADDRESS_958848] igator Indemn ity ................................ ................................ ....... 92 
11.14.  Confidentiality ................................ ................................ ...................  92 
12. REFERENCES  ................................ ................................ .............................  93 
APPENDICES  ................................ ................................ ................................ ........  95 
APPENDIX 1: VITAL SIGN AND SYSTEMIC TOXICITY ASSESSMENTS
 ................................ ................................ ................................ ..............  96 
APPENDIX 2: LABORATORY ASSESSMENTS  ................................ .............  99 
APPENDIX 3: REACTOGENICITY ASSESSMENTS  ................................ .. 104 
APPENDIX 4: INVESTIGATOR SIGNATURE [CONTACT_1783]  ................................ . 106 
APPENDIX 5: SYMPTOM MEMORY AID FOR VACCINATION PERIOD
 ................................ ................................ ................................ ............  107 
CONFIDENTIAL 10 FluGen, Inc.  CLINICAL STUDY PROTOCOL - FLUGEN -H3N2 -V003  18May 2020 (v8.0)  
 
 
 
  
LIST OF TABLES  
Table  1: Dose Cohorts  ................................ ................................ ........................  41 
Table  2: Dosing and Safety Reviews  ................................ ................................ .. 42 
Table  3: Schedule of Events  ................................ ................................ ...............  [ADDRESS_958849] OF FIGURES  
 
Figure  1: Sample labels for drug product and SPG -NaCl buffer.  ........................  53 
Figure  2: Image of the MAD301 Sprayer Device Fitted to a Syringe  .................  56 
 
 
CONFIDENTIAL 11 FluGen, Inc.  CLINICAL STUDY PROTOCOL - FLUGEN -H3N2 -V003  18May 2020 (v8.0)  
 
 
 
 PROTOCOL SYNOPSIS  
Study Title  Phase 1b clinical  study to investigate the safety and immunogenici ty of 
the Bris10 (A/Brisbane/10/2007) M2SR and Sing2016 
(A/Singapore/INFIMH -16-0019/2016) M2SR H3N2 monovalent 
influenza vaccines  
Product  Bris10 M2SR Vaccine 
(Lot#[ZIP_CODE])  
Sing2016 M2SR 
Vaccine  
(Lot# [ZIP_CODE] ) Clinical 
Phase  1b 
Protocol 
Number  FLUGEN-H3N2 -V003  Indication  Prophylactic  H3N2 mono valent 
influenza vaccines, Bris10 
(A/Brisbane10/2007) M2SR and 
Sing2016 ( A/Singapore/INFIMH -
16-0019/2016) M2SR,  for 
protection against influenza 
disease caused by [CONTACT_705569] A viruses. 
IND 
Number  IND# [ADDRESS_958850] 
Madison, WI [LOCATION_003] [ZIP_CODE] 
 
Funded by: U nited States Department of Defense (DoD)  
Sponsor Representative  Pamuk Bilsel , PhD  
Principal 
Investigator (s) 
(*Lead PI)  1. Carlos  Fierro, MD * 
2. Howard Sc hwartz, MD  
3. Mark Adams, MD  
4. Kimberly J.  Ellis, DO 
Clinical Center (s) 1. Johnson County Clin -Trials  
2. Research Centers of America  
3. Alliance for M ultispecialty  Research , Lexington  
4. Alliance for Multispecialty Research, Norfolk  
Study Period  Initiation:     August 2019   
Completion: April 2020  
Number of Subjects  Approximately 250 evaluable subjects  
CONFIDENTIAL 12 FluGen, Inc.  CLINICAL STUDY PROTOCOL - FLUGEN -H3N2 -V003  18May 2020 (v8.0)  
 
 
 
 Introduction:  
FluGen, Inc., a biotech company based in Madison WI, [LOCATION_003], is developi[INVESTIGATOR_007] a novel 
M2-deficient single replication live influenza vaccine platform M2SR to provide safe, 
effective protection against seasonal influenza strains. The vaccine virus does not express 
an essential viral protein (influenza M2), restricting it to a single replication  cycle in the 
host. The initial (prototypi[INVESTIGATOR_2855]) product, designated as Bris10 M2SR vaccine, was intended 
to elicit an immune response to the vaccine virus, A/Brisbane/10/2007 (H3N2). Available 
data from Phase [ADDRESS_958851] a highly drifted H3N2 
influenza challenge agent among adult subjects who demonstrated a serum immune 
response following vaccination. Ultimately the vaccine development p rogram aims to 
evaluate a quadrivalent M2SR vaccine containing two influenza A subtypes (H1N1 -like 
and H3N2 -like viruses) and two influenza B types.  
Previous clinical experience with the M2SR vaccine platform includes a First Time in 
Human (FTIH) Phase [ADDRESS_958852] dose of Bris10 M2SR tested (108 TCID 50) with no SAEs 
or AEs of clinical significance or observations that would halt these studies. In addition, 
in the challenge study, 48 subjects who received t he live, single -replication M2SR virus 
were subsequently challenged with a live, replicating influenza virus. A portion of those 
individuals experienced infection and symptoms consistent with influenza (e. g., nasal 
congestion, runny nose, sore throat, coug h, tiredness, headache ), but at frequency less 
than observed among individuals in the same study who did not receive vaccine prior to 
challenge. Of the 19 adolescents enrolled in the ongoing second Phase 1 study, while the 
randomization was set at 1:1 acti ve to placebo, it is not known exactly how many received 
active investigational vaccine (M2SR) , but in blinded review  no safety concerns related 
to the M2SR vaccine have been reported. Combined, these findings indicate that the 
vaccine is safe and generall y well  tolerated as a single 108 TCID 50 dose.  
The purpose of this Phase 1b dose escalation clinical study is to assess the safety, 
tolerability/reactogenicity, and immunogenicity of M2SR vaccines when delivered at 
higher dosages or in two doses to increas e the proportion of subjects responding 
serologically to the vaccine. For this study, an updated vaccine, Sing2016 M2SR, has 
been prepared that will provide the HA and NA components from A/Singapore/INFIMH -
16-0019/2016, the H3N2 strain recommended for the 2018 -2019 influenza season.  
Due to the COVID -19 pandemic , local governments may issue stay -at-home orders which 
prevent centers from conducting on -site Day 209 visits. This protocol allows for Day 209 
visit to be a safety follow -up phone c all.  
Objectives:  
Primary Objectives:  
The primary objectives are : 
1. To assess the safety and tolerability of one and two administrations of the Bris10 
M2SR influenza vaccine each at 108 TCID 50 delivered intranasally to healthy adult 
subjects.  
CONFIDENTIAL 13 FluGen, Inc.  CLINICAL STUDY PROTOCOL - FLUGEN -H3N2 -V003  18May 2020 (v8.0)  
 
 
 
 2. To assess the safety and tolerability of one and two administrations of the 
Sing2016 M2SR influenza vaccine each at 108, 108.5 and 109 TCID 50 delivered 
intranasally to healthy adult subjects  
Secondary Obje ctives:  
The secondary objectives are : 
1. To assess the immunogenicity (serum antibody, mucosal antibody and cellular 
immune responses) of one and two administrations of Bris10 M2SR vaccine at 
108 TCID 50. 
2. To assess the immunogenicity (serum antibody, mucosal a ntibody and cellular 
immune responses) of one and two administrations of Sing2016 M2SR vaccine at 
108, 108.5 and 109 TCID 50. 
3. To evaluate vaccine virus shedding after intranasal delivery.  
Exploratory Objectives:  
The exploratory objectives are : 
1. To evaluate cell mediated immunity for up to [ADDRESS_958853] vaccination.  
2. To evaluate additional vaccine -related immune responses during the period of 
study participation . 
 
Criteria for Evaluation:  
Primary endpoints:  
The primary endpoints are:  
1. The number and percentage of study participants who experience any vaccine -
associated adverse events (AEs) or serious adverse events (SAEs) after Bris10 
M2SR or placebo administration.  
2. The number and percentage of study participants who experience any vaccine -
associated AEs or SAEs after Sing2016 M2SR or placebo administration.  
Secondary endpoints:  
The secondary endpoints are:  
1. The number and percentage of study participants who after one or two doses of 
Bris10 M2SR or placebo demonstrate:  
i. Influenza -specific se rum antibody responses measured at specified time 
points;  
ii. Influenza -specific mucosal IgA antibody responses measured  at specified 
time points;  
iii. Influenza -specific cellular immune responses measured by [CONTACT_705570] -linked immunospot (ELISPOT) at specifie d time points.  
2. The number and percentage of study participants who after one or two doses of 
Sing2016 M2SR or placebo demonstrate:  
▪ Influenza -specific serum antibody responses measured at specified time 
points;  
▪ Influenza -specific mucosal IgA antibody responses measured at specified 
time points;  
▪ Influenza -specific cellular immune responses measured by [CONTACT_705571] e points.  
CONFIDENTIAL 14 FluGen, Inc.  CLINICAL STUDY PROTOCOL - FLUGEN -H3N2 -V003  18May 2020 (v8.0)  
 
 
 
 3. Vaccine virus shedding evaluated by [CONTACT_14302] A -specific qPCR on day [ADDRESS_958854] IP 
administration.  
 
 
Exploratory endpoints:  
The exploratory endpoints are:  
1. Cell-mediated immunity (CMI) assessed by [CONTACT_705572] -specific T -lymphocytes.  
2. Additional influenza -specific  immun ological  assay s may be performed.  
 
Overview of Study Design:  
This is a randomized, double -blind, placebo -controlled Phase 1 study evaluating the 
safety and immunogenicity of the Bris10 M2SR and Sing2016 M2SR H3N2 influenza 
vaccines delivered intranasally to healthy adults.  
Eligible subjects will be screened  and ran domized to receive two administrations 28 days 
apart of Sing2016 at three dose levels, Bris10 at one dose level, or placebo in a 1:1:1:1:1 
ratio. An overview of the planned dose cohorts is presented in (Table 1).  
Table 1: Dose Cohorts  
Dose Cohort  Number of 
Subjects  Number in 
Sentinel Group  Number in 
Expansion Group  
1. [ADDRESS_958855], each containing 
15 subjects (9 subjects receiving escalating doses of Sing2016 M2SR, 3 subjects 
receiving Bris10 M2SR, and 3 subjects receiving placebo), followed by [CONTACT_705573]. Cohorts are split into multiple groups to alleviate 
PBMC  processing issues of large numbers of samples. Dosing will be staggered to allow 
for review of AEs through Day [ADDRESS_958856] -administration for each sentinel group prior to 
dose escalation. A Safety Review  Committee ( SRC) will review available safety data 
from a ll sentinel subjects after subjects have completed [ADDRESS_958857] of safety parameters collected 
during the study are described  in Table  3.  
CONFIDENTIAL 15 FluGen, Inc.  CLINICAL STUDY PROTOCOL - FLUGEN -H3N2 -V003  18May 2020 (v8.0)  
 
 
 
 Table 2: Dosing  and Safety Reviews  
 
*Dose Cohort 1 = Sing2016 M2SR 108, Dose Cohort 2 = Sing2016 M2SR 108.5, Dose Cohort 3 = 
Sing2016 M2SR 109, Dose Cohort 4 = Bris10 M2SR108, Dose Cohort 5 = saline placebo  
Note s: Safety indicates a review by [CONTACT_705574] [INVESTIGATOR_1238]/or Medical Monitor as detailed below in Study 
Conduct. SRC indicates a review by [CONTACT_705575].  The Expansion Group 
schedule may be extended  based on speed of enrollment.  
 
Using one nasal sprayer per nare, up to 0.5 mL of the Sing2016 M2SR vaccine or placebo 
(a total of up to 1.0 mL) and up to 0.2 mL of the Bris10 M2SR vaccine (a total of up to 
0.4 mL), will be delivered per subject per administration. The study will administer 
escalating doses of Sing2016 M2SR vaccine, with a starting dose of 108 TCID 50 
increasing in half log (3 -fold) increments to a maximum dose of 109 TCID 50. Controls 
will be sal ine placebo and a 108 TCID 50 dosage of Bris10 M2SR.  
Five (5) dose cohorts of 50 subjects each will be enrolled, for a total of approximately 250 
subjects randomized 1:1:1:1:1 to receive either Sing2016 M2SR 108, Sing2016 M2SR 
108.5, Sing2016 M2SR 109, Bris10 M2SR or saline placebo. A sentinel group of 9 subjects 
(~18% of each escalating dose cohort) will be vaccinated first, followed by [CONTACT_705576]. Subjects in each sentinel group will be actively 
followed for 3 d ays and if the Medical Monitor and /or Lead PI [INVESTIGATOR_705524], the next sentinel  group  will be enrolled. After all sentinel subjects 
have completed 7 days following vaccination, a Safety Review  Committee ( SRC) will 
review available safety data prior to enrollment and vaccination of the expansion groups. 
All dosed subjects will receive a second dose of the assigned investigational product (IP) 
approximately [ADDRESS_958858] dose. The SRC review  of sentinel  data prior 
to enrollment of expansion subjects may occur concurrently with or following the 
administration of second doses of vaccine to sentinel subjects.  
SAEs occurring at any time during the study will be recorded. Administration site and 
solicited AEs will be recorded through 7 days after each vaccination (Days 8 and 29) and 
unsolicited AEs will be recorded through [ADDRESS_958859] vaccination (Day 57). An 
SRC, comprised at a minimum of two independent physicians experienced in vacci ne 

CONFIDENTIAL 16 FluGen, Inc.  CLINICAL STUDY PROTOCOL - FLUGEN -H3N2 -V003  18May 2020 (v8.0)  
 
 
 
 research and a biostatistician, will be available to review safety data at specified time 
points and as needed.  
Based on the safety reviews, an intermediate or lower dose may be chosen to replace the 
planned dose for a dose cohort. If a lower or interme diate dose is chosen that dose will be 
used for an entire dose cohort. Should dosing be delayed for safety review or enrollment 
issues, subjects may receive their second dose at a time later than defined in the proposed 
dosing window.  
While safety and tole rability are the primary objectives, this clinical study is also designed 
to assess the immune response to one and two doses of each of the investigational vaccines 
at each of the designated dose levels. Immunogenicity will be assessed by [CONTACT_705577] a ntibody responses by [CONTACT_35318] (HAI) and/or 
microneutralization (MN) assay. Additional immune parameters will be assessed 
including mucosal antibody titers and cell -mediated immunity. Subjects will be pre -
screened, under a site-specific Informed Consent Form ( ICF), to avoid enrollment of 
individuals with high MN titers (>  1:20) against the target component 
(A/Singapore/INFIMH -16-0019/2016 [H3N2]).  
Study Conduct  
After subjects have signed an informed consent and have met the inclusion /excl usion 
criteria, healthy adults will receive a single administration of the IP (active M2SR or 
placebo) delivered intranasally as a liquid formulation. The Phase [ADDRESS_958860] demonstrated that a single dose 
of Bris10 M2SR at 108 TCID 50 with and without a subsequent administration of a live, 
replicating influenza virus is generally safe and well  tolerated with no shedding of 
infectious vaccine virus. Hence, the study will be conducted in an outpatient setting and 
with safety reviews as shown in Table 2 and summarized here:  
1. Deliver first dose to sentinel group [ADDRESS_958861] dose (Day 4), confirms that no halting rules have 
been met, and communicates this to the Sponsor.  
2. If no safety concerns in sentinel group 1, deliver first dose to sentinel group 2. 
Lead PI [INVESTIGATOR_705525] [ADDRESS_958862] administration of the second dose (Day 32) are 
conducted in the same manner as outlined above for second doses of sentinel 
groups.  
CONFIDENTIAL 17 FluGen, Inc.  CLINICAL STUDY PROTOCOL - FLUGEN -H3N2 -V003  18May 2020 (v8.0)  
 
 
 
 6. After sentinel subjects have completed [ADDRESS_958863] vaccination (Day 8), 
SRC reviews available safety d ata for sentinel groups [ADDRESS_958864] completed 7 days following second vaccination 
(Day 36), SRC reviews cumulative safety data. If no safety co ncerns are identified, 
deliver second dose to expansion group subjects.    
8. During enrollment of the expansion cohorts, the occurrence of events which could 
prompt a study halt will be reviewed weekly by [CONTACT_1689], until all 
subjects have completed  7 days following second vaccination (Day 36).  
Each subject will undergo the following testing (also depi[INVESTIGATOR_419450]  3): [Note that a 
Pre-screen with blood draw to assess the subject’s microneutralization (MN) titer to 
Sing2016 may be conducted under a site-specific ICF  in the period spanning 90 calendar 
days before enrollment in this study.] Subjects who meet eligibility criteria will be 
enrolled in the proposed Phase 1b study, have a baseline blood draw, be randomized to a 
dose cohort and administered IP of either active M2SR vaccine or placebo on Days 1 
(Visit 01) and 29 (Visit 04). For [ADDRESS_958865] 
symptoms in a Symptom Memory Aid  (Appendix 5 ) and after 3  days (Days 4 and 32) will 
be contact[CONTACT_705578]. 
Subjects will attend the investigational site for follow -up on Days 8, 29, 36, 57 and 209 
(Visits 03, 04, 06, 07  and 08, respectively) for a limited physical exam, safety evaluation, 
nasal swabs and blood draws. Day [ADDRESS_958866] 
in the study. Serum samples for analysis of anti -HA antibody titers for the H3N2 antigen 
in Sing2016 and Bris10 will be collected at baseline and on Days 8, 29, 36, 57 and 209. 
PBMC samples for analysis of ce ll-mediated immunity and/or innate transcriptome gene 
expression will be collected at baseline and on Days 4 (optional) , 8, 29, 32 (optional), [ADDRESS_958867] sites . Nasal swabs will be collected on Days 1, 8, 29, 36, 57 and 209 
for analysis of IgA -specific anti -HA antibody titers. Nasal swabs will be collected at Days 
1, 8, 29, and 36 to evaluate shedding of vaccine virus. A nasal swab collected at Day 1 
may be eval uated for presence of respi[INVESTIGATOR_13531]. Safety clinical laboratory testing 
will be performed at screening, and on Days 1, 8, 29, and 36. During the treatment period 
(Day 1 – Day 57), subjects will be asked to notify the site immediately if symptoms of  
influenza (fever, chills, sore throat, rhinorrhea, cough, muscle/body aches) occur. When 
increased influenza infections are being reported in the geographic region  of the 
investigational site , subjects will additionally be contact[CONTACT_705579] 15 ±2, 21 ±2, 43 ±2, and 
50±[ADDRESS_958868] will be asked to return 
to the site for laboratory confirmation of influenza using nasal swabs.   
Halting Rules  
Vaccination of subjects will be suspended until after review of safety data by [CONTACT_705580]:  
1. One or more subjects experience a Grade 4 AE, vital sign or laboratory AE that 
cannot be clearly attributed to another cause.  
2. Three or more subjects within a single sentinel group or ten or more subjects 
within the expansion group experience the same Grade 3 AE, vital sign or 
laboratory AE that cannot be clearly attributed to another cause.  
3. One or more subjects experiences a SAE assessed as related to IP.  
CONFIDENTIAL 18 FluGen, Inc.  CLINICAL STUDY PROTOCOL - FLUGEN -H3N2 -V003  18May 2020 (v8.0)  
 
 
 
 4. One or more subject s has laryngospasm, bronchospasm, or anaphylaxis associated 
with the study product within [ADDRESS_958869] administration.  
Any AE or SAE that falls into the above criteria for suspending or terminating the study 
(including the occurrence of any Grade 3 AE, vital sign or laboratory AE that cannot be 
clearly attributed to another cause) must be reported by [CONTACT_25741] (within 24 hours).  
In the case of halting rules being met , the SRC will be convened as quickly as possible. 
After review of the safety data the SRC will make a recommendation to the Sponsor 
whether to resume, suspend or terminate the study. The Sponsor will communicate a 
decision to suspend or terminate the study to the Investigators.  
Subsequent review of seriou s, unexpected, and related AEs by [CONTACT_1689], 
SRC, IRB, the Sponsor(s), or the FDA or relevant local regulatory authorities may also 
result in suspension of further trial interventions/administration of study product at a 
site. The FDA and study S ponsor(s) retain the authority to suspend additional 
enrollment and study interventions/administration of study product for the entire study, 
as applicable.  
Safety Parameters  
Visual assessment of the nose on the day of IP administration (pre-dose, [ADDRESS_958870] -dose) and at follow -up assessments along with exam 
of throat and lungs on Patient Days 8, 29, 36, 57 and 209 will be part of a limited 
physical exam. Note: Appropriate medical treatment and supervision must be available 
to manage possible anaphylactic reactions following administration of the vaccine.  
Clinical pathology  will be evaluated at screen, Day [ADDRESS_958871] -dose.  
SAEs from vaccination until Day 209.  
Changes in physical examination, vital signs, laboratory safety tests, lung function and 
pregnancy tests over the course of the study.  
Study Population:  
Healthy male and non -pregnant /lactating  female subjects ages 18 -49 years old.  
The study plans to enroll approximately 250 subjects who will receive two doses of 
experimental Bris10 or Sing2016 M2SR vaccine or placebo (physiological saline) on 
Study Days 1 and 29. Subjects will be randomized 1:1:1:1:1 (Sing2016 M2SR 108, 
Sing2016 M2SR 108.5, Sing2016 M2SR 109, Bris10 M2SR or Saline placebo).  
Inclusion Criteria:   
1. Give written informed consent to participate ; a legally authorized representative 
(LAR) may not be used . 
2. Age 18 – 49 years old, inclusive.  
3. Judged suitable by [CONTACT_978], as determined by [CONTACT_9870], physical examination, 
vital signs, and clinical safety laboratory examinations.  
CONFIDENTIAL 19 FluGen, Inc.  CLINICAL STUDY PROTOCOL - FLUGEN -H3N2 -V003  18May 2020 (v8.0)  
 
 
 
 4. Negative test for pregnancy at screening visit and on Day 1. A positive test on 
Patient Day [ADDRESS_958872] (urine) for drugs of abuse at screening.  Patients who are on stable (6 
months or longer) medications prescribed by [CONTACT_705581] a 
positive screen for that substance  are allowed  at the discretion of the investigator . 
6. Female subjects should fulfill one of the following criteria:  
a. Post-menopaus al status defined as no menses for 12 consecutive months 
without an alternative medical cause.  
b. Surgically sterile.  
c. Willing to use oral, implantable, transdermal or injectable contraceptives, 
or sexual abstinence as outlined in inclusion criteria 7, from sc reening and 
until 28 days after second vaccine dose (Patient Day 57).  
7. Female subjects of childbearing potential must agree to sexual abstinence, use a 
reliable form of contraception approved by [CONTACT_737] (e.g., oral, 
implantable, transdermal, or inj ectable contraception, combined oral, intrauterine 
device [IUD], or a sterile sexual partner) from screening and until 28 days after 
the second vaccine dose (Patient Day 57). Non -surgically sterile male subjects 
who are sexually active with a female partne r(s) of childbearing potential (i.e. 
males who have not been sterilized by [CONTACT_705582] 6 months prior to 
screening) must be willing to use condoms from screening and until 28 days after 
the second vaccine dose (Patient Day 57).  
8. Willing to adher e to the requirements of the study and willing and able to 
communicate with the Investigator and understand the requirements of the study.  
9. Non-smoker (defined as no use of tobacco products and no use of inhaled non -
tobacco products in the past 30 days prior to Study Day 1 ; nicotine patches and 
gum are allowed). Subject must also agree to restrict the use of these products until 
[ADDRESS_958873] vaccine  administration.  
10. H3N2 Sing2016 MN titers ≤1:20 (determin ation  within 90 calendar days of study 
enrollment is acceptable and does not need to be repeated for entry to this study).  
Exclusion Criteria:   
1. Any subject who is a family member of a) study site pers onnel and other personnel 
directly involved in conduct or monitoring of study, or b) the Sponsor.  
2. Any condition that would limit the subject’s ability to complete the study based 
on the opi[INVESTIGATOR_689] (for example, a recent surgical procedure) . 
3. Clinically significant a bnormal screening hematology or chemistry value , as 
assessed by [CONTACT_093].  
4. Pulse rate or blood pressure outside the reference range for this study population 
and considered as clinically significant by [CONTACT_737].  
5. Has an acute or chronic medical condition or history of a medical condition that, 
in the opi[INVESTIGATOR_689], would render the study procedures unsafe or 
would interfere with the evaluation of the responses, including but not limited to, 
respi[INVESTIGATOR_696],  autoimmune, or immune suppression conditions, neuroinflammatory 
conditions, mental illness (including depression), active hematological, renal, 
hepatic, pulmonary, central nervous, neurological, cardiovascular, endocrine 
(including diabetes mellitus) or g astrointestinal disorders.  
CONFIDENTIAL 20 FluGen, Inc.  CLINICAL STUDY PROTOCOL - FLUGEN -H3N2 -V003  18May 2020 (v8.0)  
 
 
 
 6. Has been vaccinated against influenza within the last 6 months or plans to be 
inoculated with an influenza vaccine (other than study vaccine) until one month 
after completion of follow up on Patient Day 20 9. 
7. Had a flu -like illnes s (i.e., fever, chills and myalgia), influenza treatment (i.e., 
commercial drug such as Oseltamivir, etc.), or prophylactic influenza viral drug 
administered in the previous [ADDRESS_958874] or known infection with human immunodeficiency virus 
(HIV), hepatitis B virus ( HBV ) and hepatitis C virus ( HCV ). 
9. History of cancer within 5 years prior to screening (except basal cell carcinoma 
and cervical carcinoma in situ).  
10. Presence or clinical ly significant history of lung disease,  asthma, chronic 
obstructive pulmonary disease  (COPD) , or otherwise poor lung function. 
Childhood asthma that resolved by [CONTACT_654]  [ADDRESS_958875] swabbing by [CONTACT_705583]’s 
discretion.  
12. Any confirmed or suspected immunosuppressive or immunodeficient state 
including: asplenia, recurrent severe infections and chronic (more than 14 days) 
immunosuppressant m edication (such as systemic corticosteroids at a dose of 
≥ 0.5 mg/kg/day for longer than 1 week, or immunosuppressants such as cytotoxic 
drugs) within the last 6 months (topi[INVESTIGATOR_12977]).  Use of 
immunosuppressive medications, such as allergy  shots, immune globulin, 
interferon, or immunomodulators in the past [ADDRESS_958876] 7 days 
before screening.  
13. Significant adulthood history of seasonal hay fev er, a seasonal allergic rhinitis, 
perennial allergic rhinitis, chronic nasal or sinus condition such as sinusitis, at the 
discretion of the investigator.  
14. Received any licensed vaccine within 1 month before screening and during the 
course of the study.  
15. Received or planned administration of another investigational vaccine or drug 
during the period from 90 days prior to Day 1 to one month after completion of 
Day 209  follow up  
16. History of allergy/hypersensitivity to any vaccine component (sucrose, sodium 
chlor ide, phosphate, glutamate), or material in nasal delivery device 
(polycarbonate, polypropylene, synthetic rubber).  
17. Experienced a life -threatening reaction(s) after a previous administration of any 
vaccine or experienced an allergic reaction after a previou s administration of any 
influenza vaccine or component.  
18. A history or prior diagnosis of Guillain -Barré Syndrome.  
19. Living in the same household with any person with a non -functional or suppressed 
immune system , or with a confirmed influenza infection or febrile illness within 
the previous two weeks . 
20. History of drug or alcohol abuse in the 6 months before the study.  
CONFIDENTIAL 21 FluGen, Inc.  CLINICAL STUDY PROTOCOL - FLUGEN -H3N2 -V003  18May 2020 (v8.0)  
 
 
 
 21. Current u se of any new prescription or new over-the-counter (OTC) medications 
starting within [ADDRESS_958877] vaccination.  
24. Females who are pregnant  or lactating (i.e., a nursing mother).  
25. Acute febrile illness within 72 hours prior to vaccination, defined as the presence 
of a moderate or severe illness with or without fever (as determined by [CONTACT_705584]), or presence of a 
fever >38ºC orally. Vaccination (or administration of the second dose of vaccine) 
should be delayed until the subject has recovered. Persons with a minor illness, 
such as diarrhea, or mild upper respi[INVESTIGATOR_705526] -
grade fever, may be enrolled after resolution of the illness.  
26. Any condition, in the opi[INVESTIGATOR_689], (such as subjects who have 
medically high -risk conditions) that might interfere with the primary study 
objectives for safety of th e study subject.  
27. Previous exposure to M2SR investigational vaccine.  
28. Any active military personnel /member . 
 
Exclusions at Day 29:  
Pregnancy, receipt of a prohibited medication, or new prohibited diagnosis , including 
laboratory confirmed influenza  and or tre atment for influenza , or high -risk condition are 
exclusions for second vaccination.  
 
Note: At the discretion of the investigator, subjects may be rescreened; out -of-range 
clinical laboratory tests may be repeated twice, and vital signs may be repeated three 
times. Results of any retest must be available prior to enrollment.  
Test Product, Dose, Mode of Administration:  
Bris10 M2SR Vaccine:  One IP is termed Bris10 M2SR and is a recombinant, 
monovalent influenza A virus that encodes the viral antigens, hemagglutinin (HA) 
and neuraminidase (NA) from Influenza A/Uruguay/716/2007, an 
A/Brisbane/10/[ADDRESS_958878] -time-in-humans (FTIH) study FluGen -H3N2 -V001 under US IND 
016968 (also see ClinicalTrials.gov identifier [STUDY_ID_REMOVED]), in a Phase 1 
adolescent study in the US (BB -IND [ZIP_CODE]) and in a Phase 2a virus challenge study 
in Belgium (EudraCT 2017 -004971 -30). The vaccine (Lot# 15100251) for these three 
studies was manufactured using a master virus stock and working cell bank at 
Meridian Life Sciences (Memphis, Tenness ee, [LOCATION_003]) under current Good 
Manufacturing Practice (cGMP) in a liquid formulation.  
Sing2016 M2SR Vaccine:  The second IP is termed Sing2016 M2SR and is a 
recombinant, monovalent influenza A virus that provides the HA and NA components 
CONFIDENTIAL 22 FluGen, Inc.  CLINICAL STUDY PROTOCOL - FLUGEN -H3N2 -V003  18May 2020 (v8.0)  
 
 
 
 from A/Singapore/INFI MH-16-0019/2016 that were recommended for the 2018 -2019 
influenza season.  
The Bris10 M2SR vaccine (Lot# [ZIP_CODE]) and the Sing2016 M2SR (Lot# [ZIP_CODE] ) for 
this Phase 1b study were manufactured at Ology Bioservices (Alachua, [LOCATION_012], [LOCATION_003]) 
under current Good Manu facturing Practice (cGMP) in a liquid formulation. The 
Bris10 M2SR vaccine and the  Sing2016 M2SR vaccine will be provided frozen and 
in single -use. A pharmacist or designee will thaw the vial contents to room 
temperature just prior to dose administration. The contents will be diluted to the 
target dosing concentration with provided SPG diluent for each subject. The final 
diluted product will be drawn into two 1 mL disposable polypropylene syringes each 
fitted with a mucosal atomization device (MAD301; Telef lex, Salt Lake City, Utah, 
[LOCATION_003]) for intranasal delivery.  
For delivery, on each of Days 1 and 29, subjects will receive a single intranasal dose 
of vaccine (or placebo) via two nasal spray devices. Subjects will be in a semi -
recumbent position and receive approximately two administrations of ~50% volume 
per nasal cavity by [CONTACT_705585] . Devices will be weighed pre - and 
post-dose to allow calculation of dose eliminated from the devices. Subjects will 
remain semi -recumbent and under observation  for thirty (30) minutes and will not be 
allowed to blow their noses, eat or drink during this time.   
Reference Product, Dose, Mode of Administration:  
The reference product (placebo) is a physiological saline suitable for intranasal delivery. 
The placebo will be provided as a liquid and in single -use vials. The placebo will be 
drawn into two 1 mL disposable syringes that are fitted with a Teleflex MAD 301 
sprayer for intranasal delivery. Administration will be as described for the M2SR 
vaccines.  
The placebo is a clear solution whereas the M2SR vaccines are a light yellowish color. 
The unblinded pharmacy staff will prepare the vaccine and placebo doses, fill delivery 
devices and apply an opaque label to the device barrel to obscure any coloration of t he 
contents or volume differences and maintain the blind.  
CONFIDENTIAL 23 FluGen, Inc.  CLINICAL STUDY PROTOCOL - FLUGEN -H3N2 -V003  18May 2020 (v8.0)  
 
 
 
 Study/Treatment Duration:  
All subjects will receive either active vaccine or placebo on Days [ADDRESS_958879] dose on Day 1, be contact[CONTACT_705586] 4 for report of symptoms/AEs  (or optionally may attend the clinic  if 
consenting to PBMC collection at select sites)  and will attend the clinic on Day 8 for 
safety follow -up. Subjects will return to the site for a second dose administration on Day 
29, be contact[CONTACT_705587] 32 for report of symptoms/AEs and will attend the 
clinic on Day 36 for safety follow -up. Subjects return to the clinic on Day 57 and then 
on Day  209 ([ADDRESS_958880] dose) for the final study follow -up vis it. If Day [ADDRESS_958881] vaccination 
(Day  8), SRC will review available safety data for sentinel groups [ADDRESS_958882] completed study visits through day 28 after the second dose (Day 57) 
and/or after all study subjects have completed study visits throug h 28 days after the 
second dose administration (Day 57), the study sponsor may be unblinded. Study 
subjects, blinded investigational site personnel and blinded study monitors will remain 
blinded until all subjects have completed the study.  
For vaccine program planning purposes, an early review of partial data may occur prior 
to all subjects completing the day [ADDRESS_958883] treatment. Specified team 
members ( as defined in a Blinding Plan) will receive the datasets unblinded by [CONTACT_705588]. This will allow for summary tables to be 
generated by [CONTACT_705589]. The 
data will not be used to make decisions about the dis/continuation of or alter ations to the 
trial. 
 
Statistical Methods:  
The Statistical Analysis Plan (SAP), including table shells will be finalized prior to 
database lock.  
The final analysis will be done after the last subject has had the day [ADDRESS_958884] diaries, solicited and unsolicited AEs, vaccine -associated AEs, 
SAEs, safety labs, vital signs, and physical examinations . 
 
CONFIDENTIAL 24 FluGen, Inc.  CLINICAL STUDY PROTOCOL - FLUGEN -H3N2 -V003  18May 2020 (v8.0)  
 
 
 
 Exposure  
Vaccine ex posure will be summarized by [CONTACT_705590], % of expected dose, and % of 
subjects receiving the expected dose.  
 
Adverse Events  
Treatment -emergent AEs (local and systemic) will be summarized as N (%) with AEs, 
with related  AEs, and by [CONTACT_34691].  
Incidenc e of TEAEs will be reported by [CONTACT_10607]  
(MedDRA )-coded System Organ Class ( SOC ), Preferred Term ( PT) and maximum 
severity.  
Incidence of most frequent TEAEs and most frequent treatment -related TEAEs will be 
reported by [CONTACT_49517] C and PT  
Listings of subjects who died, discontinued the study due to an AE, or experienced an 
SAE will be provided.  
Dose -site reactions will be presented by [CONTACT_705591].  
Post-administration symptoms (memory aid) will be summarized by [CONTACT_11191],  worst 
occurrence, and days with symptoms.  
 
Clinical Laboratory Tests  
Biochemistry and hematology laboratory results and change from baseline results will be 
summarized by [CONTACT_705592].  
Shift tables of maximum grade compared to baseline tabulated according to the FDA 
guidance: Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled 
in Preventive Vaccine Clinical Trials, or in accordance with the normal ranges of the 
clinical laboratory (below, within, or above  normal range) for parameters for which no 
toxicity grades are defined.  
A listing of clinical laboratory test results outside the reference ranges will be provided.  
 
Vital Signs  
Vital sign results and change from baseline results will be summarized by [CONTACT_705593].  
 
Limited Physical Examination  
Abnormal findings in physical examination will be listed.  
 
Pregnancy  
A listing of pregnant subjects will be dis played.  
 
Additional Analyses ( descriptive only; p -values are descriptive and not corrected for 
multiple testing)  
 
Immunogenicity  
Serum antibody, mucosal antibody and cellular immune response will be summarized 
using descriptive statistics by [CONTACT_705594].  
CONFIDENTIAL 25 FluGen, Inc.  CLINICAL STUDY PROTOCOL - FLUGEN -H3N2 -V003  18May 2020 (v8.0)  
 
 
 
 Seroconversion rates will be presented by [CONTACT_705595].  
 
Vaccine virus detection  
Viral shedding will be summarized using descriptive statistics.  
 
Additional (exploratory) endpoints may be analyzed.  
 
Sample size  
The sample size of [ADDRESS_958885] one administration of IP.  
The full analysis set (FAS) will include all subjects randomized, received IP and had at 
least one post baseline assessment.  
If necessary, a per protocol set (PPS) will include all subjects in the FAS with no major 
protocol violations or deviations.  
 
Issue Date (Version)  18May 2020 (v8.0) 
 
 
FluGen, Inc.  CLINICAL STUDY PROTOCOL - FLUGEN -H3N2 -V003  18May 2020 (v8.0) 
[ADDRESS_958886] time in human  
GCP  Good Clinical Practice  
GLP  Good Laboratory Practice  
HA hemagglutinin  
HAI hemagglutination inhibition  
HbsAg  hepatitis B surface antigen  
HBV  hepatitis B virus  
HCV  hepatitis C virus  
HIV human immunodeficiency virus  
HRPO  Human Research Protection Office  
IB Investigator’s Brochure  
ICF Informed Consent Form  
ICH International Conference on Harmonisation  
ICS intracellular cytokine staining  
IEC Independent or Institutional Ethics Committee  
IgA immunoglobulin A  
IgG immunoglobulin G  
IN intranasal(ly)  
IND Investigational New Drug Application  
IP investigational product  
IRB Institutional Review Board  
FluGen, Inc.  CLINICAL STUDY PROTOCOL - FLUGEN -H3N2 -V003  18May 2020 (v8.0) 
27 CONFIDENTIAL  
 
 
 
 
 IUD intrauterine device  
LAR  Legal Authorized Representative  
M2SR  M2-deficient Single Replication vaccine   
MAD  mucosal atomization device  
MedDRA Medical Dictionary for Regulatory Activities  
mL milliliter  
mM millimolar  
MMWR  Morbidity and Mortality Weekly Report  
MN microneutralization  
MNT  microneutrali zation test  
N number (typi[INVESTIGATOR_19737])  
NA neuraminidase  
NAI neuraminidase inhibition assay  
NSAID  nonsteroidal anti -inflammatory drug  
OTC  over the counter  
PBMC  peripheral blood mononuclear cell  
PE physical exam  
PCR  polymerase chain reaction  
PI [INVESTIGATOR_27333]-protocol  Set 
PT Preferred Term  
QIV quadrivalent influenza vaccine  
qRT-PCR  real-time quantitative reverse transcription PCR  
RT-PCR  reverse transcription polymerase chain reaction  
SAE  serious adverse event 
SAP Statistical Analysis Plan  
SE standard error  
SRC Safety Review  Committee  
SPG-NaCl  sucrose phosphate glutamate with sodium chloride  
SOC  System Organ Class  
SOP Standard Operating Procedure  
SS Safety Set 
S[LOCATION_003]R  suspected unexpected serious adverse reaction  
TCID  50% t issue culture infective dose  
TEAE  treatment -emergent adverse event  
TIV trivalent influenza vaccine  
US DoD  [LOCATION_002] Department of Defense  
US [LOCATION_002]  
VE vaccine effectiveness  
 
FluGen, Inc.  CLINICAL STUDY PROTOCOL - FLUGEN -H3N2 -V003  18May 2020 (v8.0) 
28 CONFIDENTIAL  
 
 
 
 
 Definiti ons of Terms  
Baseline Day of vaccine /placebo  administ ration; typi[INVESTIGATOR_705527], determined at the record, not the visit level.  
BMI Weight in kilo gram divi ded by [CONTACT_705596] m eters 
FluGen, Inc.  CLINICAL STUDY PROTOCOL - FLUGEN -H3N2 -V003  18May 2020 (v8.0) 
29 CONFIDENTIAL  
 
 
 
 
 STUDY ADMINISTRATIVE STRUCTURE AND INVESTIGATORS  
 
Sponsor : FluGen  Corporation  
[ADDRESS_958887]  
Madison, WI [ZIP_CODE] [LOCATION_003]  
Funded by: U nited States Department of Defense (DoD)  
Lead Principal 
Investigator:   
 [INVESTIGATOR_705528] -Trials  
[ADDRESS_958888]  
Lenexa, KS [ZIP_CODE]  
Medical Monitor:    
 Ruth D. Ellis, MD , MPH  
Biologics Consulting, Inc.  
Mobile: [PHONE_14718]    
Email: [EMAIL_13519]  
Sponsor Clinical Project 
Manager : Renee Herber  
FluGen Corporation  
[ADDRESS_958889]  
Madison, WI [ZIP_CODE] [LOCATION_003]  
Clinical Laboratories:  LabCorp  
[ADDRESS_958890]  
Burlington, NC [ZIP_CODE] -3361  
Bioanalytical Laboratory:  Viroclinics  Biosciences  
Marconistraat 16, [ADDRESS_958891]  
Madison, WI [ZIP_CODE] [LOCATION_003]  
 
Southern Research Institute  
FluGen, Inc.  CLINICAL STUDY PROTOCOL - FLUGEN -H3N2 -V003  18May 2020 (v8.0) 
[ADDRESS_958892]. Louis, MO   [ZIP_CODE]  
 
Storage:  Brooks Life Sciences  
[ADDRESS_958893], Suite E  
Indianapolis, IN [ZIP_CODE] [LOCATION_003]  
Pharmacovigilance : Ruth D. Ellis, MD, MPH  
Biologics Consulting, Inc.  
Mobile: 1 -[PHONE_14719]   
Email: [EMAIL_13519]  
FluGen, Inc.  
[ADDRESS_958894]  
Madison, WI [ZIP_CODE] [LOCATION_003]  
FluGen, Inc.  CLINICAL STUDY PROTOCOL - FLUGEN -H3N2 -V003  18May 2020 (v8.0) 
[ADDRESS_958895] seasonal 
influenza strains. The vaccine virus does not express an essential viral protein (influenza M2), 
restricting it to a single replication cycle in the host. Bris10 M2SR has been  tested in a 
Phase  1, fir st-time-in-humans (FTIH) study FluGen -H3N2 -V001  (ClinicalTrials.gov 
identifier [STUDY_ID_REMOVED] ) under [LOCATION_002] (US) Investigational New Drug (IND) 
Application [ADDRESS_958896] 
2017 -004971 -30. A Phase 1 study in adolescents (BB -IND [ZIP_CODE]; sponsored by [CONTACT_705597] ; [STUDY_ID_REMOVED] ) is also underway.  The proposed study will be a FTIH study for 
Sing2016 M2SR.  
This Phase 1b dose escalation study is to assess the safety, tolerability/r eactogenicity, and 
immunogenicity of M2SR vaccines when delivered at higher dosages or in two doses to 
increase the proportion of subjects responding serologically to the vaccine. For this study, an 
updated vaccine, Sing2016 M2SR, has been prepared that wi ll provide the hemagglutinin 
(HA)  and neuraminidase (NA)  components from A/Singapore/INFIMH -16-0019/2016, the 
H3N2 strain recommended for the [ADDRESS_958897] persons who become infected will recover without sequelae, influenza 
can cause serious illness and death, particularly among persons age ≥  65 years, children 
< 2 years, and individuals with  underlying medical conditions that confer an increased risk 
of influenza -related complications  (Centers for Disease Control and Prevention [ CDC ] 2013 ). 
Over the past [ADDRESS_958898] ranged from 3,000 to 
49,000 annually, with approximately 200,000 hospi[INVESTIGATOR_705529] ( CDC 
2015 ).  
Annual influenza vaccination has long remained the primary means of  preventing influenza 
infection and its complications, and has been consistently recommended by [CONTACT_705598] 60 years. Although routine vaccination was initially recommended only 
for high -risk populations  in the US , the CDC  and the  Advisory Committee on Immunization 
Practices (ACIP) have recommended since 2010 that all persons aged ≥  [ADDRESS_958899] contraindications should be vaccinated ( CDC 2015 ). Recent evaluations conducted by 
a US government -supported network of large clinics (US Flu -VE Network; Treanor 2012 ), 
have demonstrated an overall vaccine effectiveness (VE) of at most 60% (95% confidence 
interval [ CI], 53-66) for prevention of laboratory -confirmed, medically at tended influenza 
illness due to any influenza virus, even in years in which there was a good match between 
vaccine and circulating strains ( Treanor 2012 ). VE estimates in the US among individuals 
FluGen, Inc.  CLINICAL STUDY PROTOCOL - FLUGEN -H3N2 -V003  18May 2020 (v8.0) 
32 CONFIDENTIAL  
 
 
 
 
 age ≥  [ADDRESS_958900] been consistently lower than in younger age groups, which is consistent 
with the well -documented reduction in immunogenicity of influenza vaccine in older adults 
(Osterholm 2012 ). Given the substantial and further increasing resourc e allocations to the US  
influenza vaccination program s, the continued search for more effective vaccines to further 
improve the population -level impact of the program ‒ and particularly among older adults 
and others at high risk of serious influenza compli cations ‒ remains a critically important 
public health challenge.  
1.2.2.  Current Influenza Vaccines  
Currently available inactivated and recombinant influenza vaccines primarily aim to induce 
neutralizing antibodies that recognize the virus envelope protein HA. Th ese antibodies can 
provide effective immunity, but they depend on a close match between the vaccine 
immunogen and circulating viruses. Such vaccines are therefore relatively ineffective against 
newly emerging viruses or viruses that have drifted away from the vaccine strain. 
Conventional egg -derived inactivated vaccines, which currently comprise approximately 
90% of the US market, generally provide limited or no broadly cross -reactive 
(heterosubtypic) immunity needed to protect against divergent strains. Cu rrently available 
trivalent (TIV) or quadrivalent (QIV) preparations provide only the HA antigen and either 
none or limited and non -standardized amounts NA antigen. Moreover, at least one HA 
component of these vaccines must often be updated due to accumula ted point mutations in 
the HA protein that allow the viruses to evade the human immune response. In addition, while 
a strong relationship has been established between pre -existing T cell immunity and illness 
severity in subjects seronegative for influenza virus -specific antibody ( Wilkinson 2012 ), no 
or minimal cellular immune responses have been shown to be elicited following vaccination 
with these conventional preparations.  
1.2.3.  Live attenuated vaccines  
In contrast to conventional i nactivated and recombinant vaccines, live influenza virus 
vaccines are generally believed to offer broad -spectrum immune responses because they 
induce diverse types of adaptive responses, including serum antibodies, mucosal immunity, 
and induction of cytot oxic T lymphocytes, which target conserved virus epi[INVESTIGATOR_322] ( Clements 
1986 , Tamura 2005 , Zhu 2010 ; Lanthier 2011 , Ambrose 2012 , Jin 2015 ). Only one such live 
vaccine, (FluMist®), which has been attenuated empi[INVESTIGATOR_705530] -adaptation, has been 
approved in the US, and is presently indicated only for persons [ADDRESS_958901] 
vaccine are not fully understood; serum antibodies, mucosal antibodies, and influenza -
specific T cells may play a role  but there is no establis hed surrogate of efficacy.  Accumulating 
data also indicate that pre -existing cross -reactive immunity present in most adults limits 
vaccine virus replication, which in turn reduces a consistently effective immune response  
(Eick 2009 , Ohmit 2006 , Wang 2009 , Monto 2009 ). This in part explains the observation that 
young, seronegative children are the population in which FluMist vaccination is typi[INVESTIGATOR_705531].  
FluGen, Inc.  CLINICAL STUDY PROTOCOL - FLUGEN -H3N2 -V003  18May 2020 (v8.0) 
33 CONFIDENTIAL  
 
 
 
 
 1.2.4.  FluGen’s H3N2 (A/Brisba ne/10/2007) M2SR vaccine  
FluGen is developi[INVESTIGATOR_007] a novel live virus vaccine platform known as “M2SR” to address the 
need for more effective influenza vaccines that will provide more consistent and broad -
spectrum immunity for adults, and especially the elderly . The product is a live virus vaccine 
for intranasal administration that has been shown to provide protection against multiple 
influenza A subtypes in animal models (see below). The vaccine is a replication -defective 
recombinant influenza virus that does n ot express the essential  M2 protein (and hence, the 
derivation of the “M2SR” naming convention [ Single Replication phenotype due to lack of 
M2]). The M2SR vaccine viru s backbone is comprised of (1) five of the six  internal proteins 
of the donor virus Influ enza A/Puerto Rico/8/34 (PR8), a strain that has been used for decades 
in traditional inactivated influenza vaccine manufacturing; (2) the sixth internal protein, M2, 
which is acquired from the cell substrate used to grow the vaccine virus, M2 Vero cells, which 
stably express and supply M2 protein for vaccine virus growth; and (3) the two influenza 
virus surface protein antigens, HA and neuraminidase (NA), which can be derived from any 
selected Type A influenza strain. The resulting vaccine virus can infect  normal cells in the 
respi[INVESTIGATOR_705532] a wild -type influenza virus, thereby [CONTACT_705599]. However, because the 
M2SR genome does not encode for M2 protein, no vira l progeny are subsequently produced 
after the initial (single round) infection, such that no cell -to-cell spread or subsequent 
shedding of virus occurs. The HA and NA of an A/Brisbane/10/2007 -like H3N2 virus was 
chosen as the prototype monovalent vaccine t o be initially tested in humans and is further 
referred to here as “Bris10 M2SR”.  
Like FluMist, Bris [ADDRESS_958902] been recalled after heterosubtypic challenge. Flow cytometric analyses of CD8+ T cells 
in bronchoalveolar lavage studies in animals have also revealed that the majority of these 
cells have an effector/me mory or effector phenotype, the presence of which has been shown 
in humans to reduce influenza related symptoms upon exposure to wild -type influenza 
(Wilkinson 2012 ). By [CONTACT_22242], cell -mediated responses (either effector or memory) are 
generally not elicited by [CONTACT_705600]  (Hoft 201 7, He 2006 ). These 
properties suggest that vaccines based on this approach may potentially confer additional 
advantag es over currently available influenza vaccines, including FluMist, and are intended 
to model natural (wild -type) infection, while at the same time incorporate the critical safety 
feature of only precipi[INVESTIGATOR_2505] a single round of virus replication.  
1.2.5.  FluGen’s H 3N2 (A/Singapore/INFIMH -16-0019/2016) M2SR vaccine  
Sing2016 M2SR and is a recombinant, monovalent influenza A virus that was generated as 
described above for Bris10 M2SR. It contains a similar PR8 backbone but with nine amino 
FluGen, Inc.  CLINICAL STUDY PROTOCOL - FLUGEN -H3N2 -V003  18May 2020 (v8.0) 
34 CONFIDENTIAL  
 
 
 
 
 acid changes distributed over five genes (PB1 , PB2, PA, NP and NS1) that facilitate growth 
in the production cell line, M2VeroA. The mechanism of attenuation (deletion of the M2 
gene) is not affected. The Sing2016 M2SR also provides the HA and NA components from 
A/Singapore/INFIMH -16-0019/2016 that were recommended for the 2018 -2019 influenza 
season.  The current study  is the FTIH study for Sing 2016 M2SR.  
1.3. Non-Clinical Studies of  M2SR  
In addition to the features described above, and as further summarized in the Investigator’s 
Brochure  (IB) accompanying this protocol, data obtained in animal models provide a strong 
basis for proceeding with clinical testing of the Bris 10 M2SR prototype vaccine in humans 
based on the following features:  
1.3.1.  Non-Clinical Safety  
The safety of Bris10 M2SR monovalent vaccine was evaluated in a Good Laboratory Practice 
(GLP )-compliant, repeat -dose toxicity study in ferrets. In that study (Battelle Study Number 
37234E), male and female ferrets were intranasally administered Bris10 M2S R once on Days 
1 and 28 at dosages of 1.1 x 107 or 1.1 x 108 50% tissue culture infective dose ( TCID 50) using 
the clinical spray device (Teleflex VaxINator). Overall, there were no observed toxicities 
from the t wo administrations of vaccine. The M2SR H3N2 vaccine was considered well 
tolerated, with only a transient reduction in physical activity being obser ved after the initial 
administration of 1.[ADDRESS_958903] and second administration of Bris10 M2SR 
(on Days 3 and 30), partic ularly in the high dose group. The inflammation was not associated 
with any adverse clinical signs, clinical pathology, gross pathology or organ weight changes 
and was transient in nature, completely resolving by [CONTACT_2671] 21 -day reco very period.  
In mu ltiple non -GLP studies of M2SR -based constructs (including H1N1, H3N2, and H5N1), 
there was (a) no evidence of weight loss or clinical symptoms in ferrets after intranasal 
administration; (b) no adverse histopathologic findings in any of the respi[INVESTIGATOR_705533]; and (c) no transmission of vaccine virus in any ferrets (3 donors and 6 
contacts).  
There is no evidence of M2SR vaccine virus replication when organs and nasal washes were 
analyzed for presence of virus. Moreover, the M2SR constr uct deletion prevents reversion, 
as confirmed by >10 serial passages in permissive cells and blind passage in non -permissive 
cells and in mice.  
1.3.2.  Non-Clinical Efficacy  
Non-clinical studies of the M2SR  platform confirm:  
FluGen, Inc.  CLINICAL STUDY PROTOCOL - FLUGEN -H3N2 -V003  18May 2020 (v8.0) 
35 CONFIDENTIAL  
 
 
 
 
 • M2SR -based constructs (including H1N1, H3N2, and H5N1) stimulate potent 
systemic and mucosal immune responses and confer protective immunity  to animals 
against lethal homo -, hetero -, and intra -subtypic influenza virus challenge;  
• Protection following vaccination is superior to that conferred by [CONTACT_705601] (split) or 
live attenuated vaccines (FluMist); and  
• Robust immune responses are elicited in vaccinated animals, even in the presence of 
pre-existing anti -influenza antibody.  
These characteristics illustrate the potential for the M2SR platform to  become a potentially 
safe and effective alternative to  existing influenza vaccines.  
Please see the IB for a more complete description of the product and additional details of the 
pre-clinical studies.  
1.4. Clinical Studies  
Previous clinical experience with t he M2SR vaccine platform includes a FTIH Phase 1 dose 
escalation study in healthy adults, an on -going Phase 1 safety and immunogenicity study in 
adolescents , and a Phase 2a challenge study in healthy adults using the H3N2 vaccine Bris10 
M2SR. Sing2016 M2SR  has not been previously studied in humans.  
1.4.1.  Phase 1 Dose Escalation Study  
For the FTIH Phase 1 study, 96 healthy adult male and non -pregnant female subjects ages 
18-49 years, were stratified by [CONTACT_705602] -inhibition (HAI) antibody titers 
(<10 to 80) against influenza A/Brisbane/10/2007 (Bris10) and enrolled under US IND 
016968 (also see ClinicalTrials.gov identifier [STUDY_ID_REMOVED]). First subject first visit 
occurred in July [ADDRESS_958904] visit (Day 180) was in April 2017. Subjects were 
randomly assigned to receive either a single administration of Bris10 M2SR at dose levels of 
106, 107 or 108 TCID 50 (24 subjects per dose level) or saline placebo (N=24; 8 for each Bris10 
M2SR dose group). Each subject received ~ 0.1 mL of vaccine or placebo intranasally (IN) 
in each nostril ‒ except for the 108 group, who received 0.15 mL per nostril ‒ using a mucosal  
atomization device (MAD) from the Teleflex VaxINator kit  including a MAD301 sprayer . 
The vaccine was safe and well tolerated at all dose levels, generated a dose -response effect 
for humoral (hemagglutination -inhibition antibody) and mucosal antibodies aga inst both 
homologous and heterologous influenza variants, and elicited robust T -cell responses. No 
infectious virus was detected in nasal swabs collected on Days 1, 2, [ADDRESS_958905] in the placebo cohort 
self-reported fevers as high as 38.2°C (day [ADDRESS_958906] -dose) and 38.4°C (day [ADDRESS_958907] -dose), 
respectively. Subjects were followed through Day [ADDRESS_958908] 7 -day diaries, no reported serious adverse events 
(SAEs ) or adverse events (AEs) of significance (attributed to the treatment) and none of the 
pre-specified halting rules (including laryngospasm, bronchospasm or anaphylaxis) were 
met.  
FluGen, Inc.  CLINICAL STUDY PROTOCOL - FLUGEN -H3N2 -V003  18May 2020 (v8.0) 
36 CONFIDENTIAL  
 
 
 
 
 1.4.2.  Phase 1 Study in Adolescen ts 
In a Phase 1 study in adolescents (BB -IND [ZIP_CODE]; sponsored by [CONTACT_705603])  50 males 
and non -pregnant females ages 9 to 17 years old, inclusive  are being enrolled . Subjects are 
randomized 1:[ADDRESS_958909] acebo 
administered intranasally (IN) followed by [CONTACT_705604] (QIV) administered intramuscularly [ADDRESS_958910] been enrolled (first subject first visit was in August 2018) and h ave received both dose 
treatments. These subjects have been followed through at least the Day  113 visit (21 days 
after administration of the QIV) with no reported SAEs, AEs of significance or halting rules 
met. 
1.4.3.  Phase 2a Challenge Study  
The Phase 2a challen ge study  included  108 healthy male and non -pregnant female subjects 
ages 18 -55 years old  who had microneutralization titers (MN T) of ≤ 20 to H3N2 
A/Belgium/4217/2015 . Subjects  were randomized 1:1 into two cohorts (Bris10 M2SR or 
Placebo) each receiving inv estigational product (IP) of either a 108 TCID 50 dose of Bris10 
M2SR vaccine (N=48) or a saline control  (N=51) under EudraCT [ADDRESS_958911] H3N2 
A/Belgium/4217/2015. The first subject first dose was in May [ADDRESS_958912]-IP follow -up visit in March  2019. In the period following IP 
treatment (Day -28) until Day 1, there were no severe AEs or severe local or systemic 
complaints and there were no reported fevers (≥38°C). The active phase of this Phase 2a 
challenge study h as been completed and there were no SAEs, AEs of significance or 
observations that would halt the study. All subject samples (including serum, PBMC and 
nasal swabs for humoral, cellular and mucosal immunity, respectively) have been collected 
and are underg oing analytical testing. Nasal swabs collected for detection of influenza virus 
have been analyzed. The finalization and locking of the  clinical database and final analys es 
are in process.  
Preliminary results from the Phase 2a challenge study suggest that the vaccine was effective 
against challenge in subjects for whom a detectable serum immune response was measured 
after vaccination. Subjects who demonstrated any increase from baseline in serum antibody 
response (~50% of the M2SR cohort) by [CONTACT_518561] T to the intr anasal M2SR vaccine had lower 
viral load and influenza -like symptoms than placebo subjects. These preliminary results 
suggest that M2SR could potentially provide higher efficacy levels if a greater proportion of 
M2SR recipi[INVESTIGATOR_705534]. In an effort to increase 
the number of sero -responders to H3N2 M2SR, the Phase 1b study  described in this protocol  
is planned to further optimize the dose and schedule for M2SR vaccinations. Subjects in the 
proposed Phase 1b study must have a MN T ≤ 20 to A/Singapore /INFIMH -16-0019/[ADDRESS_958913] dose of Bris10 M2SR tested (108) with no SAEs or AEs of 
significance or observations that would halt these studies. In addition, in the challenge study, 
48 subjects who received the live, single -replication M2SR virus were subsequently 
challenged with a live, replicating influenza virus . A portion of those individuals experienced 
FluGen, Inc.  CLINICAL STUDY PROTOCOL - FLUGEN -H3N2 -V003  18May 2020 (v8.0) 
37 CONFIDENTIAL  
 
 
 
 
 infection and symptoms consistent with influenza ( e.g., nasal congestion, runny nose, sore 
throat, cough, tiredness, headache ), but at frequency less than observed among individuals in 
the same study who did not  receive vaccine prior to challenge. Of the 19 adolescents enrolled 
in the ongoing second Phase 1 study, while the randomization was set at 1:1 active to placebo, 
it is not known exactly how many received active investigational vaccine (M2SR) , but in 
blind ed review  no safety concerns related to the M2SR vaccine have been reported. 
Combined, these findings indicate that the vaccine is safe and generally well  tolerated as a 
single 108 TCID 50 dose.  
1.5. Overall Rationale for the Study  
Currently available inactivated and recombinant influenza vaccines primarily aim to induce 
neutralizing antibodies that recognize only the HA and depend on a close match between the 
vaccine and circulating viruses , rendering them much less ef fective agains t drift viruses.  In 
addition, while a strong relationship has been established between pre -existing T cell 
immunity and illness severity, inactivated vaccines do not elicit cellular immune responses 
and therefore generally do not provide broadly cross -reactive (heterosubtypic) immunity 
needed to prot ect against divergent strains. For example, t he severity of the [ADDRESS_958914] 13%  (Paules 2018 ). Similarly, during the 2017 
influenza season in Australia, the inactivated vaccines displayed a preliminary VE estimate 
of only 10%, again related  to mismatch between the vaccine strain and the circulating 
seasonal H3N2 virus that had accumulated antigen ic changes (i.e., “dr ifted”)  (Paules 201 8). 
These recent examples indicate the need for an influenza vaccine that can protect against 
seasonal influenza drift variants.  
In contrast to currently available influenza vaccines, pre -clinical testing of M2S R vaccine has 
shown induction of broadly reactive immune responses against multiple influenza subtypes 
and heterosubtypic protection in animal models, including demonstration of robust systemic, 
cellular and mucosal immun ogenicity  (Sarawar 2016 , Hatta 2017 ), even in the presence of 
pre-existing anti -influenza immunity. In a pre -clinical proof -of-concept study, Bris10 M2SR 
(one of the vaccine s to be used in the current  study) provided protection to ferrets against a 
drifted H3N2 challenge virus, A/Alaska/140/2015, a vi rus belonging to clade 3c .2a1. In 
addition, adult subjects who received Bris10 M2SR (108 TCID 50 dose) in the Phase 1a FTIH  
and Phase 2a studies demonstrated broad -spectrum immune responses. In the FTIH study, 
vaccine induced serum and mucosal antibody responses were cross -reactive against multiple 
antigenically different H3N2 viruses including recent strains that belong to the same clade 
(3c.3b) as the challenge virus used in the P hase 2a study  (FluGen IB). In the Phase 2a study, 
early data suggest that the vaccine was effective against challenge with an antigenically 
drifted virus in subjects for whom a serum response to the vaccine was detected  (data on file) . 
This Phase 2a dose e scalation clinical study is designed to assess the safety, 
tolerability/reactogenicity, and immunogenicity of M2SR vaccines when delivered at higher 
dosages or in two doses to increase the proportion of subjects responding serologically to the 
vaccine. For  this study, an updated vaccine, Sing2016 M2SR, has been prepared that will 
provide the HA and NA components from A/Singapore/INFIMH -16-0019/2016, the H3N2 
strain recommended for the 2018 -2019 influenza season . 
FluGen, Inc.  CLINICAL STUDY PROTOCOL - FLUGEN -H3N2 -V003  18May 2020 (v8.0) 
38 CONFIDENTIAL  
 
 
 
 
 1.6. Risk/ Benefit Analysis  
1.6.1.  Potential Risks 
In previously conducted trials, [ADDRESS_958915] been treated with 
Bris10 M2SR (or placebo in adolescents as the ongoing study is still blinded). No SAEs or 
AEs of significance have been reported . In the challenge study, 48 subjects w ho received the 
live, single -replication M2SR virus were subsequently challenged with a live, replicating 
influenza virus. A portion of those individuals experienced infection and symptoms 
consistent with influenza ( e.g., nasal congestion, runny nose, sore  throat, cough, tiredness, 
headache ), but at frequency less than observed among individuals in the same study who did 
not receive vaccine prior to challenge. Combined, these findings indicate that the vaccine is 
safe and generally well tolerated as a singl e 108 TCID 50 dose.  
As outlined in greater detail in the accompanying IB, the potential risks of vaccine 
administration are expected to be similar to those associated with other live attenuated 
influenza vaccines (such as FluMist) . Subjects with contraindi cations to live vaccines, such 
as severe allergic reaction s (e.g., anaphylaxis) after a previous dose of any influenza vaccine , 
and immunocompromised persons, are excluded from study participation. Severe r isks 
known to be associated with vaccine administr ation include anaphylaxis. As with any 
experimental product, there may be unknown risks.  
1.6.2.  Potential Bene fits 
There are no expected benefits to individual subjects participating in this study. There is a 
need for an influenza vaccine that can protect against seasonal influenza drift variants. Bris10 
M2SR administration has shown induction of broadly reactive immun e responses against 
multiple influenza subtypes and heterosubtypic protection in animal models, including 
demonstration of robust systemic, cellular and mucosal immune, even in the presence of pre -
existing anti -influenza immunity. This study is expected to  provide important additional 
information to guide continued development of M2SR vaccine in a quadrivalent formulation 
with the aim of improving efficacy relative to currently licensed influenza vaccines.  
 
FluGen, Inc.  CLINICAL STUDY PROTOCOL - FLUGEN -H3N2 -V003  18May 2020 (v8.0) 
39 CONFIDENTIAL  
 
 
 
 
 2. STUDY  OBJECTIVES AND ENDPOINT S 
2.1. Study Objectives  
2.1.1.  Primary  Objectives 
The primary objectives are:  
1. To assess the safety and tolerability of one and two administrations of the Bris10 M2SR 
influenza vaccine each at 108 TCID 50 delivered intranasally to healthy adult subjects.  
2. To assess the safety and tolerability of one and two administrations of the Sing2016 
M2SR influenza vaccine each at 108, 108.5 and 109 TCID 50 delivered intranasally to 
healthy adult subjects  
2.1.2.  Secondary  Objectives 
The secondary objectives are:  
1. To assess  the immunogenic ity (serum antibody, mucosal antibody and cellular 
immune responses)  of one and two administrations of  Bris10 M2SR vaccine at 108 
TCID 50. 
2. To assess  the immunogenic ity (serum antibody, mucosal antibody and cellular 
immune responses)  of one and two administrations of  Sing2016 M2SR vaccine at 108, 
108.5 and 109 TCID 50. 
3. To evaluate vaccine virus shedding after intranasal delivery.  
2.1.3.  Exploratory Objectives  
The exploratory objectives are:  
1. To evaluate cell mediated immunity for up to [ADDRESS_958916] vaccination.  
2. To evaluate additional vaccine -related immune responses during the period of study 
participation.   
2.2. Study Endpoints  
2.2.1.  Primary  Endpoints  
The primary endpoints are:  
1. The number and  percentage of study participants who experience any vaccine -
associated AEs or SAEs  after Bris10 M2SR or placebo administration.  
2. The number and percentage of study participants who experience any vaccine -
associated AEs or SAEs  after Sing2016 M2SR or placebo administration.  
FluGen, Inc.  CLINICAL STUDY PROTOCOL - FLUGEN -H3N2 -V003  18May 2020 (v8.0) 
40 CONFIDENTIAL  
 
 
 
 
 2.2.2.  Secondary Endpoints  
The secondary endpoints are:  
1. The number and percentage of study participants who after one  or two doses of Bris10 
M2SR or placebo demonstrate:  
i. Influenza -specific serum antibody responses measured at specified time 
points;  
ii. Influenza -specific mucosal immunoglobulin A ( IgA) antibody responses 
measured  at specified time points;  
iii. Influenza -specific cellular immune responses measured by [CONTACT_705605] -
linked immunospot (ELISPOT) at specified time points.  
2. The number and percentage of study participants who after one or two doses of 
Sing2016 M2SR or placebo demonstrate:  
i. Influenza -specific serum antibody responses measured at specified time 
points;   
ii. Influenza -specific mucosal IgA antibody responses measured  at specified 
time points;  
iii. Influenza -specific cellular immune responses measured by [CONTACT_705571] e points.  
3. Vaccine virus shedding evaluated by [CONTACT_14302] A -specific qPCR on day [ADDRESS_958917] IP 
administration.  
2.2.3.  Exploratory Endpoints  
The exploratory endpoints are:  
1. Cell-mediated immunity  (CMI) assessed by [CONTACT_705606] -
specific T -lymphocytes.  
2. Additional influenza -specific  immun ological  assay s may be performed.  
 
 
FluGen, Inc.  CLINICAL STUDY PROTOCOL - FLUGEN -H3N2 -V003  18May 2020 (v8.0) 
41 CONFIDENTIAL  
 
 
 
 
 3. STUDY DESIGN  
3.1. Overview of Study Design  
This is a randomized, double -blind, placebo -controlled Phase 1 study evaluating  the safety and 
immunogenici ty of the Bris10 M2SR and Sing2016 M2SR H3N2 in fluenza vaccines d elivered 
intranasally to  healthy adults.  
Eligible subjects will be screened  and randomized to receive two administrations 28 days apart 
of Sing2016 at three dose levels, Bris10 at one dose level, or placebo in a 1:1:1:1:1 ratio. An 
overview of the planned dose cohorts is presented in Table  1. 
Table  1: Dose Cohorts  
Dose Cohort  Number of 
Subjects  Number in 
Sentinel Group  Number in 
Expansion Group  
1. 108   TCID 50 Sing2016 M2SR  50 9 41 
2. 108.5 TCID 50 Sing2016 M2SR  50 9 41 
3. 109   TCID 50 Sing2016 M2SR  50 9 41 
4. 108   TCID 50 Bris10 M2SR  50 9 41 
5. Placebo  50 9 41 
Total  250 45 205 
Abbreviations: TCID 50=50% tissue culture infective dose.  
 
As shown in Table  2, three sentinel groups will be vaccinated first, containing 15 subjects 
([ADDRESS_958918] bo), followed by [CONTACT_705607]. 
Cohorts are split into two groups to alleviate PBMC processing issues of large numbers of sampl es. 
Dosing will be staggered to allow for review of AEs through day [ADDRESS_958919] -administration f or each 
sentinel group prior to dose escalation. A Safety Review  Committee ( SRC) will review available 
safety data from all sentinel subjects, after subjects have completed [ADDRESS_958920] of safety parameters collected during the 
study are described  in Table  3.  
FluGen, Inc.  CLINICAL STUDY PROTOCOL - FLUGEN -H3N2 -V003  18May 2020 (v8.0) 
42 CONFIDENTIAL  
 
 
 
 
 Table  2: Dosing and Safety Reviews  
 
*Dose  Cohort 1 = Sing2016 M2SR 108, Dose Cohort 2 = Sing2016 M2SR 108.5, Dose Cohort 3 = Sing2016 
M2SR 109, Dose Cohort 4 = Bris10 M2SR108, Dose Cohort 5 = saline placebo  
Note: Safety in dicates a review by [CONTACT_95702] [INVESTIGATOR_1238]/or Medical Monitor as detailed below in Study Conduct.  
Note: SRC indicates a review by [CONTACT_705575].  The Expansion Group schedule 
may be extended based on speed of enrollment.  
Using one nasal sprayer per nare the IP, up to 0.5 mL of the Sing2016 M2SR vaccine or placebo 
(a total of up to 1.0 mL) and up to 0.2 mL of the Bris10 M2SR vaccine (a total of up to 0.4 mL), 
will be delivered per subject per administration. The study will administer  escalating doses of 
Sing2016 M2SR vaccine, with a starting dose of 108 TCID 50 increasing in half log (3 -fold) 
increments to a maximum dose of 109 TCID 50. Controls will be saline placebo and a 108 TCID 50 
dosage of Bris10 M2SR.  
Five (5) dose cohorts of 50 subjects each will be enrolled, for a total of approximately 250 subjects 
randomized 1:1:1:1:1 to receive either Sing2016 M2SR 108, Sing2016 M2SR 108.5, Sing2016 
M2SR 109, Bris10 M2SR or saline placebo. A sentinel group of 9 subjects (~ 18% of each 
escalati ng dose cohort) will be vaccinated first, followed by [CONTACT_705608]. Subjects in each sentinel group will be actively followed for 3  days and if the 
Medical Monitor and /or Lead PI [INVESTIGATOR_705535], the next sentinel  
group  will be enrolled. After all sentinel subjects have completed 7 days following vaccination, a 
Safety Review  Committee ( SRC) will review safety data prior to enrollment and vaccination of 
the expansion groups. Note that the expansion subjects will be dosed in rolling waves in order to 
accommodate time-consuming study procedures , i.e., PBMC isolation, and not due to safety 
concerns. All dosed subjects will receive a second dose of the assigned IP approxim ately [ADDRESS_958921] dose. The SRC review of sentinel data prior to  enrollment of expansion 
subjects may occur concurrently with or following the administration of second doses of vaccine 
to sentinel subjects.  

FluGen, Inc.  CLINICAL STUDY PROTOCOL - FLUGEN -H3N2 -V003  18May 2020 (v8.0) 
43 CONFIDENTIAL  
 
 
 
 
 SAEs occurring at any time during the study will be recorded. Administration site and solicited 
AEs will be recorded through 7 days after each vaccination (Days 8 and 29) and unsolicited AEs 
will be recorded through [ADDRESS_958922] vaccination (Day 57). An SRC, comprised at a 
minimum of two independent physicians experienced in vaccine research and a biostatistician, will 
be available to review safety data at specified time points and as needed.  
Based on the safety reviews, an intermediate or lower d ose may be chosen to replace the planned 
dose for a dose cohort. If a lower or intermediate dose is chosen that dose will be used for an entire 
dose cohort. Should dosing be delayed for safety review or enrollment issues, subjects may receive 
their second dose at a time later than defined in the proposed dosing window.  
While safety and tolerability are the primary objectives, this clinical study is also designed to assess 
the immune response to one and two doses of each of the investigational vaccines at ea ch of the 
designated dose levels. Immunogenicity will be assessed by [CONTACT_705609]/or microneutralization (MN) assay. Additional immune parameters will be assessed 
including mucosal antibody titers and cell -mediated immunity . Subjects will be pre -screened, 
under a site-specific Informed Consent Form ( ICF), to avoid enrollment of individuals with high 
MN titers (>  1:20) against the target component (A/Singapore/INFIMH -16-0019/2016 [H3N2]).  
3.2. Study Conduct and Safety Reviews  
After subjects have signed an informed consent and have met the inclusion /exclusion criteria, 
healthy adults will receive a single administration of the IP (active M2SR or placebo) delivered  
intranasally as a liquid formulation. The Phase [ADDRESS_958923] demonstrated that a single dose of Bris10 M2SR at 108 TCID 50 
with and without a subsequent administration of a live, replicating influenza virus is generally safe 
and well -tolerated with no shedding of infectious vaccine virus. Hence, the study will be conducted 
in an outpatient setting and with safety reviews as shown in  Table  2 and summarized here: 
1. Deliver first dose to sentinel group [ADDRESS_958924] dose (Day 4), confirms that no halting rules have been met, and 
communicates this to the Sponsor.  
2. If no safety concerns i n sentinel group 1, deliver first dose to sentinel group 2. Lead PI 
[INVESTIGATOR_705525] [ADDRESS_958925] administration of the second dose (Day 32) are 
conducted in the same manner as outlined above for second doses of sentinel groups.  
6. After sentinel subjects have completed [ADDRESS_958926] vaccination (Day 8), SRC 
reviews available safety data for sentinel groups [ADDRESS_958927] dose to expansion g roup subjects.  
FluGen, Inc.  CLINICAL STUDY PROTOCOL - FLUGEN -H3N2 -V003  18May 2020 (v8.0) 
[ADDRESS_958928] completed 7 days following second vaccination (Day 36), 
SRC reviews cumulative safety data. If no safety concerns are identified, deliver second 
dose to expansion group subjects.    
8. During enrollment of the expansion cohorts, the occurrence of events which could prompt 
a study halt will be reviewed weekly by [CONTACT_221422], until all subjects have 
completed 7 days following second vaccination (Day 36).  
Each subject will undergo the following testing (also depi[INVESTIGATOR_419450]  3): [Note that a Pre -screen 
with blood draw to assess the subject’s microneutralization (MN) titer to Sing2016  may be 
conducted under a site-specific ICF  in the period spanning 90 calendar days before enrollment in 
this study. ] Subjects who meet eligibility criteria will be enrolled in the proposed Phase 1b study, have 
a baseline blood draw, be randomized to a dose cohort and administered IP of either active M2SR 
vaccine or placebo on  Days 1 (Visit 01) and 29 (Visit 04). For [ADDRESS_958929] symptoms in a Symptom Memory Aid (Appendix 5 ) and after 3 days (Days 4 
and 32) will be contact[CONTACT_61936] a phone call by [CONTACT_705610]. Subjects will  attend the investigational site  for follow-up on Days 8, 29, 36, 57 and 209 
(Visits 03, 04, 06, 07 and 08, respectively) for a limited physical exam, safe ty evaluation, nasal  
swabs and blood draws. Day [ADDRESS_958930] in the s tudy. 
Serum samples for ana lysis of ant i-HA anti body titers  for the H3N2  antigen in Sing2016 and 
Bris10 will be collected at baseline and on D ays 8, 29, 36, 57 and 209. PBMC samples for analysis 
of cell -mediated immunity and/or innate transcriptome gene expression will be collected at 
baseline and on D ays 4 (optional), 8, 29, 32 (optional), [ADDRESS_958931] sites  for ~160 sub jects. 
Nasal swabs w ill be collected on D ays 1, 8, 29, 36, 57 and 209 for analysis of IgA -specific anti -
HA antibody titers. Nasal swabs will be collected at D ays 1, 8, 29, and 36 to evaluate shedding of 
vaccine virus. A nasal swab collected at Day 1 may be evaluated for prese nce of respi[INVESTIGATOR_46264]. Safety clinical laboratory testing will be performed at screening, and on Days 1, 8, 29, 
and 36. During the treatment period (Day 1 – Day 57), subjects will be asked to notify the site 
immediately if symptoms of influenza (fev er, chills, sore throat, rhinorrhea, cough, muscle/body 
aches) occur. When increased influenza infections are being reported in the geographic region  of 
the investigational site , subjects will additionally be contact[CONTACT_705579] 15 ±2, 21 ±2, 43 ±2, and 50 ±[ADDRESS_958932] will be asked to return to the site for 
laboratory confirmation of influenza using nasal swabs.  
A Safety Review Committee (SRC) will review blinded safety data, as needed. The SRC includes 
3 me mbers, 2 independent  infectious disease clinicians and a statistician. The SRC will be 
convened if halting rules are met (Section  7.3) or at the re quest of the Sponsor, Medical Monitor, 
Investigator, or any SRC member  if they have cause for concern regarding subject safety in relation 
to the vaccine where no other cause could be attributed (Section 9.11). 
3.3. Expected Duration of a Subject’s Participation in the Entire Study  
Subjects are expected to participate in person for a duration of up to approximately [ADDRESS_958933] signs consent.   
FluGen, Inc.  CLINICAL STUDY PROTOCOL - FLUGEN -H3N2 -V003  18May 2020 (v8.0) 
45 CONFIDENTIAL  
 
 
 
 
 3.4. Total Study Duration  
It is anticipated that the total study length will be  8 to 9 months . 
3.5. Discussion of Study Design  
3.5.1.  Rationale for Use of Bris10 M2SR (H3N2)  Vaccine  and Route of Administration  
The Bris10 M2SR (H3N2) and Sing2016 M2SR vaccine s contain live, single -replication virus es. 
Intranasal administration of the vaccine s, as proposed for this trial, mimics the natural route of 
infection of a wild -type influenza virus in which the virus adsorbs onto cells in the upper 
respi[INVESTIGATOR_4352], enters the cell and uses host cell processes to generate viral RNA  and proteins 
and stimulat e mucosal and systemic immune responses  by [CONTACT_40689] .  
3.5.2.  Rationale for Dose Selection  
FluGen has conducted 3 clinical trials  with Bris10 M2SR (a FTIH Phase 1 study, an ongoing 
Phase  1 study in adolescents, and a Phase 2a challenge study ). See Sections  1.4.1 ,  1.4.2 , and  1.4.3 , 
respectively, for summaries of these studies .  
Combined, the findings of these  3 clinical trials indicate that (1) the vaccine is safe and generally 
well tolerated as a single 108 TCID 50 dose; and (2) did not lead to exacerbated symptoms when 
followed by [CONTACT_17814] a live, replicating wild -type influenza virus. Thus, there ar e no 
signals indicating that a safety concern might exist for studies that will increase either the dose 
level or exposure to more than one consecutive administration of M2SR  as proposed in the current 
protocol . 
3.5.3.  Rationale for Placebo Control  
Placebo contro l will be used to establish the frequency and magnitude of changes in laboratory  
and clinical endpoints that may occur in the absence of active vaccination . 
3.5.4.  Rationale for Randomization and Blinding  
Randomi zation will be  used to avoid bi as in the  assignment of subjects to, to in crease the likelihood 
that known and unknown subject attributes (e.g., demographic and baseline characteristics) are 
evenly balanced across t reatment groups,  and to enhance the validity of statistical comparisons 
across treatment groups.  
Blinded treatment will be  used to reduce potential bias during data collection and evaluation of  
clinical endpoints.  Only the pharmacis t or their designee preparing the treatment , the unblinded 
monitor and the unblinded statistician who prepares the randomization list are unblinded with 
respect to treatment.  
FluGen, Inc.  CLINICAL STUDY PROTOCOL - FLUGEN -H3N2 -V003  18May 2020 (v8.0) 
[ADDRESS_958934] an existing site database 
that can suppor t the study requirements. Once the sites are allowed to screen, they will be 
instructed to search within the site database for candidates based generally on the 
inclusion/exclusion criteria ( Section 4.1 and Section 4.2 , respectively). Candidates who have 
indicated an interest in future study participation will be contact[CONTACT_705611] “email blast”. FluGen will also provide the sites with IRB -approved advertising (emails, 
posters, flyers). Sites may request to use their own advertising (i ncluding radio, print, social 
media) and these requests will be considered on a case -by-case basis and must be IRB -approved. 
Potential candidates may also contact [CONTACT_67896] a provided phone number in the email blast or 
advertising. As a follow -up, train ed interviewers from the site will make phone calls to responsive 
candidates.  
Screening for eligible subjects, healthy male and non -pregnant/lactating female subjects ages [ADDRESS_958935] the opportunity 
to ask questions, and will be queried to confirm general eligibility (e.g. pregnancy status, age). 
Eligible and willing candidates will then be  scheduled to attend the on -site screening visit. At this 
visit, the site staff will discuss study details with potential candidates. If the candidate agrees to 
be screened to determine eligibility for participation in the study, he/she will be asked to re view 
and sign the informed consent prior to any study procedures. Activities conducted at the screening 
visit (e.g., collecting subject health information and biological samples, and a physical exam) are 
listed in Section 6.1.1  and further described in Section 6.2 . Candidates who screen fail will be 
added to the site database if they agree to participate in future studies. Recruitment and enrollment 
metrics will be provided by [CONTACT_705612] . 
The study will enroll approximately 250 subjects who will receive two doses of experimental 
Bris10 or Sing2016 M2SR vaccine or placebo (physiological saline) on Study Days 1 and 29. 
Subjects will be randomized 1:1:1:1:1 (Sing2016 M2SR 108, Sing2016 M2SR 108.5, Sing2016 
M2SR 109, Bris10 M2SR or Saline placebo).  
For details on the  sample  size calculation, pl ease refer to Section  8.3.1 . 
Because  this is a Department of Defense funded study and  subjects are expected to attend all study 
related visits, active military personnel are excluded from  participat ing in this study.  
4.1. Inclusion Criteria  
Subjects  meeting all the following criteria are eligible to participate in this stu dy: 
1. Give written informed consent to participate ; a legally authorized representative (LAR) 
may not be used . 
2. Age 18 – [ADDRESS_958936] from a second dose.  
FluGen, Inc.  CLINICAL STUDY PROTOCOL - FLUGEN -H3N2 -V003  18May 2020 (v8.0) 
[ADDRESS_958937] (urine)  for drugs of abuse at screening.  Patients who are on stab le (6 months 
or longer) medications prescribed by [CONTACT_705581] a positive screen for 
that substance are allowed  at the discretion of the investigator . 
6. Female subjects should fulfill one of the following criteria:  
a. Post-menopausal status d efined as no menses for 12 consecutive months without 
an alternative medical cause.  
b. Surgically sterile.  
c. Willing to use oral, implantable, transdermal or injectable contraceptives, or sexual 
abstinence as outlined in inclusion criteria 7, from screening and  until 28 days after 
second vaccine dose (Patient Day 57).  
7. Female subjects of childbearing potential must agree to sexual abstinence, use a reliable 
form of contraception approved by [CONTACT_737] (e.g., oral, implantable, transdermal, or 
injectable con traception, combined oral, intrauterine device [IUD], or a sterile sexual 
partner) from screening and until 28 days after the second vaccine dose (Patient Day 57). 
Non-surgically sterile male subjects who are sexually active with a female partner(s) of 
childbearing potential (i.e. males who have not been sterilized by [CONTACT_705582] 
6 months prior to screening) must be willing to use condoms from screening and until 
28 days after the second vaccine dose (Patient Day 57).  
8. Willing to adhere to the re quirements of the study and willing and able to communicate 
with the Investigator and understand the requirements of the study.  
9. Non-smoker (defined as no use of tobacco products and no use of inhaled non -tobacco 
products in the past 30 days prior to Study Day 1; nicotine patches and gum are allowed). 
Subject must also agree to restrict the use of these products until [ADDRESS_958938] vaccine 
administration . 
10. H3N2 Sing2016 MN titers ≤1:20 ( determin ation  within 90 calendar days of study 
enrollment is acceptab le and does not need to be repeated for entry to this study ). 
4.2. Exclusion Criteria  
Subjects meeting any of the following criteria are excluded from participation in this study:  
1. Any subject who is a family member of a) study site personnel and other personnel directly 
involved in conduct or monitoring of study, or b) the Sponsor.  
2. Any condition that would limit the subject’s ability to complete the study based on the 
opi[INVESTIGATOR_689] (for example, a recent surgical procedure).  
3. Clinically sig nificant a bnormal screening hematology or chemistry value , as assessed by 
[CONTACT_093].  
4. Pulse rate or blood pressure outside the reference range for this study population and 
considered as clinically significant by [CONTACT_737].  
5. Has an acute or ch ronic medical condition or history of a medical condition that, in the 
opi[INVESTIGATOR_689], would render the study procedures unsafe or would interfere 
with the evaluation of the responses, including but not limited to, respi[INVESTIGATOR_696], autoimmune, 
or immune suppression conditions, neuroinflammatory conditions, mental illness 
FluGen, Inc.  CLINICAL STUDY PROTOCOL - FLUGEN -H3N2 -V003  18May 2020 (v8.0) 
48 CONFIDENTIAL  
 
 
 
 
 (including depression), active hematological, renal, hepatic, pulmonary, central nervous, 
neurological, cardiovascular, endocrine (including diabetes mellitus) or gastrointestinal 
disorders.  
6. Has been vaccinated against influenza within the last 6 months or plans to be inoculated 
with an influenza vaccine (other than study vaccine) until one month after completion of 
follow up on Patient Day 20 9. 
7. Had a flu -like illness (i.e., fever, chills and myalgia), influenza treatment (i.e., commercial 
drug such as Oseltamivir, etc.), or prophylactic influenza viral drug administered in the 
previous [ADDRESS_958939] or known infection with human immunodeficiency virus ( HIV), 
hepatitis B virus ( HBV ) and hepatitis C virus ( HCV ). 
9. History of cancer within 5 years prior to screening (except basal cell carcinoma and cervical 
carcinoma in situ).  
10. Presence or clinical ly significant his tory of lung disease, asthma, chronic obstructive 
pulmonary disease  (COPD) , or otherwise poor lung function. Childhood asthma that 
resolved by [CONTACT_654]  [ADDRESS_958940] 
swabbing by [CONTACT_705583]’s discretion.  
12. Any confirmed or suspected immunosuppressive or immunodeficient state including: 
asplenia, recurrent severe infections and chronic (more than 14 days) imm unosuppressant 
medication (such as systemic corticosteroids at a dose of ≥ 0.5 mg/kg/day for longer than 
1 week, or immunosuppressants such as cytotoxic drugs) within the last 6 months (topi[INVESTIGATOR_705536]).  Use of immunosuppressive medications,  such as allergy shots, 
immune globulin, interferon, or immunomodulators in the past [ADDRESS_958941] 7 days 
before screening.  
13. Significant adulthood history of seasonal hay fever, a seasonal allergic rhinitis, perennial 
allergic rhinitis, chronic nasal or sinus condition such as sinusitis, at the discretion of the 
investigator.  
14. Received any licensed vaccine within 1 month before screening and during the course of  
the study.  
15. Received or planned administration of another investigational vaccine or drug during the 
period from 90 days prior to Day 1 to one month after completion of Day 209  follow up.  
16. History of allergy/hypersensitivity to any vaccine component (sucr ose, sodium chloride, 
phosphate, glutamate), or material in nasal delivery device (polycarbonate, polypropylene, 
synthetic rubber).  
17. Experienced a life -threatening reaction(s) after a previous administration of any vaccine or 
experienced an allergic reactio n after a previous administration of any influenza vaccine or 
component.  
18. A history or prior diagnosis of Guillain -Barré Syndrome.  
FluGen, Inc.  CLINICAL STUDY PROTOCOL - FLUGEN -H3N2 -V003  18May 2020 (v8.0) 
49 CONFIDENTIAL  
 
 
 
 
 19. Living in the same household with any person with a non -functional or suppressed immune 
system , or with a confirmed influenza  infection or febrile illness within the previous two 
weeks .  
20. History of drug or alcohol abuse in the 6 months before the study.  
21. Current u se of any new prescription or new over-the-counter (OTC) medications starting 
within [ADDRESS_958942] vaccination.  
24. Females who are pregna nt or lactating (i.e., a nursing mother).  
25. Acute febrile illness within 72 hours prior to vaccination, defined as the presence of a 
moderate or severe illness with or without fever (as determined by [CONTACT_705613]), or presence of a fever >38ºC orally. 
Vaccination (or administration of the second dose of vaccine) should be delayed until the 
subject has recovered. Persons with a minor illness, such as diarrhea, or mild upper 
respi[INVESTIGATOR_705526] -grade fever, may be enrolled after resolution 
of the illness.  
26. Any condition, in the opi[INVESTIGATOR_689], (such as subjects who have medically 
high-risk conditions) tha t might interfere with the primary study objectives for safety of 
the study subject.  
27. Previous exposure to M2SR  investigational  vaccine.  
28. Any active military personnel/member.  
 
Exclusions at Day 29:  
Pregnancy, receipt of a prohibited medication, or new prohibited diagnosis , including lab oratory 
confirmed influenza  and/or treatment for influenza , or high -risk condition are exclusions for 
second vaccination.  
 
Note: At  the discretion of the investigator, subjects may be rescreened; out -of-range clinical 
laboratory tests may be repeated twice , and vital signs may be repeated three times. Results of 
any retest must be available prior to enrollment.  
4.3. Lifestyle Guidelines  
No blood don ation will be  allowed until 30 days  after the second vaccination . 
Information on p rohibited th erapi[INVESTIGATOR_705537]  5.9.2 . 
FluGen, Inc.  CLINICAL STUDY PROTOCOL - FLUGEN -H3N2 -V003  18May 2020 (v8.0) 
50 CONFIDENTIAL  
 
 
 
 
 4.3.1.  Contraception  
Female subje cts are either postmenopausal (defined as without menses for at least 12 consecutive 
months without an alternative medical ), are surgically sterile, or if of childbearing potential, must 
agree to sexual abstinence or the use of a reliable m ethod of contracepti on as noted in Section  4.1.  
Non-surgically sterile male subjects who are sexually active with a female partner(s) of 
childbearing potential must also agree to use a reliable method of contraception as noted in 
Section  4.1.  
FluGen, Inc.  CLINICAL STUDY PROTOCOL - FLUGEN -H3N2 -V003  18May 2020 (v8.0) 
51 CONFIDENTIAL  
 
 
 
 
 5. TREATMENTS  
5.1. Study Vaccines  
Bris10 M2SR Vaccine:  One IP, Bris10 M2SR, is a recombinant, monovalent influenza A virus 
that was initially generated by [CONTACT_2363] a plasmid rescue system. The virus does not express an 
essential viral protein (influenza M2), restricting it to a single replication cycle in the host. 
Therefore, for production it is grown in an M2 -complementing cell line, M2VeroA. The Bris10 
M2SR also provides the HA and NA components from A/Brisbane/ 10/200 7. 
Sing2016 M2SR Vaccine : The second  IP is termed Sing2016 M2SR and is a recombinant, 
monovalent influenza A virus that was generated as described above for Bris10 M2SR. It contains 
a similar PR8 backbone but with nine amino acid changes distributed over five genes (PB1, PB2, 
PA, NP and NS1) that f acilitate growth in the production cell line, M2VeroA. The mechanism of 
attenuation (deletion of the M2 gene) is not affected. The Sing2016 M2SR also provides the HA 
and NA components from A/Singapore/INFIMH -16-0019/2016 that were recommended for the 
2018 -2019 influenza season.  
The Bris10 M2SR vaccine (Lot# [ZIP_CODE]) and the Sing2016 M2SR (Lot# [ZIP_CODE] ) for this Phase 1b 
study were manufactured using master virus stocks and working cell bank at Ology Bioservices 
(Alachua, [LOCATION_012], [LOCATION_003]) under current Good Manufac turing Practice (cGMP)  in a liquid 
formulation . The Bris10 M2SR vaccine will be provided frozen and in single -use cryovials. The 
Sing2016 M2SR vaccine will be provided frozen and in single -use cryovials. Details for IP titer 
and dilutions will be provided in the study -specific Pharmacy Manual.  
Copi[INVESTIGATOR_705538] (CoAs) of the Bris10 M2SR  and Sing2016 M2SR vaccine s 
will be provided upon request . 
A pharmacist  or designee  will thaw the vial contents to room temperature just prior to dose 
administration. The contents will be diluted to the target dosing concentration with provided SPG 
diluent for each subject. The final diluted product will be drawn into two 1 mL disposable  
polypropylene syringes each fitted with a mucosal atomization device (MAD301; Teleflex, Salt 
Lake City, Utah, US) for intranasal delivery.  
5.2. Placebo Administered in the Study  
The reference product (placebo) is a physiological saline suitable for intranasal delivery. The 
placebo will be provided as a liquid and in single -use vials. The placebo will be drawn into two 
1 mL disposable syringes ( ~50% volume  each) that are fitted with a Teleflex MAD [ADDRESS_958943] -dose restrictions will be as described for the M2SR 
vaccines .  
The placebo is a clear solution whereas the M2SR vaccine s are a light yellowish color. The 
unblinded pharmacy staff will prepare the vaccine and placebo doses, fill delivery devices and 
apply an opa que label to the device barrel to obscure any coloration of the contents and maintain 
the blind.  
Comm ercially available suppli es of the placebo  will be  used and will be suppli ed by [CONTACT_705614] . 
FluGen, Inc.  CLINICAL STUDY PROTOCOL - FLUGEN -H3N2 -V003  18May 2020 (v8.0) 
[ADDRESS_958944] s and for the SPG -NaCl buffer is a 2 mL cryovial 
with a threaded cap closure. The vaccine and buffer  will be  labeled according to lo cal law and 
regulatory requirements. Each vial label will include the following information: product  name , 
item and lot numbers, date of manufacture, storage condition, volume, vial number, manufacturer , 
and “Caution : New Drug – Limited by [CONTACT_336820] .” The vial label for the 
vaccine is a light-blue label with black text and for the SPG -NaCl buffer is a white  label with black 
text. Sample vial labels are shown in Figure  1. 
The vaccine and buffer v ials will be packed into separate multi -vial boxes. Each box will be labeled  
with the following information: product name, item and lot numbers, storage conditio n, vial 
number range  and volume, manufacturer and  “Caution : New Drug – Limited by [CONTACT_336821] .” The box label for the vaccine will be a light-blue label with black text and 
for the buffer will be a white  label with black text.  
FluGen, Inc.  CLINICAL STUDY PROTOCOL - FLUGEN -H3N2 -V003  18May 2020 (v8.0) 
53 CONFIDENTIAL  
 
 
 
 
 Figure  1: Sample labels for drug product and SPG -NaCl buffer.  
 
5.3.2.  Placebo  
The placebo is a commercially available physiological saline that will be supplied in single -use 
containers. The 0.9% sodium chloride for injection, USP, is a sterile, nonpyrogenic, isotonic 
solution of sodium chloride and water for injection. It is preservative -free and supplied in a 
single -dose container. The pharmacist  or designee will aseptically fill placebo into the delivery 
devices on an as needed basis. A CoA will be provided for the placebo.  
5.4. Storage and Drug Accountability  
The Investigator (or designee) is responsib le for the safe storage of all stu dy drugs assigned to the  
clinical site, in a  locked, secure storage facility with access limit ed to those  individu als authorized 
to disp ense the study drugs and  maintained within the appropriate ranges of temperature. All stu dy 
drugs must be  stored as specified at delivery and in the  original packaging. Instructions for the 
storage and handling  of the study drugs will also be  provided to the  clinical site. 
5.4.1.  Vaccine s 
The M2SR vaccine product s and the SPG -NaCl buffer will be delivered frozen and must be 
stored frozen at < -65°C in the provided multi -vial boxes. Each vaccine vial is a single -use vial. 
Once the vial contents have been thawed, the vial must be stored at 2 -8°C prior to use in vacci ne 
administration. The thawed vial contents wi ll remain stable in the Sponsor -identified cryovials, 
neat or diluted with SPG -NaCl buffer, for up to [ADDRESS_958945]  
Item #.: 10 -0002305 Lot #.: XXXXXXX  
DOM: DDMMMYYYY Store at  ≤ -65°C  
Volume: 0.5 mL Vial # XYZ  
Manufactured by [CONTACT_705615], Inc.  
Caution: New Drug -Limited by [CONTACT_705616]2016  M2SR Drug Product  
Item #.: 10-0004082  Lot #.: XXXXXXX  
DOM: DDMMMYYYY Store at ≤ -65°C  
Volume: 0.5 mL Vial # XYZ  
Manufactured by [CONTACT_705615], Inc.  
Caution: New Drug -Limited by [CONTACT_705617] -NaCl Diluent  
I/N: 10 -0001613 L/N: XXXXXXX  
DOM: DDMMMYYY Store at ≤ -65°C  
Vial# XYZ Volume: 0.5 mL  
Manufactured by [CONTACT_705615], Inc . 
Caution: New Drug - Limited by [CONTACT_705618], Inc.  CLINICAL STUDY PROTOCOL - FLUGEN -H3N2 -V003  18May 2020 (v8.0) 
54 CONFIDENTIAL  
 
 
 
 
 thawed and held at 2 -8°C for longer than [ADDRESS_958946] Operating Procedures ( SOPs ) and a certificate of 
destruction , or equivalent  should be filed on site and provided to the Sponsor for internal filing.   
Each SPG -NaCl buffer vial is a single -use vial. Once the vial contents have been thawed, the 
vial must be stored at 2 -8°C prior to use in treatment administration. The thawed vial contents 
will remain stable in the Sponsor -identified cryovials for up to [ADDRESS_958947] that 
has been thawed and held at 2 -8°C for longer than [ADDRESS_958948] be readily available for inspection by [CONTACT_68601]/or auditor, and open 
to regulatory inspections at any time.  
As mis allocations of  study  drugs may have a detrimental effect on subj ects’ safety and/or the study 
drugs’ efficacy and are a potential sou rce of bias, utmost care should be  taken to correctly dispense 
the study drugs as assigned by [CONTACT_705619] . 
The vaccine and placebo  should be  dispensed und er the supervision of  the Investigator, a qualified 
member of the clinical staff, or by a hospit al/clinic pharmacist or designee . The  pharmacist  or 
designee must m aintain accurate records demonst rating date and amount of  vaccine and the 
placebo  suppli ed to whom and by [INVESTIGATOR_412937]. The investigational vaccine and placebo will be  suppli ed 
only to sub jects participating in the  study. 
The Sponso r’s designated study  monitor  will p eriodically check the  suppli es of vaccine and the 
placebo  held by [CONTACT_96928]/designee  to ensure accountability and appropriate 
storage conditions of  all vaccine and placebo  used. 
Unus ed vaccine and placebo  must be available for verification by [CONTACT_705620]-site 
monito ring visits. A ny dis crepancies between returned and expected returned vaccine and placebo  
should be explained and do cumented. 
After the database has been locked  and all on -site drug accountability has been completed by [CONTACT_36102], any unus ed vaccine (including neat and diluted remnants) may be returned to the  Sponso r 
or destroyed at the clinical site  with the  Sponso r’s written permission (in this case a certificate of 
destruction or equivalent  will be  provided and filed in the  electronic Trial Master File [eTMF]). 
Hazardous m aterials su ch as used ampoul es, needles, syringes and vi als containing h azardous 
liquids, should  be dispos ed of immediately in a safe manner and therefore will not be  retained for 
drug accountability purposes. 
FluGen, Inc.  CLINICAL STUDY PROTOCOL - FLUGEN -H3N2 -V003  18May 2020 (v8.0) 
55 CONFIDENTIAL  
 
 
 
 
 5.4.2.  Placebo  
Each placebo cartridge is a single -use container. The solution will be stored at USP controlled 
room  temperature (20 – 25°C) prior to use in treatment administration. The contents may be used 
up to the date of expi[INVESTIGATOR_705539].  
Procedures for handling and sto rage of the commercially available placebo a re detailed on the  
product -specific labels. 
5.5. Randomization  
Subjects will be  assigned to IP ( M2SR vaccine s or saline) using a permuted block design. The  
randomization li st will be p repared prior to stu dy start by [CONTACT_2728]’s statistician and shared with 
the unblinded pharmacist  or designee . This treatment assignment list is to be treated as a 
controlled document and is not to be shared with other blinded  personnel.  Eligible subjects will 
be randomized to receive two administrations 28 days apart of Sing2016 at three dose levels, 
Bris10 at o ne dose level, or placebo in a 1:1:1:1:1 ratio . Approximately 15 subjects will be 
vaccinated  at a time  in up to 3  sentinel groups , and approximately 41 subjects will be vaccinated 
in  expansion groups . 
5.6. Blinding  
The blind will be maintained during this trial, including use of  the following measures:  
(1) All subjects, whether receiving a M2SR vaccine or placebo, will undergo the same 
procedures, i.e., administration, AE assessment , blood collections, nasal swabs, etc.  
(2) The unblinded pharmac ist or designee  will prepare doses (active and placebo), fill 
delivery devices and apply an opaque label to the device barrel to obscure any 
coloration of the contents.  
(3) The unblinded site staff and unblinded study monitor  will agree to maintain the blind 
by [CONTACT_705621] (active or placebo) to any blinded clinic staff 
including the Investigator  and to study subjects . Furthermore, the unblinded individuals 
will be restricted from participating in other study procedures  the interpretation of  
which could be impacted by [CONTACT_705622], such as  evaluation of  AEs. 
(4) If any blinded investigational site staff learn of treatment assignments, a record of the 
event will be maintained,  and the investigator will be informed. The investigator will  
consult with FluGen on how to preserve the blind.  
With the exception of the unblinded statistician who generates the randomization list , the 
unblinded pharmacist (s) or their designee (s) who prepare the study product for administration  and 
the unblinded study monitor who may observe the study product preparation and performs IP 
accountability , all subjects, the Investigator, statistic al programmers  and all clinical site staff will 
be blinded to IP treatment (vaccine or placeb o). All clin ic staff who may be involved in making 
assessments of safety (including local reactions ) will be blinded to treatment. Should a blinded 
monitor observe study product preparation, precautions must be taken to maintain the blind.  
Masking of the IP (vaccine o r placebo) will be described in the Pharmacy Manual.  
FluGen, Inc.  CLINICAL STUDY PROTOCOL - FLUGEN -H3N2 -V003  18May 2020 (v8.0) 
56 CONFIDENTIAL  
 
 
 
 
 The randomization schedule will be inaccessible to the Investigator or to the blinded study team 
(monitors and/or FluGen team) during the study. After the Day [ADDRESS_958949] dosages and in the event of an emergency 
code break (see below).  
In the event of a medical emergency wherein knowledge of the IP treatment assignment will 
influence the subject's care, the Principal Investigator (PI)  may be provided with the IP treatment 
assignment  for that subject , at the discretion of the PI . The unblinded pharmacist or their designee  
will use the IP treatment assignment code to break the blind for the PI  [INVESTIGATOR_705540]. 
The PI [INVESTIGATOR_705541], and no later than [ADDRESS_958950]’s paper  source . Subjects 
who are unblinded for any reason during their participation in the study will not be replaced and 
will be withdrawn immediately from the stud y; however, all attempts will be made to collect safety 
data through [ADDRESS_958951] -dose of the vaccine/placebo . In the event of a request to break a 
treatment code, the study monitor will be notified within 24 hours and the rationale for breaking 
the code w ill be documented.  
5.7. Dose and Administration  
5.7.1.  Vaccine  
A rationale for the doses of vaccine  selected in this stu dy is provided in Section  3.5.2 . 
Subjects will be  randomly  and sequentially assigned, according to the  randomization s chedule and 
in a blind ed fashion, to one  of 3 IP treatments: i. e., vaccine or placebo.   
Each vaccine and placebo dose will be filled into a sterile 1 mL polypropylene syringe that is 
fitted with a Teleflex MAD 301 sprayer for  intranasal delivery ( Figure  2) by [CONTACT_705623] .  
Figure  2: Image of the MAD [ADDRESS_958952] awn into the syringe barrel via a n 18-gauge needle . The 
needle  is removed and replaced with the MAD301  sprayer  via a Luer lock fitting. The spray device 

FluGen, Inc.  CLINICAL STUDY PROTOCOL - FLUGEN -H3N2 -V003  18May 2020 (v8.0) 
[ADDRESS_958953]’s ID on the label. The clinic al staff credentialed to administer 
vaccines will then use the masked, filled spray device to administer the dose (active or placebo) 
intranasally to the subject.  
For delivery, on each of Days 1 and 29, subjects will receive a s ingle intranasal dose of vaccine 
(or placebo) via a MAD 301 spray device. Subjects will be in a semi -recumbent position and 
receive approximately two administrations of ~50 % volume per nasal cavity by [CONTACT_18120]  [ADDRESS_958954] -dose to allow calculation of dose eliminated from 
the devices. Subjects will remain semi -recumbent and under observation  for thirty (3 0) minutes  
and will not be allowed to blow their noses, eat, or drink during this time ; any deviations are 
captur ed in the source documents  and reported to the study  monitor /Clinical Project Manager . 
Any deviation from the  dose defined in the  protocol must be  documented on source and in the 
eCRF  system . 
5.8. Treatment Compliance  
Monitoring treatment compliance is not applicable because treatment will be administered per 
protocol in the clinic by [CONTACT_3462].  
5.9. PRIOR AND CONCOMIT ANT THERAPY 
The use of concomitant therapi[INVESTIGATOR_705542] a  minimum th roughout the  study. All th erapi[INVESTIGATOR_705543] (prescriptions and ov er-the-counter medications) , other than the  vaccine , from 
informed consent until the  day [ADDRESS_958955] be  recorded in the sou rce documents and in the  
concomitant therapy section of  the Electronic Case Report Form ( eCRF) (name [CONTACT_18467], dosage, 
route and dates of administ ration). 
In the event that medical conditions after study treatment dictate use of medications, subjects are 
encouraged to obtain adequate care, comply with the course of therapy as prescribed by [CONTACT_153155], and  inform the Investigator as soon as practical.  
The Sponsor  must be  notified in advance (or as soon as possible  thereafter) of any inst ances in 
which prohibited therapi[INVESTIGATOR_705544] a study subject . 
Female subjects of childbearing potential and non-vasectomized male subjects having a female 
partner of childb earing potential must agree to the  use of an effective method of contraception 
throughout the study, as outlin ed in Section  4.1. The  use of oral, inj ectable, and impl antable 
hormonal contraceptives is to be  recorded in the  source documents and in the  concomitant therapy 
section of  the eCRF. 
5.9.1.  Permitted Concomitant Therapi[INVESTIGATOR_705545] 1: 
• Non-steroidal anti -inflammatory drugs (NSAIDs), acetaminophen, or 
antihistamines may be used after dosing if the subject ha s a fever ≥ 38.0C (100 .4F) 
FluGen, Inc.  CLINICAL STUDY PROTOCOL - FLUGEN -H3N2 -V003  18May 2020 (v8.0) 
[ADDRESS_958956] has significant nasal pain, myalgia, or headache. NSAIDs or 
acetaminophen should only be taken after documentation of symptoms or fevers on 
the Symptom Memory Aid and should not be taken prophylactically . 
• Low-dose aspi[INVESTIGATOR_248]  
5.9.2.  Prohibited Concomitant Therapi[INVESTIGATOR_705546] 7 days prior to each vaccination  and 
continuing until 7 days after each vaccination:  
• Concomitant use of any new prescription  or over-the-counter (OTC) m edications  
(except for contraceptive pi[INVESTIGATOR_3353], implants, transdermal or injections)  
Any medication th at is not covered by [CONTACT_705624] -permitted medication s ections can be 
allowed at the discretion of  the Investigator and documented on eCRF . 
FluGen, Inc.  CLINICAL STUDY PROTOCOL - FLUGEN -H3N2 -V003  18May 2020 (v8.0) 
59 CONFIDENTIAL  
 
 
 
 
 6. ASSESSMENTS 
6.1. Timing of Assessments 
An ov erview of the timing  of treatment(s) and assessments is given in the  Schedule of Events  
(Table  3). Details of safety and efficacy  assessments are provided in Section  6.2.1  through 
Section  6.2.3 , and Section  6.2.4 , respectively.  
When  visit assessments are planned at the same time point in the  study, the order of assessments 
should be  in order of less invasive to more invasive. For example, during the randomization visit, 
vitals, medical history, pregnancy testing and drug testing should be conducted before blood work 
and subsequent nasal swab.  
FluGen, Inc.  CLINICAL STUDY PROTOCOL - FLUGEN -H3N2 -V003 
 18May 2020 (v8.0) 
CONFIDENTIAL 60  
 
 Table  3: Schedule of Events  
Study Visit Number  V00 V01 V02 V03 V04 V05 V06 V07 V08 
Early 
Term7 Study Day  
Post-First Dose  Days -30 
to -1 Day 1  Day 4  
±1 Day 8 
±1 Day 29 
+/- [ADDRESS_958957]-Second Dose      D1 Day 4  
±1 Day 8  
-1/+7 Day 29  
+/-7 D181 
+/-14 
Informed Consent  X          
Inclusion/ Exclusion  X X2   X2      
Demography  X          
Physical e xam X1         X8 
Limited physical exam10  X2,4  X X2,4  X X X X9 
Medical/medication history  X X2   X2      
Vital sign s (height, weight, BP, HR , temp)16 X X2, 4  X X2, 4  X X X X8 
Pregnancy testing ( urine ) X X3   X3      
Hematology6 X X2,5  X X  X   X13 
Chemistry6 X X2,5  X X  X   X13 
Urinalysis  (dipstick)  X X2, 5  X   X   X13 
Urine Drug Screen  X          
Serology for HIV, Hep B & C  X          
Symptom Me mory Aid 11  X  X X  X   X 
Scripted p hone call with site to report 
symptoms    X   X     
Assessment for influenza19  X X X X X X X   
Serum collection (HAI, MN, NAI and 
ELISA)  X X2  X X2  X X X X 
PBMC collection (CMI)  & plasma18  X2, 15 X17 X15 X2, 15 X17 X15 X  X 
Nasal swab for secretory IgA immune 
response and/or vaccine virus detection  X12 X2, 9, 
12,14  X9, 12 X2, 9, 12  X9, 12 X12 X12 X9, 12  
Dose admin istration   X   X      
Device Weights   X   X      
AEs  X4 X X X2,4 X X X  X 
Conmeds  X X2 X X X2 X X X  X 
SAEs and medically attended AEs  X X X X X X X X X X 
 
1Complete Physical is required; neurological, rectal and gynecological exams do not need to be performed unless clinically indicated  
FluGen, Inc.  CLINICAL STUDY PROTOCOL - FLUGEN -H3N2 -V003 
 18May 2020 (v8.0) 
CONFIDENTIAL [ADDRESS_958958] be negative and reviewed prior to dosing 
4At 5 (+/- 1) and 30 (+/- 3) min after dosing  
[ADDRESS_958959] does not complete the study within 28 days after dose administration  
8Limited physical exam and vital sign evaluations will be completed if early termination occ urs within 28 days after dose administration  
9Sample aliquoted for vaccine virus detection (qPCR & infectivity)  
10 Specifically includes the nares (including edema), throat, and lungs (including evaluation for wheezing). A targeted physical  examination may  be performed on other 
body systems if indicated based on review of interim medical history or subject symptoms as observed by [CONTACT_705625].  
11 Dispense/Review/Collect for [ADDRESS_958960]’s arm after the subject has be en at rest ( seated or semi -recumbent ) for approximately [ADDRESS_958961] mmHg . Height and weight will be measured only at the screening vi sit. 
17 Optional PBMC collection (Days 4 and 32) at select sites  based on subject consenting  on Day 4 and/or Day [ADDRESS_958962] sites  for ~160 subjects  
19 During the treatment period (Day 1 – Day 57), subjects will be asked to notify the site immediately if symptoms of influenza (fever, chills, sore throat, rhinorrh ea, 
cough, muscle/body aches) occur. Subjects will be reminded at every scheduled visit and ph one call, and in addition to visit s and calls scheduled above  (when  increased 
influenza infections are being reported in the geographic region of the investigational site)  will be contact[CONTACT_705579] 15±2, 21±2, 43±2, and 50±[ADDRESS_958963] will be asked to return to the site for laboratory confirmation of influenza using nasa l swabs.  
20 Due to the COVID -19 pandemic , local governments may issue stay -at-home orders which prevent centers from conducting on -site Day 209 visits. This protocol allows 
for Day 209 visit to be a safety follow -up phone call.  
 
62 CONFIDENTIAL  
FluGen, Inc.     CLINICAL STUDY PROTOCOL – FLUGEN -H3N2 -V003   18May 2020 (v8.0) 
 
 
 6.1.1.  Screening Period 1 (Days  -30 to Dosing ) 
In a private , individual  setting, s ubjects will be  given a full explanation of  the nature of the study 
and written informed consent (IRB approval will be  obtained before any study-related assessment) 
will be  carried out.  Group consenting will not be permitted  and subjects requiring a Legal ly 
Authorized Representative may not participate in this study .  
Screening for eligible and consenting  subjects will be  performed within approximately 30 days 
prior to randomi zation/IP administration .  
Subjects may be consented and screened for serosusceptibility under a site-specific  IRB-approved 
ICF.  
At screening, subj ects will be  asked to attend the  clinical site  to have assessments p erformed as 
indicated in the Schedule of Events  (Table  3). 
All results from the  screening procedure needed to evaluate eligibility, including the clinical 
laboratory results, must be  available prior to study vaccination  on Day 1. Any abnormal assessment 
at the screening visit will be  assessed acc ording to its clinical relevance, and if  found clinically 
significant , the subject will n ot be included in the  study. 
During the screening period, the following procedures and assessments will be carried out for each 
subject to determine their eligibility  for participation in the study:  
• Obtain informed consent prior to any procedures being performed  
• Record demographics  
• Confirm eligib ility criteria for enrollment and vaccination  
• Obtain medical history  
• Record concomitant medications  
• Perform c omplete physical examination (neurological, rectal and gynecological exams do 
not need to be performed unless clinically indicated)  
• Vital signs (height, weight, blood pressure, heart rate, and temperature)  
• Collect urine  for drug  screen  
• Collect urine  for pregnancy test ( applicable females only)  
• Collect blood for serology for HIV, Hep atitis  B & HCV 
• Collect blood for serum chemistry and he matology  
• Collect blood for immunogenicity assays  
• Urinalysis (dipstick)  
• Perform nasal swab  
• Record any concomitant therapy/ medically attended AEs/SAEs after signing of consent  
Unscheduled visits m ay be planned to assess, confirm, and follow -up on out-of-range clinical 
laboratory test, or vital sign values that determine  a subject’s eligibility, or in case of a positive  
63 CONFIDENTIAL  
FluGen, Inc.     CLINICAL STUDY PROTOCOL – FLUGEN -H3N2 -V003   18May 2020 (v8.0) 
 
 
 urine drug screen. The result of the retest will be  considered for subj ect eligibility. Findin gs made 
during unscheduled visits should be  reported in the  eCRF system . 
A record of the number of screening failures and the reasons for screening failure will be captured 
in eCRF , but subj ects who fail screening and are not enrolled will  not otherwise be in cluded in the  
database. The failure details will be  documented in the  subjects’ study  file. 
6.1.2.  Treatment Period (Day 1 to Day 57) 
Assessments will be  performed as indi cated in the Schedule of Events  (Table  3). 
[IP_ADDRESS].  Day 1  
• Update medical  history  
• Vital signs (blood pressure, heart rate, and temperature)  
• Collect urine for pregnancy test (applicable females  only)  
• Collect blood for serum chemistry and  hematology  
• Urinalysis  (dipstick)  
• Review of inclusion and exclusion criteria  
• Collect pre -dose blood sample for humoral immunogenicity assays (baseline MNT and 
other serum  assays)  
• Collect pre -dose blood sample (PBMC) for cellular immunogenicity assays (ELIS pot) 
and/or innate transcriptome gene expression – select sites  only 
• Collect  pre-dose blood  sample  (plasma)  for cytokine  expression  – only if PBMC  collected 
by [CONTACT_3725] 
• Perform limited physical  examination  
• Nasal swab into buffer for mucosal IgA and virus  shedd ing 
• Symptom  Memory  Aid (distribute  and provide  instructions,  fill out form  pre-dose to train 
subject on  execution)  
• Randomization  
• Device weights (pre - and post -IP administration)  
• IP administration  
• Record concomitant therapy  prior to dosing  
• Record AEs/SAEs  at 5 (+/- 1) and 30 (+/- 3) min after dosing  
[IP_ADDRESS].  Day 4 ± 1 day  
• Optional on -site visit for collection of blood sample (PBMC  and plasma ) for innate 
transcriptome gene expression  – select sites only  
• If subject does not attend on -site visit, s cripted p hone call with site to report symptoms  (if 
unable to reach subject then email or SMS is acceptable)  
64 CONFIDENTIAL  
FluGen, Inc.     CLINICAL STUDY PROTOCOL – FLUGEN -H3N2 -V003   18May 2020 (v8.0) 
 
 
 • Record concomitant therapy/AEs/SAEs  
[IP_ADDRESS].  Day 8 ± 1 day  
• Perform  limited physical examination  
• Vital signs (blood pressure, heart rate, and temperature)  
• Collect blood for serum chemistry and hematology  
• Urinalysis (dipstick)  
• Symptom Memory Aid reviewed  
• Nasal swab into buffer for mucosal IgA and virus shedding  
• Collect blood sample for humoral immunogenicity assays (MNT and other serum assays)  
• Collect blood sample (PBMC) for cellular immunogenicity assays (ELISpot)  and/or innate 
transcriptome gene expression – select sites only  
• Collect blood sample (plasma) for cytokine  expression – only if PBMC collected by [CONTACT_3725]  
• Record concomitant therapy/AEs/S AEs 
[IP_ADDRESS].  Day 29 ± 7 days  
• Confirm eligibility for second vaccination  
• Update medical  history  
• Vital signs (blood pressure, heart rate, and  temperature)  
• Collect urine pre -dose for pregnancy test (applicable females  only)  
• Collect blood for serum chemistry and  hematology  
• Perform  limited  physical examination  
• Nasal swab into buffer for mucosal IgA and virus shedding  
• Collect pre -dose blood sample for humoral immunogenicity assays (MNT and other serum 
assays)  
• Collect pre -dose blood sample (PBMC ) for cellular immunog enicity assays (ELISpot)  – 
only by [CONTACT_705626]  
• Collect pre -dose blood sample (plasma) for cytokine  expression – only if PBMC collected 
by [CONTACT_3725]  
• Symptom Memory Aid (distribute and provide  instructions)  
• IP administration  
• Device weights (pre - and post-IP administration)  
• Record concomitant therapy/AEs/SAEs  prior to dosing and at 5 (+/- 1) and 30 (+/- 3) 
min after dosing  
65 CONFIDENTIAL  
FluGen, Inc.     CLINICAL STUDY PROTOCOL – FLUGEN -H3N2 -V003   18May 2020 (v8.0) 
 
 
 [IP_ADDRESS].  Day 32 ( 3 days ± 1 day after second dose)  
• Optional on -site visit for collection of blood sample (PBMC and plasma) for innate 
transcriptome gene expression – select sites only  
• If subject does not attend on -site visit, scripted phone call with site to report symptoms (if 
unable to reach subject then email or SMS is acceptable)  
• Record concomitant therapy/AEs/SAEs  
[IP_ADDRESS].  Day 36 (7 days -1/+7 day after second dose)  
• Perform limited physical examination  
• Vital signs (blood pressure, heart rate, and temperature)  
• Collect blood for serum chemistry and hematology  
• Urinalysis (dipstick)   
• Symptom Memory Aid reviewed  
• Nasal swab into buffer for mucosal  IgA and virus shedding  
• Collect blood sample for humoral immunogenicity assays (MNT and other serum assays)  
• Collect blood sample (PBMC ) for cellular immunogenicity assays (ELISpot)  – only by 
[CONTACT_705626]  
• Collect blood sample (plasma) for cytokine  expression – only if PBMC collected by [CONTACT_3725]  
• Record concomitant therapy/AEs/SAEs  
[IP_ADDRESS].  Day 57 (28 days ± 7 days after  second dose ) 
• Perform  limited  physical examination  
• Vital signs (blood pressure, heart rate, and temperature)  
• Nasal swab into buffer for mucosal I gA and virus shedding  
• Collect blood sample for humoral immunogenicity assays (MNT and other serum assays)  
• Collect blood sample (PBMC) for cellular immunogenicity assays (ELISpot)  – only by 
[CONTACT_705626]  
• Record concomitant therapy/AEs/SAEs  
[IP_ADDRESS].  Day 209 (180 days ± 14 days after second dose) - on-site visit  
• Perform limited physical examination  
• Vital signs (blood pressure, heart rate, and temperature)  
• Nasal swab into buffer for mucosal IgA and virus shedding  
• Collect blood sample for humoral immunogenicity ass ays (MNT and other serum assays)  
• Record SAEs  
66 CONFIDENTIAL  
FluGen, Inc.     CLINICAL STUDY PROTOCOL – FLUGEN -H3N2 -V003   18May 2020 (v8.0) 
 
 
 Due to the COVID -19 pandemic , local governments may issue stay -at-home orders which prevent 
centers from conducting on -site Day 209 visits. This protocol allows for the Day 209 visit to be a 
follow -up phone call  focusing on the following safety points:  
• Has the subject received  any licensed vaccines since Day 1 of the trial?  
• Has the subject received  any investigational product (other than study IMP/placebo) since 
Day 1?  
• Has the subject had any SAEs or medically at tended AEs  since the last contact [CONTACT_705627]? 
6.1.3.  Testing for Influenza  
During the treatment period (Day 1 – Day 57), when  increased influenza infections are being 
reported in the geographic region  of the investigational site , subjects will be  asked to notify the 
site immediately if they experience symptoms of influenza (fever, chills, sore throat, rhinorrhea, 
cough, muscle/body aches). If influenza is suspected the subject will be asked to return to the site 
and will have nasal swabs collected for laboratory confirmation of influenza. Subjects will be 
reminded at every scheduled visit and phone call, and in addition to visits and calls scheduled  
above, will be contact[CONTACT_705579] 15 ±2, 21 ±2, 43 ±2, and 50 ±[ADDRESS_958964] performed and may be treated for influenza at the 
investigator’s discretion.   
6.1.4.  Early Termination Visit  
Subjects who withd raw consent will be asked to attend the clinic for safety evaluation as described 
in Early Termination assessments . 
Early Termination assessments should be completed within 7 (±  3) days of discontinuation for 
subjects who discontinue from the study . The following ass essments are to be p erform ed: 
• Complete physical examination (neurological, rectal and gynecological exams do not need 
to be performed unless clinically indicated) ; a limited physical exam will be completed if 
early termination occurs within 28 days after d ose administration  
• Vital signs (height, weight, blood pressure, heart rate, and temperature)  
• Collect blood for serum chemistry and hematology  
• Urinalysis (dipstick)  
• Symptom Memory Aid  
• Nasal swab into buffer for mucosal IgA and virus shedding  
• Collect blood sample for humoral immunogenicity assays (MNT and other serum assays)  
• Collect blood sample for cellular immunogenicity assays (PBMC, ELISpot)  – only for 
select sites  
• Collect blood for gene  expression (PBMC, plasma)  – only for select sites  
• Record concomitant therapy/AEs/SAEs  
67 CONFIDENTIAL  
FluGen, Inc.     CLINICAL STUDY PROTOCOL – FLUGEN -H3N2 -V003   18May 2020 (v8.0) 
 
 
 6.1.5.  Unsch eduled Visits 
Unscheduled visits can be planned: 
− To obtain addition al information to ensure safety to the  subject. Addition al blood and urine 
samples may be taken at the discretion of the Investigator. 
− To obtain a nasal swab for assessment of potential influenza infection.  
−  To assess, confirm, and follow-up on out -of-range clinical laboratory test, or vital sign 
values that will d etermine  a subject’s eligibility, or in case of a positive  drug screen. 
− The result of  the retest will be  consid ered for subject eligibility. 
Findin gs made during unscheduled visits should be  reported in the  eCRF . 
6.2. Study Assessments  
6.2.1.  Clinical Evaluations  
[IP_ADDRESS].  Medical History  
A complete medical history will include a review of all major body systems. Significant past and 
present medical history will be obtained by [CONTACT_705628].  
[IP_ADDRESS].  Concomitant Medications  
Details of prescription and over -the-counter medicat ions (including vitamins) currently used will 
be recorded during the screening visit. Concomitant medications will be reviewed at each visit and 
any new medications will be documented on the eCRF.  
[IP_ADDRESS].  Demographics  
Demographics will be obtained during screening only. Demographics will include the age and race 
as described by [CONTACT_423].  
[IP_ADDRESS].  Physical Examination  
[IP_ADDRESS].1.  Complete Physical Examination  
A complete physical examination will be performed for each subject at the time points specified 
in the Schedule of Events (Table  3). The examination will consist of assessment of the following 
organs/systems:  
• Head  
• Eyes  
• Ears, nose, throat  
• Neck  
• Cardiovascular  
• Chest  
68 CONFIDENTIAL  
FluGen, Inc.     CLINICAL STUDY PROTOCOL – FLUGEN -H3N2 -V003   18May 2020 (v8.0) 
 
 
 • Respi[INVESTIGATOR_696]  
• Abdomen  
• Genitourinary – only if clinically ind icated  
• Extremities  
• Musculoskeletal  
• Nervous system – only if clinically indicated  
• Dermatological  
• Other conditions of note  
[IP_ADDRESS].2.  Limit ed Physical Examination  
A limit ed physical exam will be performed for each subject at the time points specified in the 
Schedule of  Events (Table  3). The examination will include the nares (including edema), throat, 
and lungs (including evaluation for wheezing). A targeted physica l examination may be performed 
on other body systems if indicated based on review of interim medical history or subject symptoms 
as observed by [CONTACT_705625] .  
[IP_ADDRESS].  Vital Signs  
Vital signs include height, weight, oral temperature (°C), blood pressure (mmHg), pu lse rate (beats 
per minute) . Vital signs will be obtained at the time points specified in the Schedule of Events 
(Table  3). Subjects should have weight and height measured while wearing light street clothing 
and with shoes off. Blood pressure will be measured from the subject’s arm after the subject has 
been seated or semi -recumbent  for approximately [ADDRESS_958965] mmHg.  
[IP_ADDRESS].  Symptom Memory Aids  
Subjects will be asked to record post -treatment symptoms in a  Symptom Memory Aid  
(Appendix  5) at the time points specified in the Schedule of Events (Table  3) for reactogenicity . 
At time of first dose, t he first entries will be in concert with study staff as a training session at  pre-
dose, the second entry will be the evening of vaccination and subsequent 6 entries  will be made  
each evening following the IP delivery . Since visit Day 36 may occur ± [ADDRESS_958966] diaries will be retained as s ource 
documents.  
Events that are re ported  in the Symptom Memory Aid  will be reviewed by [CONTACT_705629] ( Appendix 1  for vital 
signs and systemic AEs  and Appendix 3  for reactogenicity assessments ). During this time, subjects 
are asked to take their oral temperature (at approximately the same time each evening using the 
thermometer provided to them  by [CONTACT_779] ) and record it in the Symptom Memory Aid . Any 
medications taken by [CONTACT_705630]. In addition, 
69 CONFIDENTIAL  
FluGen, Inc.     CLINICAL STUDY PROTOCOL – FLUGEN -H3N2 -V003   18May 2020 (v8.0) 
 
 
 subjects will be asked to record symptoms they may be experiencing during this time period, 
including:  
• Feverish  
• Nasal irritation  
• Nasal bleeding  
• Runny nose  
• Stuffy nose/Congestion  
• Sore/scratchy/itchy or painful throat  
• Body/muscle aches  
• Joint pain  
• Headache  
• Cough  
• Body rash  
• Tiredness  
• Nausea  
• Vomiting  
• Other symptoms  
 
[IP_ADDRESS].  Urine Samples  
Urine samples for the determination of  pregnancy  for women of childbearing potential , drug  
screening, and urinalysis will be collected at the time points specified in the Schedule of Events 
(Table  3). 
A midstream urine sample will be collected for urinalysis by [CONTACT_705631], pH, 
glucose, protein, ketones, bilirubin, urobilinogen, nitrite, leukocyte esterase, and occult blood. If 
dipstick urinalysis is abnormal, microscopic examination for WBC, RBC, and epi[INVESTIGATOR_705547] . Crystals, casts, and bacteria will only be reported if present . 
A urine drug of abuse screen will be performed.  
6.2.2.  Bioanalysis 
Blood  and urine samples for determination of  the concentration of analytes specified in 
Appendix  [ADDRESS_958967] any change 
occurring during the  study he consid ers to be  clinically relevant in the  AE section in the  EDC  
system. Laboratory values outside  the normal range will be  flagged and their clinical relevance as 
70 CONFIDENTIAL  
FluGen, Inc.     CLINICAL STUDY PROTOCOL – FLUGEN -H3N2 -V003   18May 2020 (v8.0) 
 
 
 an AE will be assessed by [CONTACT_737]. Laboratory values which are Grade  3 or higher based 
on the grading scales in Appendix  2 will be reported to the Sponsor within 24 hours  of 
investigator awareness , and assessment of clinical relevance will be reviewed by [CONTACT_22955].   
The laboratory analysis will be  carried out following  the principles of Good Laboratory Practice 
(GLP) regulations.  
6.2.3.  Adverse Eve nts 
Adverse events will be  monito red continuous ly from first administration  of IP treatment until study  
Day 57. At regular intervals du ring the study, subj ects will be  asked non -leading questions to 
determine  the occurrence of any AEs. All AEs  reported spont aneously during the course of the 
study will be recorded as well. Solicited and unsolicited signs and symptoms will be reported as 
AEs after review by [CONTACT_18370], either separately using the corresponding 
Medical Dictionary for Regulatory Activities (MedDRA) terminology of the sign or symptom or 
combin ed using the appropriate term. For example, a subject who experiences dysuria with blood, 
WBCs, and bacteria in the urine would be recorded as having a urinary tract infection.  
For detailed definitions and reporting procedures of AEs, s ee Section  9. 
6.2.4.  Efficacy Evaluations  
[IP_ADDRESS].  Nasal Swabs  
Nasal swabs will be collected from subjects for the following purposes:  
1. To determine mucosal immunity  
2. To test for t he presence of shedding influenza virus  
3. To test for the presence of respi[INVESTIGATOR_4451]  (Optional)  
Nasal swabs will be collected at the time points specified in the Schedule of Events (Table  3) from 
all subjects. Individual  swabs will be collected from each nostril and combined into a single vial 
of media. Samples will be aliquoted to use in various tests.  
To evaluate mucosal immunity, an ELISA -based test will be used to measure 1) mucosal IgA 
antibody titer to HA  and 2 ) total IgA concentration   
To detect shedding influenza virus, a quantitative H3N2 RT -PCR  assay will be used. Only swabs 
that have a positive qRT -PCR test result will be subjected to quantitative infectious  culture assay.  
Possible infection with respi[INVESTIGATOR_705548] a qualitative 
PCR test . This multiplex ed assay will be performed  by [CONTACT_2363]  a commercial, qualitative viral and 
bacterial upper respi[INVESTIGATOR_705549] (adventitious agent screening).  
If a subject presents within 7 days of vacci nation with symptoms of fever, upper respi[INVESTIGATOR_76100], 
nephritis/cystitis, conjunctivitis or diarrhea, regardless of the severity of the symptoms, an 
additional nasal swab (s) should be collected and/or analyzed outside of the defined time points.  
71 CONFIDENTIAL  
FluGen, Inc.     CLINICAL STUDY PROTOCOL – FLUGEN -H3N2 -V003   18May 2020 (v8.0) 
 
 
 [IP_ADDRESS].  Delivery Device Weights  
The weight of each IP-filled device will be collected prior to dose administration and the weight 
recorded in the eCRF  at the time point specified in the Schedule of Events (Table  3). Following 
administration  of the dose (active and placebo ) the actuated device will again be weighed,  and the 
weight recorded in the eCRF. A calculation of the filled device weight minus the  emptied device 
weight will indicate the weight of dose that was delivered from the device and will be used to 
determine volume dispensed.  
[IP_ADDRESS].  Blood Collection for Influenza Antibody Testing  
Blood samples will be collected and used for serum antibody titers against influenza using 
microneutrali zation (MN) and research assays. Samples will be collected as indicated in the 
Schedule of Events (Table  3). 
The MN T will measure all serum antibodies that neutralize the virus and prevent infection of cells 
and will be analyzed as directed in the Laboratory Manual.   
Research testing will be performed by [CONTACT_175227] a vendor under supervision of the Sponsor . 
The research assays include enzyme -linked immunosorbent assays (ELISAs) or similar methods 
that may be used to detect anti -influenza immunoglobulin G ( IgG) and/or IgA antibodies against 
influenza HA, HA stalk or NA . Additional assays may be conducted  for detection of antibody 
response to influenza or other respi[INVESTIGATOR_130286] , for examp le neuraminidase inhibition assays 
(NAI) . 
Further details regarding sample collection, processing and shippi[INVESTIGATOR_369898].  
[IP_ADDRESS].  PBMCs for Cell -mediated  Immunity Testing  
Blood samples will be collected from all subjects at select sites and peripheral blood mononuclear 
cells (PBMCs) will be isolated and cryopreserved to be tested for CMI. Samples are taken as 
indicated in the Schedule of Events (Table  3) for ~160 subjects . 
PBMCs will be used to evaluate T cell responses by [CONTACT_705632]. PBMCs may also be evaluat ed using flow 
cytometric (FACS) methods  and intracellular cytokine staining (ICS) to characterize the duration 
of the responses, and whether memory phenotypes are generated. PBMCs may also be used in a 
direct ex -vivo ELISPOT assay for evaluation of plasma B cell responses or for detection of 
memory B cell responses after stimulation.  
Further details regarding sample collection, processing and shippi[INVESTIGATOR_369898]. PBMC preparation will be the responsibility of each site.  
[IP_ADDRESS].  Plasma fo r Gene Expression and Cytokine  Testing  
The plasma fraction will be collected from all subjects at select sites from blood samples processed 
for PBMC  isolation. The plasma will be isolated , at select sites,  and cryopreserved for later use for 
innate transcr iptome gene expression and cytokine  profile  analysis. Samples are taken as indicated 
in the Schedule of Events (Table  3). These exploratory samples are being collected for research 
purposes only.  
72 CONFIDENTIAL  
FluGen, Inc.     CLINICAL STUDY PROTOCOL – FLUGEN -H3N2 -V003   18May 2020 (v8.0) 
 
 
 Further details regarding sample collection, processing and shippi[INVESTIGATOR_369898].  
Serum,  plasma, PBMC and nasal swab s amples that remain after protocol -specific assessments 
have been performed may be used for further exploratory work on pharmacokinetics, metabolites, 
plasma protein binding, protein analysis, and biochemistry. No human deoxyri bonucleic acid 
(DNA) or ribonucleic acid (RNA) analysis will be performed, except cytokine  expression as 
specified in the protocol or study manual.  
 
73 CONFIDENTIAL  
FluGen, Inc.     CLINICAL STUDY PROTOCOL – FLUGEN -H3N2 -V003   18May 2020 (v8.0) 
 
 
 7. STUDY  TERM INATI ON/COMPLETI ON 
7.1. Study Completion and End of Study Definition  
A subj ect will be  consid ered to have compl eted the study if he or she received the last study 
vaccination and attended the last protocol -defined follow -up visit. 
End of study will be defined as the point when all patients have completed follow  up. The Sponsor 
will notify all applicable regulatory agencies in accordance with local requirements when the study 
has ended.  
7.2. Termination of the Study by [CONTACT_705633], failure to meet expec ted 
enrollment goals, administrative reasons, or at the discretion of the Sponsor. Should the study be 
terminated prematurely, the Sponsor will provide written notification to all Investigators and 
regulatory authorities and will specify the reason(s) for early termination. The  Lead  PI [INVESTIGATOR_705550](s) for the termination.  
7.3. Study Halting Rules  
Vaccination of subjects will be suspended until after review of safety data by [CONTACT_705634]:  
1. One or more subjects experience a Grade [ADDRESS_958968] administration.  
Any AE or SAE that falls into the above criteria for suspending or terminating the study (including 
the occurrence of any Grade 3 AE, vital sign or laboratory AE that cannot be clearly attributed to 
another cause) must be reported by [CONTACT_13657] (within 24 hours).  
In the case of halting rules being met , the SRC will be convened as quickly as possible. After 
review of the safety data the SRC will make a recommendation to the Sponsor whether to resume, 
suspend or terminate the study. The Sponsor will communicate a decision to suspend or terminate 
the study to the I nvestigators.  
Subsequent review of serious, unexpected, and related AEs by [CONTACT_1689], SRC, IRB, 
the Sponsor(s), or the FDA or relevant local regulatory authorities may also result in suspension 
of further trial interventions/administration of stu dy product at a site. The FDA and study 
Sponsor(s) retain the authority to suspend additional enrollment and study 
interventions/administration of study product for the entire study, as applicable.  
74 CONFIDENTIAL  
FluGen, Inc.     CLINICAL STUDY PROTOCOL – FLUGEN -H3N2 -V003   18May 2020 (v8.0) 
 
 
 7.4. Removal of Subjects from the Study  
Subjects have the right to withd raw from the  study at any time for any reason, including p ersonal 
reasons. A subj ect can withd raw without giving a reason. The  Investigator should ho wever try to 
determine  why a subject withd raws from the  study and document the  reason for withd rawal in the  
source documents and in the  EDC  system. 
Subjects may be withd rawn from the  study in the event of: 
 
- Meeting any of the halting rules in Section  7.3 
 
- A severe AE or  serious AE (SAE); 
 
- Difficulties in obt aining blood or  other samples; 
 
- Failure of the subject to comply with the  protocol requirements or  to cooperate with 
the Investigator. 
 
Subjects must be withd rawn from the  study in the  event of: 
 
− Withdrawal of consent  
− Lost to follow -up 
− Death  
− Termination of the study by [CONTACT_1034] (described in Section  7.2) 
− For safety reasons, it being in the best interest of the subject that he/she be withdrawn, in 
the Investigator’s opi[INVESTIGATOR_1649];  
− A positive pregnancy test (the subject or, if reported by a male sub ject, his female partner), 
or if the subject/partner is non -compliant with the contraception requirements (see 
Section  4.1); 
− Development of a medi cal condition that requires concomitant treatment with a prohibited 
therapy (see Section 5.9.2 ); 
− Breaking of the randomization code during adminis tration of the study drugs. If the code 
is broken for safety reporting purposes, the subject may remain in the study ; however, in 
such case subject and site staff will remain blinded to IP treatment . 
The monitor  and Sponsor will be  informed in the event of a subject being withd rawn from the  
study. In case of withd rawal due  to an SAE (for details on AE  reporting see Section  9.7), the 
Sponsor  should be  notified within 24 hou rs; in case of withdrawal for oth er reasons; the  Sponsor  
should be  notified within [ADDRESS_958969] etion of  the scheduled stu dy procedures 
for any reason (AE, withd rawal of consent, etc.) should be  invited to compl ete the assessments as 
much as possibl e: as long  as the subject consents, all relevant assessments of  the day on whi ch the 
subject withd rew from the  study should be  compl eted, at least those  related to s afety, and the 
subject should come for a safety follow -up visit 4 w eeks after vaccination . In case of an AE, the 
appropriate follow -up w ill be done. 
Subjects who are withd rawn from the  study will not be  replaced. 
75 CONFIDENTIAL  
FluGen, Inc.     CLINICAL STUDY PROTOCOL – FLUGEN -H3N2 -V003   18May 2020 (v8.0) 
 
 
 8. STATISTICAL  METHODS  AND CONSIDERATIONS  
8.1. General Considerations  
Prior to the analysis of the study data , statistical methods and table shells will be  detailed in a  
Statistical Analysis Plan (SAP) and finalized before database lock.  
The final analysis will be done after the last subject has had the day 57 visit and the data base has 
been locked. The day 209 data will be included as a supplemental analysis.  
Statistical analysis w ill be  the responsibility of Northrim Consulting, Inc,  using  SAS® (SAS 
Institute  Inc., Cary, NC, [LOCATION_003]; version 9.4 or  higher). 
There are primary, secondary and exploratory objectives, endpoints and analys es. Depending upon 
the result of the primary and secondary analyses, not all exploratory analyses may be done.  
Safety and subject disposition analyses will be conducted on the safety analysis set.  
Summarization of primary and secondary efficacy endpoints will be done using FAS. These 
summaries may be repeated using the PP analysis set. 
There are no formal tests of hypotheses in this study. Efficacy outcomes are descriptive only.  
The data will be summarized in tables listing the number, mean, standard deviation, median,  
minimum, maximum, standard error (SE) and a 95% CI of subjects for continuous data, or in tables 
listing count and percentage for categorical data where appropriate. Tables will be presented by [CONTACT_705635]. Data listing by [CONTACT_705636].  
8.2. Analysis Sets  
The following  popu lations are defined for this study:  
- Safety Set (SS) – consists of any subject who receives at least one administration of  IP; 
- Full Analysis Set (FAS) – consists of all subjects randomized, received IP and had at least 
one post baseline assessment.  
- (If necessary) Per-protocol  Set (PP) - consists of all subjects in FAS with no major protocol 
violations or deviations . 
Unless otherwise specified  the FAS popul ation w ill be used for analysis.  
8.3. Subject Disposition and Baseline Comparability  
Subject  disposition will be tabulated; the number of enrolled, randomized, prematurely  terminated 
and completed subjects will be summarized by [CONTACT_705637]. A  list of dropouts 
will be prepared includ ing reason and (study) time of discontinuation.  
Subject  IP treatment groups will be characterized using tables, figures and descriptive statistics for 
demographic and baseline variables. Observed differences between the groups, should there be 
any, will be  interpreted for clinical significance and their potential use as covariates in the analysis 
of efficacy endpoints  
76 CONFIDENTIAL  
FluGen, Inc.     CLINICAL STUDY PROTOCOL – FLUGEN -H3N2 -V003   18May 2020 (v8.0) 
 
 
 8.3.1.  Sample S ize 
The sample size of [ADDRESS_958970] Characteristics Data Set  
Demographics will include by -treatment summaries of age, height, weight, BMI, race, and gender.   
BMI will be  calculated in metric units using the formula pr ovided below:  
   BMI = weight (kg)/height (m)[ADDRESS_958971] diaries, solicited and unsolicited AEs, vaccine -associated AEs, SAEs, safety labs, vital 
signs, and physical examinations .  
Exposure  
Vaccine exposure will be summarized by [CONTACT_705590], % of expected dose, and % of subjects 
receiving the expected dose.  
Adverse Events  
Treatment -emergent AEs (local and systemic) will be summarized as N (%) with AEs, with 
related -AEs, and by [CONTACT_34691].  
Incidence of TEAEs will be reported by [CONTACT_61132] -coded SOC, PT and maximum severity.  
Incidence of most frequent TEAEs and most frequent treatment -related TEAEs will be reported 
by [CONTACT_705638], discontinued the study due to an AE, or experienced an SAE will 
be provided.  
Dose -site reactions will be presented by [CONTACT_705591].  
Post-administration of sympt oms (memory aid) will be summarized by [CONTACT_7206], worst 
occurrence, and days with symptoms.  
Clinical Laboratory Tests  
Biochemistry and hematology laboratory results and change from baseline results will be 
summarized by [CONTACT_705639].  
Shift tables of maximum grade compared to baseline tabulated according to the FDA guidance: 
Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive 
Vaccine Clinical Trials, or in accordance with the normal ranges of  the clinical laboratory (below, 
within, or above normal range) for parameters for which no toxicity grades are defined.  
A listing of clinical laboratory test results outside the reference ranges will be provided.  
77 CONFIDENTIAL  
FluGen, Inc.     CLINICAL STUDY PROTOCOL – FLUGEN -H3N2 -V003   18May 2020 (v8.0) 
 
 
 Vital Signs  
Vital sign results and change  from baseline results will be summarized by [CONTACT_705593].  
Limited Physical Examination  
Abnormal findings in physical examination will be listed.  
Pregnancy  
A listing of pregnant subjects will be displayed.  
8.3.4.  Additional Analyses  
Additional analyses will be descriptive only; p -values are descriptive and not corrected for multiple 
testing . 
Immunogenicity  
Serum antibody, mucosal antibody and cellular immune response will be summarized using 
descriptive statistics by [CONTACT_277470] f or all subjects and by [CONTACT_489774].  
Seroconversion rates will be presented by [CONTACT_705595].  
Viral shedding will be summarized using descriptive statistics.  
Additional (exploratory) endpoints may be analyzed.  
8.4. Appropriateness of  Measurements  
The assessments whi ch will be  made in this study  are standard, and are generally recognized as 
reliable, accurate, and relevant. 
78 CONFIDENTIAL  
FluGen, Inc.     CLINICAL STUDY PROTOCOL – FLUGEN -H3N2 -V003   18May 2020 (v8.0) 
 
 
 9. ADV ERSE  EVENT REPORTING 
9.1. Definitions  
Adverse Event 
An AE is any untow ard medical occurrence in a clinical study subject administered a m edicinal 
(investigational or non-investigational) product. An AE do es not  necessarily have a causal 
relationsh ip with the  treatment. An  AE can therefore be any unfavorable and unint ended sign 
(including  an abnormal finding), symptom, or  disease temporally associated with the  use of a 
medicinal (investigational or non-investigational) product, wh ether or not related to that medicinal 
(investigational or non-investigational) product. 
This in cludes any occurrence that is new in on set or aggravated in s everity or frequency from the  
baseline condition, or  abnormal result of  diagnostic  procedures, including clinical laboratory test 
abnormalities. 
AEs will be monito red continuous ly from the first administration of IP treatment  until Day 57. 
SAEs or medically attended  events will be  documented until Day 209. Events recorded at the 
follow -up phone c all will be assessed and followed up as appropriate.  
Serious Adverse Event 
An SAE is any untoward medical occurrence that meets any of the following conditions:  
− results in death; 
− is life-threatening, i.e., the subject was at risk of  death at the  time of the event (e.g., 
ventricular fibrillation and anaphylaxis). The  term do es not refer to an event whi ch 
hypothetically might h ave caused death if it were more severe. 
− requires inp atient hospit alization or  prolongation of  existing  inpatient hospit alization: 
o Hospit alization refers to an overnight admission into hospit al for the purpose of 
investigating and/or  treating the AE. Hospit alization for an elective procedure, or 
routin ely scheduled treatment for a pre-existing  condition th at has not wo rsened, is 
not an SAE. 
− results in p ersistent or  signi ficant dis ability/incapacity, i.e., causing subst antial disruption 
of the subject’s ability to condu ct normal life; 
− is a congenital anomaly/birth defect; 
− is medically significant, i.e., may not be  immediately life-threatening or result in d eath or  
hospit alization but m ay jeopardize the subject’s health or  may require int ervention to 
prevent one of the above outcomes. Examples of such events are intensive  treatment in an 
emergency room or  at home for allergic bronchospasm, blood dyscrasias, or convulsions 
that do not result in hospit alization or d evelopm ent of drug dependency or drug abuse. 
Unlisted (Unexpected) Adverse Event 
An AE is consid ered unl isted if the nature or severity is not consist ent with the  applicable p roduct 
reference safety information (FluGen  IB). 
79 CONFIDENTIAL  
FluGen, Inc.     CLINICAL STUDY PROTOCOL – FLUGEN -H3N2 -V003   18May 2020 (v8.0) 
 
 
 Suspected Unexpected Serious Adverse Reactions (S[LOCATION_003]Rs)  
A S[LOCATION_003]R is an unexpected serious adverse reaction to the IP.  
The Sponsor is to determine if the event is unexpected or not and if unexpected  and to report the 
S[LOCATION_003]R to the Lead PI [INVESTIGATOR_383094]. The Lead PI [INVESTIGATOR_705551](s) to the central IRB. For 
death and li fe-threatening cases, reporting should be done within [ADDRESS_958972] to be reported within 
15 days . 
9.2. Intens ity of  Adverse Events  
All AEs will be assessed by [CONTACT_705640]  (Appendix 1  for vital signs and systemic AE assessment; Appendix 2  for laboratory AE 
assessment , and as described in Section  6.2.2  ). For assessment of reactogenicity in this study, see 
Appendix 3. For events not included in the protocol -defined grading system, then the following 
guidelines will be used to quantify intensity.  
Mild : events require minimal or no treatment and do not interfere with the patient’s daily activities.  
Moderate : events result in a low level of inconvenience or concern with the therapeutic measures. 
Moderate events ma y cause some interference with functioning.  
Severe : events interrupt a patient’s usual daily activity and may require systemic drug therapy or 
other treatment. Severe events are usually incapacitating.  
Life threatening : any adverse drug experience that pla ces the patient or subject, in the view of the 
investigator, at immediate risk of death from the reaction as it occurred, i.e., it does not include a 
reaction that had it occurred in a more severe form, might have caused death.  
Changes in the severity of a n AE should be documented to allow an assessment of the duration of 
the event at each level of intensity to be performed. Adverse events characterized as intermittent 
require documentation of onset and duration of each epi[INVESTIGATOR_1865].  
9.3. Causal ity Assessment  
The cli nician’s assessment of an AE's relationship to test article (vaccine  or placebo ) is part of the 
documentation process, but it is not a factor in determining what is or is not reported in the study. 
If there is any doubt as to whether a clinical observation is an AE, the event should be reported. 
All AEs must have their relationship to study product assessed using the terms related or not 
related. In a clinical trial, the study product must always be suspect. To help assess, the following 
guidelin es are used.  
Related  – There is a reasonable possibility that the study product caused the AE. Reasonable 
possibility means that there is evidence to suggest a causal relationship between the study product 
and the AE. 
Not Related  – The AE is not related to  the study product if there is evidence that clearly indicates 
an alternative explanation. If the subject has not received the study product , the timing of the 
exposure to the study product and the onset of the AE are not reasonably related in time, or oth er 
facts, evidence or arguments exist that strongly suggest an alternative explanation, then the AE is 
not related.  
80 CONFIDENTIAL  
FluGen, Inc.     CLINICAL STUDY PROTOCOL – FLUGEN -H3N2 -V003   18May 2020 (v8.0) 
 
 
 9.4. Reactogenicity  
Reactogenicity events may be  common and are known to occur for the vaccine  being studied and 
will be collected as solicited AEs in a standard, systematic format using a grading scale based on 
functional assessment or magnitude of reaction. In this study, the following reactogenicity events 
will be collected for the first 7 days after each dose of IP : 
• Feverish  
• Nasal irritation  
• Nasal bleeding  
• Runny nose  
• Stuffy nose /Congestion  
• Sore/scratchy/itchy or painful throat  
• Body/muscle aches  
• Joint pain  
• Headache  
• Cough  
• Body rash  
• Tiredness  
• Nausea  
• Vomiting  
• Other symptoms  
These will be evaluated and graded daily based on the f unctional scale specified within the 
Symptom Memory Aid (Appendix 5 ). 
Should a subject experience a severe reaction (graded as a 3) and/or measure a body temperature 
equal to or greater than 39°C , he/she  should immediately contact [CONTACT_779].  
9.5. Outcome 
The outcome of each AE must be  rated as follow s: 
− Recovered/resolved; 
− Recovering/resolvi ng; 
− Not recovered/not resolved; 
− Recovered with s equelae/resolved with s equelae; 
− Fatal; 
− Unknown.  
81 CONFIDENTIAL  
FluGen, Inc.     CLINICAL STUDY PROTOCOL – FLUGEN -H3N2 -V003   18May 2020 (v8.0) 
 
 
 9.6. Recording of Adverse Events  
All (S)AEs o ccurring during the clinical inv estigation must be  documented in the  source 
documents and eCRF . 
Whenever possibl e, diagnos es should be  given when signs and symptoms  are due to a common 
etiology (e.g., cough, runny nose, sneezing, sore throat, and head congestion should be  reported as 
“upper respi[INVESTIGATOR_4416]”). Investigators must record their opi[INVESTIGATOR_705552] (S)AE to the  study drugs in the  EDC  System. All m easures required for (S)AE management 
must be  recorded in the  source documents and reported according to Sponso r’s inst ructions . 
All AEs o ccurring at any time during the study (including  the in-person follow-up period) will be 
follow ed by [CONTACT_368697] s atisfactory resolution (e.g., value back to baseline v alue) or 
stabilization or  until final database lock. If necessary, in o rder to obtain addition al information to 
ensure safety of the subject, addition al blood and urine samples may be taken at the discretion of  
the Investigator. Certain lon g-term AEs related to th erapy cannot be  followed until resolution 
within  the setting of this stu dy. In these cases, follow -up will be  the responsibili ty of the treating 
physician. 
9.7. Reporting of Serious Adverse Events to the Sponsor for 
Pharmacovigilance  
All SAEs, independent of  the circumst ances or suspected cause, must be  recorded  on a Serious 
Adverse Event Form by [CONTACT_705641] 24 hours of  knowl edge 
of the event. The SAE may be initially reported by [CONTACT_648] ([CONTACT_705667]; 703 -401-8189 ), with the 
completed SAE Form  sent to FluGen by [CONTACT_6968] ([EMAIL_13520]) or fax (608 -260-7704 ) within 
24 hours of knowledge of the event .  
The Sponsor will immediately notify the Medical Monitor, who will evaluate the SAE report(s) 
within [ADDRESS_958973]’s subsequent course must be submitt ed to FluGen and 
IRB (as applicable)  until the  event has subsid ed or, in case of permanent imp airment, until the  
condition st abilizes. 
82 CONFIDENTIAL  
FluGen, Inc.     CLINICAL STUDY PROTOCOL – FLUGEN -H3N2 -V003   18May 2020 (v8.0) 
 
 
 9.8. Pregn ancy 
All initial reports of pregnancy in subj ects or in partners of male subjects must be reported to the  
Sponso r by [CONTACT_13658] 24 h ours of his/h er knowl edge of the event. This is done by  
[CONTACT_705642] ([EMAIL_13520]) or fax (608 -260-7704). Any subject who  
becomes pregnant du ring the study must be  prompt ly withd rawn from the  study (Code of Federal 
Regulations [ CFR ] Section 8 ). 
The Investigator will contact [CONTACT_705643] -up and will 
provid e the pregnancy outcome  to the Sponsor . Abno rmal pregnancy outcomes (e.g., spont aneous 
or induced abortion, stil lbirth, neonatal death, congenital abnormality, birth defect) are considered 
SAEs and must  be reported using  the Serious Ad verse Event Form. 
9.9. Reporting of Serious Adverse Events to Competent 
Authorities/Ethics Committees  
Adverse events reporting, in cluding  suspected unexpected serious adverse reactions  (S[LOCATION_003]Rs), 
will be  carried out in accordance with applicable local regulations. 
All S[LOCATION_003]Rs will be the subject of expedited reporting. The Sponsor and Investigator shall  ensure 
that all relevant information about a S[LOCATION_003]R that is fatal or life -threatening is reported to the 
relevant competent authorities and IEC/IRB within 7 days after  knowledge by [CONTACT_63404] 
a case , and that relevant follow -up information is communicated within an additional 8 days , or 
according to the IEC/IRB’s required time frame . All other S[LOCATION_003]Rs will be reported to the relevant 
competent authorities and IE C/IRB within 15 days after knowledge by [CONTACT_63404] a case.  
FluGen will provide investigators with all details of all SAEs reported to regulatory authorities.  
9.10. Medical Monitor  
The Medical Monitor is a n independent clinician (i.e. not directly employed by [CONTACT_705644]) responsible for safety  oversight of the study.  He/she  should have  no apparent conflict of 
interest and cannot be under the supervision of the PI [INVESTIGATOR_705553].  The 
Medical Monitor will oversee  interventions, interactions, data matching, data collection and data 
analysis, review the clinical monitoring plan, review SAE and S[LOCATION_003]R reports  (Section 9.7), 
review AEs which may prompt a study halt  (Section 7.3), participate in the Safety Review 
Committee  (Section 9.11), participate in decisi ons regarding emergency unblinding ( Section 5.6), 
participate in review of Grade 3 laboratory abnormalities, and review summary AE data prior to 
final database lock . The Medical Monitor is  responsible to promptly report his/her  observations to 
the IRB or other designated official and to the HRPO. The Medical Monitor has the authority to 
stop the study , remove individual human subjects from a research  protocol if needed  and take any 
steps necessary to protect the safety and well -being of the subjects until the IRB can assess the 
monitor’s report. The Medical Monitor will also participate via phone in site training and  will be 
available to answer questions related to study eligibility and safety  for the duration of the study  
and may discuss the research protocol with investigators . 
 
83 CONFIDENTIAL  
FluGen, Inc.     CLINICAL STUDY PROTOCOL – FLUGEN -H3N2 -V003   18May 2020 (v8.0) 
 
 
 9.11. Safety Review  Committee  
Safety oversight will be under the direction of a n SRC which is  composed of an independent group 
of experts including two clinicians and a statistician who will be available to review blinded safety 
data, as needed . The SRC will monitor subject s afety and advise the Sponsor. SRC members will 
be separate and independen t of study personnel participating in this study and should not have 
scientific, financial or other conflict of interest related to the study.    
The SRC will operate under the rules and procedures of a Sponsor -approved charter. The SR C will 
review applicab le data including,  but not limited to , enrollment, demographic, dosing, laboratory 
and safety data if study halting rules are met,  as defined in the protocol and the SRC charter. The 
SRC may receive data in aggregate and presented by [CONTACT_1570], but w ithout t he treatment 
group identified. The SRC may review aggregate safety data for increased rate of occurrence of 
seriou s suspected adverse reactions. The SRC may be unblinded to study treatment, as ne eded, to 
assess safety issues. As an outcome of each review/meeting, the SRC will advise the Sponsor  of 
its findings and make recommendations with respect to continuation of the study.  
Throughout the study, the SRC will be convened if halting rules are met. The SRC also may be 
convened at the request of the Investigator, Medical Monitor, Sponsor or any SRC member, if they 
have cause for concern regarding subject safety.  The SRC can recommend study enrollment and 
vaccinations be stopped if AEs that meet the halting criteria are reported or for any overriding 
safety concern. Further details regarding composition and operation of the S RC are provided in 
the S RC Charter.  
84 CONFIDENTIAL  
FluGen, Inc.     CLINICAL STUDY PROTOCOL – FLUGEN -H3N2 -V003   18May 2020 (v8.0) 
 
 
 10. ETHICAL  ASPECTS 
10.1. Study-Specific Design Considerat ions 
Potential subj ects will be  fully informed of the nature of the study and of the risks and requirements 
of the study before any study-related assessment will be  carried out. Du ring the  study, subj ects will 
be given any new information th at may affect their decision to continue  participation. They will 
be informed that their participation in the  study is volunt ary and th at they may withd raw from the  
study at any time with no  reason given and without p enalty or loss of  benefits to whi ch they would 
otherwise be entitled. On ly subj ects who are fully able to und erstand the  risks, benefits, and 
potential AEs of  the stu dy, and who provide  their consent volunt arily will be  enrolled in the  study. 
10.2. Regulat ory Ethics Compliance  
10.2.1.  Investigator Responsibilities 
The Investigator(s) should be  qualified by [CONTACT_8640], t raining, and experience to assume 
responsibili ty for the proper condu ct of the study, should m eet all the  qualifications sp ecified by 
[CONTACT_1214], and should p rovide  evidence of su ch qualifications th rough 
up-to-date curriculum  vitae or other relevant documentation requested by [CONTACT_13099] r, the  
IRB/IEC, or the regulatory authorities. 
The Investigator is responsible  for ensuring that the clinical study is performed in accordance with 
the protocol, current International Council for Harmoni sation (ICH) guidelines on G CP, and 
applicable regulatory and country-specific requirements. 
Good Clinical Practice is an int ernational ethical and scientific quality standard for designing, 
conducting, recording, and reporting studies that involve  the participation of hum an subj ects. 
Compli ance with this st andard provides public  assurance that the rights, s afety, and well-being of 
study subjects are protected, consist ent with the  principles originating from the  Declaration of  
Helsinki (1964 and revisions ), and th at the clinical study data are credible. 
10.2.2.  Independent Ethics Committee or Institutional Review Board  (IEC/IRB)  
An IRB/IEC should s afeguard the  rights, s afety, and w ell-being of all study subjects. Special 
attention should be  paid to studi es that may include vulnerable subjects. 
Before the start of the study, the Sponsor  (or Investigator  where required) will p rovide the  IEC/IRB 
with current and compl ete copi[INVESTIGATOR_705554]: 
− final protocol and, if  applicable, amendments; 
− Sponso r-approved ICF (and any updates or any other written materials to be p rovided to 
the subjects); 
− Subject recruiting materials; 
− IB (or equivalent information)  and addenda; 
− available safety information; 
− information on compensation for study-related injuries or payment to subj ects for 
participation in the  study, if applicable; 
85 CONFIDENTIAL  
FluGen, Inc.     CLINICAL STUDY PROTOCOL – FLUGEN -H3N2 -V003   18May 2020 (v8.0) 
 
 
 − Investigator’s current curriculum vit ae or other documentation evidencing qualifications 
(unless not required, as documented by [CONTACT_6179]/IRB); 
− Clinical trial agreement ; 
− any other documents th at the IEC/IRB may require to fulfill its obli gation. 
This stu dy will be  undertaken only after the IEC/IRB has given full w ritten approval of the  final 
protocol and amendments (if any), the ICF(s) and upd ates (if any), applicable recruiting materials, 
and any other written information to be  provided to the  subjects, and the  Sponsor  has received a 
copy of this approval. This approval letter must  be dated and must clearly identify the IEC/IRB 
and the  documents b eing approved. 
During the study, the Sponsor  (or Investigator  where required) will s end the  following do cuments 
and upd ates to the  IEC/IRB for its review and approval, where appropriate: 
− protocol amendments;  
− revision(s) to the ICF and any other written materials to be provided to the subjects;  
− new or revised subject recruiting materials approved by [CONTACT_1034];  
− revisions to compensation for study -related injuries or payment to subjects for 
participation in the study;  
− IB addenda or new edition(s);  
− summaries of the status of the study at intervals stipulated in guidelines of the  IEC/IRB 
(at least annually);  
− reports of AEs that are serious, unlisted, and associated with the IMP;  
− new information that may adversely affect the  safety of the subjects or the conduct of 
the study;  
− deviations from or changes to the protocol to eliminate immediate hazards to the 
subjects;  
− report of death of any subjects under the Investigator’s care;  
− notification if a new Investigator is responsible  for the study at the clinical site;  
− any other requirements of the IEC/IRB.  
For all protocol amendments (excluding  the ones that are purely administ rative, with no 
consequences for subjects, data or study condu ct), the amendment and applicable ICF revisions 
must be  submi tted prompt ly to the  IEC/IRB for review and approval before impl ementation of  the 
change(s), except wh en necessary to elimin ate immediate hazard to the  study subjects. If a 
deviation from or  a change to the  protocol was implemented to elimin ate an imm ediate hazard to 
study subjects, then the  implemented deviation or change, the reasons for it, and, if  appropriate, 
the protocol amendment sh ould be submitt ed to the  IEC/IRB as soon as possibl e. 
The Sponsor  (or Investigator  will notify the IEC/IRB about the study compl etion within 90 d ays 
after the end of  the study (defined as LPLV). 
86 CONFIDENTIAL  
FluGen, Inc.     CLINICAL STUDY PROTOCOL – FLUGEN -H3N2 -V003   18May 2020 (v8.0) 
 
 
 10.2.3.  Informed Consent 
Each subj ect must  give written consent according to local requirements after the nature of the study 
has been fully explained. The consent form must be  signed before performance of any study-related 
activity. The consent form that is us ed must be approved by [CONTACT_705645]/IRB. The informed consent should be  in accordance with the  principles that originated in the  
Declaration of  Helsinki, current ICH and G CP guidelines, applicable regulatory requirements, and 
Sponsor poli cy. 
Before enrollment in the  study, the Investigator or an authorized member of the clinical staff must 
explain to pot ential subj ects the aims, m ethods, reasonably anticipated benefits, and pot ential 
hazards of  the study, and any discomfort participation in the  study may entail. Subjects will be  
informed that their participation is volunt ary and that they may refuse to participate or withd raw 
consent to p articipate at any time, without p enalty or loss of  benefits to wh ich the  subject was 
entitled. Finally, they will be  told th at the Investigator will m aintain a subject identification register 
for the purposes of long-term follow -up if needed and that their records m ay be accessed by [CONTACT_19397], US DoD representative as part of its human subject protection oversight activities  and 
authorized Sponsor  staff without viol ating the confidentiality of the subject, to the  extent permitted 
by [CONTACT_6983](s) or regulations.  By [CONTACT_705646], if needed. 
The language about the  study used in the  oral and written information, in cluding  the ICF, should 
be non-technical and practical and should  be understandable to the  subject. The subject will be  
given sufficient time  to read the  ICF and the  opportunity to ask qu estions.  After this explanation 
and before entry into the  study, consent should be  appropriately recorded by [CONTACT_19720]'s 
personally dated signature. After having obtained consent, a copy of the ICF must be given to the  
subject. 
The collection and processing  of personal data from subj ects enrolled in the  study will be limit ed 
to those  data that are necessary to inv estigate the safety, quality, and utili ty of the IMP used in the  
study. 
These data must be  collected and processed with adequate precautions to ensure confidentiality 
and compliance with applicable data privacy protection l aws and regulations. App ropriate 
technical and organizational measures to p rotect the personal data against un authorized disclosures 
or access, accidental or unlawful destruction, or accidental loss or  alteration must be  put in pl ace. 
Sponsor  personn el whose responsibiliti es require access to p ersonal data need to agree to keep the  
identity of the stu dy subjects confidential. 
The informed consent obtained from the  subjects includes explicit consent for the p rocessing of 
personal data and for the Investigator to allow di rect access to subjects’ original medical records 
for study-related monito ring, audit, IEC/IRB review, and regulatory inspection. T his consent also 
addresses the transfer of the data to oth er entities and to oth er countries. 
87 CONFIDENTIAL  
FluGen, Inc.     CLINICAL STUDY PROTOCOL – FLUGEN -H3N2 -V003   18May 2020 (v8.0) 
 
 
 11. ADMINISTRATIVE REQUIREMENTS 
11.1. Protocol Amend ments 
Neither the Investigator nor the Sponsor  will modi fy this p rotocol without a  formal amendment. 
All p rotocol amendments must be  issued by [CONTACT_705647]. 
Protocol amendments must not be  implemented without p rior IEC/IRB approval nor  when the  
relevant competent authority has raised any grounds  for non -acceptance, except when necessary 
to elimin ate immediate hazard to the subjects, in whi ch case an amendment must be  prompt ly 
submitted to the  IEC/IRB and relevant competent authority. Do cumentation of  amendment 
approval by [CONTACT_67830]/IRB must be  provided to the Sponsor  or his d esignee. When 
the change(s) involv es only logistic or administ rative aspects of the study, the IRB (and IEC where 
required) on ly needs to be  notified. 
11.2. Subject Ident ification, Enrollment , and Screen ing Logs 
The Investigator agrees to compl ete a subject identification and enrollment log to permit easy 
identification of  each subj ect during and after the study. This do cument will be reviewed by [CONTACT_705648]. 
The subject identification and enrollment log will be  treated as confidential and will be filed by 
[CONTACT_705649]. To ensure subject confidentiality, no copi[INVESTIGATOR_705555]. All 
reports and communi cations related to the  study will id entify subjects by [CONTACT_705650]/or  assigned 
number only. 
The Investigator must also compl ete a subject screening log which reports on all subj ects who w ere 
seen to d etermine eligibility for inclusion in the  study. 
11.3. Source Documentat ion 
The investigator will maintain a list of qualified staff to whom study responsibilities have been 
delegated. These individuals authorized to fulfil l these responsibilities should be outlined and 
included in the Delegation of Authority Form.  
Source documents are original documents, data, and records for which the st udy data are collected 
and verified. Example of such source documents may include, but are not limited to, subject 
hospi[INVESTIGATOR_307]/medical records, laboratory reports, physicians’ and nurses’ notes, subject diaries and 
correspondence. At a  minimum, sou rce documentation must be  available for the followi ng: subject 
identification, eligibility, and stu dy identification; d ate of subject consent,  dates of visits, results 
of safety and efficacy parameters as required by [CONTACT_760], record of all AEs, follow -up of  AEs,  
concomitant m edication, d rug receipt/disp ensing/return records, stu dy drug administ ration 
information, l aboratory printouts (if not available di gitally), date of study compl etion, and reason 
for early discontinu ation of  study drugs or withd rawal from the  study, if applicable.  
The Investigator and study staff are responsible for maintaining a comprehensive filing system of 
all subject records that are readily available to support monitoring activities in compliance with 
ICH-GCP guidelines and regula tory and institutional requirements for the protection of 
confidentiality of subjects. The Investigator shall supply the Sponsor or designee, on request, with 
any required background data from the study documentation or clinic records. Such requests may 
occur, for example, when documents are illegible or when errors in data transcription are 
88 CONFIDENTIAL  
FluGen, Inc.     CLINICAL STUDY PROTOCOL – FLUGEN -H3N2 -V003   18May 2020 (v8.0) 
 
 
 suspected. In case of requests for audit inspections and/or queries from National 
Authorities/Regulatory Agency, it will be necessary to have access to the complete stu dy records, 
provided that subject confidentiality is maintained.  
No study documents should be discarded without prior written agreement between the Sponsor 
and the Investigator. Should storage no longer be available to archive source documents or must 
be moved to an alternative location, the site should notify the key sponsor contact [CONTACT_705651][INVESTIGATOR_705556].  
11.4. Case Report Form Completion 
Authorized study site personnel will complete eCRFs designed specifically for this study and 
completion guideli nes will be provided. An eCRF is required and must be completed for each 
subject enrolled into the study and will be available for all data required to be entered into the 
clinical database and must match the data contained in the study specific source doc umentation. 
The Investigator will ensure that the eCRFs are accurate, complete and legible. The Investigator 
will ensure that source documents that are required to verify the validity and completeness of data 
transcribed on the eCRFs are never obliterated or destroyed. As required by [CONTACT_760], eCRFs 
should also be completed for those subjects who fail to complete the study. If a subject withdraws 
from the study, the reason must be noted on the eCRF and thorough efforts should be made to 
clearly document  outcome.  
The eCRFs will be maintained in an electronic data collection system for this study. After the 
Investigator or designees have been appropriately trained, they will be given access to the EDC 
system and will be able to enter the data required by [CONTACT_760]. Any change of data will be made 
via the EDC system, with all changes tracked by [CONTACT_314241].  
11.5. Study Monitoring 
The Sponsor is responsible for assuring the proper conduct of the study with regard to protocol 
adherence a nd validity of the data recorded on the eCRFs. Subject confidentiality will be 
maintained.  
In addition, monitors designated by [CONTACT_705652], including 
conducting on -site and remote monitoring visits. The on -site and remote monitoring visits will be 
conducted as frequently as necessary to ensure that all aspects of the study are carefully monitored 
for compliance with applicable government regulations with respect to current GCP practice and 
the current SOPs.  The visit s will be conducted in accordance with the Sponsor’s SOP and Clinical 
Monitoring Plan.  
The unblinded study monitor will be limited to observation (in real -time or via review of 
documentation) of IP preparation  and delivery device filling and weighing , adhe rence to 
randomization to treatment group, storage of IP  and IP accountability  and to review of consent and 
eligibility  documents . They will not participate in activities related to subject assessments.  
In general, the Investigator agrees to fully cooperat e with the monitor, allow the monitor direct 
access to all relevant documents, to allocate his time and the time of his staff to the monitors to 
discuss any findings and any relevant issues as needed.  
89 CONFIDENTIAL  
FluGen, Inc.     CLINICAL STUDY PROTOCOL – FLUGEN -H3N2 -V003   18May 2020 (v8.0) 
 
 
 11.6. Data Management  
Electronic data collection will be used  to enter study data. During the data collection process, 
automated quality assurance programs will be used to identify missing data, incorrect data and 
other data discrepancies. Requests for data clarification or correction will be queried to the 
investig ative study site for resolution via the EDC system.  
Quality assurance and quality control systems will be implemented and maintained to ensure that 
the data are generated, recorded and reported in compliance with the protocol, GCP, and applicable 
regulato ry requirements. Data collection and storage will provide an audit trail, security 
mechanisms and electronic signature [CONTACT_493354] [ADDRESS_958974] eteness du ring (on-site) monito ring visits and after transmission to t he Sponso r; any 
discrepancies will be  resolved with the  Investigator or designee, as appropriate. After upload of 
the data into t he clinical study database, their accuracy will be verified using appropriate validation 
programs. 
In accordance with Good  Clinical Research Practice Guid elines and Recommendations, the  
Sponsor  will be  entitled to audit the  facilities used in the  clinical and laboratory parts of the study, 
as well as to access all the  data files pertaining  to the  study. Similar procedures may also be  
condu cted by [CONTACT_705653], either as part of a national GCP compli ance program 
or to review the results of  this stu dy in suppo rt of a regulatory submission. The  Investigator should 
immediately notify the Sponsor if they have been contact[CONTACT_426] a regulatory agency concerning an 
upcoming  inspection. 
11.8. On-Site Audits 
Representatives of the Sponso r’s clinical quality assurance department may visit the clinical site  
at any time during or after compl etion of the study to conduct an audit of  the stu dy in compli ance 
with regulatory guidelines and company policy. These audits will require access to all study  
records, in cluding source documents, for inspection and comparison with the  eCRF  system. 
Subject privacy must, ho wever, be respected. The  Investigator and clinical staff are to be present 
90 CONFIDENTIAL  
FluGen, Inc.     CLINICAL STUDY PROTOCOL – FLUGEN -H3N2 -V003   18May 2020 (v8.0) 
 
 
 and available for consult ation du ring routinely scheduled site  audit visits condu cted by [CONTACT_705654] d esignee. 
Similar procedures may also be  condu cted by [CONTACT_705653], either as part of a 
national GCP compli ance program or to review the  results of  this stu dy in suppo rt of a regulatory 
submission. The  Investigator should imm ediately notify the Sponsor  if they have been contact[CONTACT_103793] a regulatory agency concerning an upcoming insp ection. 
11.9. Study  Termination 
The Sponsor  has the right to terminate the study at any time. In case of an early termination of  the 
study for safety reasons, or  temporary halt by [CONTACT_1034], the IEC/IRB should be  notified within 
15 calendar days and should be  provided with a d etailed w ritten explanation for the 
termination/h alt. 
An end-of-study declaration will be  submitt ed to the regulatory authorities and IEC/IRB after the 
compl ete study has ended. This noti fication will be  submitt ed wit hin [ADDRESS_958975] Retent ion 
In compli ance with the  ICH/GCP guidelines, the  Investigator/Institution will m aintain all paper 
source documents th at suppo rt the data collected from each subject, as well as all study  documents 
as specified in ICH/GCP Section 8, Ess ential Documents for the Condu ct of a Clinical Trial, and 
all stu dy documents as sp ecified by [CONTACT_8146](s). The  
Investigator/Institution will t ake measures to prevent accidental or premature destruction of  these 
documents. 
Essential documents must be  retained until at least [ADDRESS_958976] elapsed sin ce the formal discontinu ation of  clinical 
developm ent of  the IMP. These documents will be retained for a longer period if  required 
according to the  applicable regulatory requirements or  per agreement with the  Sponso r. It is the  
responsibili ty of the Sponsor  to inform the  Investigator/Institution as to wh en these documents no 
longer need to be retained.  
If the responsible  Investigator retires, relocates, or  for any other reasons withd raws from his 
responsibili ty of keepi[INVESTIGATOR_8090], custody must be  transferred to a person who will accept 
the responsibili ty. The  Sponsor  must be  notified in w riting of  the name [CONTACT_705665]. Und er no circumstance shall the  Investigator relocate or dispose  of any study documents 
without h aving obt ained written approval from the Sponso r. 
If it becomes necessary for the Sponsor  or the appropriate regulatory authority to review any 
documentation related to the  study, the Investigator must p ermit access to su ch reports. 
11.11.  Use of Informat ion and Publication 
All in formation, in cluding  but not limit ed to, in formation regarding the Bris10 or Sing2016 M2SR 
vaccine s or the Sponso r’s operations (e.g., patent application, formulas, manufacturing processes, 
basic scientific data, prior clinical data, formulation in formation)  suppli ed by [CONTACT_705655]  
91 CONFIDENTIAL  
FluGen, Inc.     CLINICAL STUDY PROTOCOL – FLUGEN -H3N2 -V003   18May 2020 (v8.0) 
 
 
 Investigator and not p revious ly publish ed, and any data generated as a result of  this stu dy are 
considered confidential and remain the  sole property of the Sponso r. The  Investigator agrees to 
maintain this in formation in confidence, to use  this in formation on ly to accomplish this study, and 
not to use  it for other purposes without the Sponso r’s prior written consent. 
The Investigator understands th at the information generated in this clinical study will be us ed by 
[CONTACT_705656], and thus m ay be 
disclosed as required to oth er clinical Investigators or regulatory agencies. To p ermit in formation 
derived from the  clinical studi es to be  used, the  Investigator is obli ged to p rovide  the Sponsor  with 
all data obtained in the  study. 
The results of  the study will be  reported in a  Clinical Study Report generated und er the 
responsibili ty of the Sponsor and will contain EDC  system data from all clinical sites that 
participated in the  study. Recruitment performance or specific expertise related to the  nature and 
the key assessment parameters of the study will be  used to determine  a coordinating Investigator. 
Clinical narratives may be written for the following  events (for example): 
− All d eaths (irrespective of drug relationship)  
− All oth er SAEs du ring treatment with the  study drugs 
− All dis continu ations of  the study drugs due to AEs  (irrespective of drug relationship)  
− Any events of  special interest explicitly requested by [CONTACT_397149] 
− At the  discretion of  the team and after statistical analysis of  the data, certain 
discontinu ations not related to AEs or  treatment failure, i.e., related to lost to follow -up or  
withd rawal of consent (irrespective of treatment group). 
The Sponsor and Medical Monitor  will si gn off the final version of  the Clinical Study Report. A 
summ ary of this final version will be  provided to the  Investigators, the applicable regulatory 
authorities, and the  IECs/IRBs, if required by [CONTACT_1214], within 1  year 
after the end of the study (LPLV). 
The Sponsor  shall have the right to publish stu dy data and in formation without approval from the  
Investigator. If an Investigator wish es to publish in formation from the  study, the Investigator must 
first request to do so in writing to the Sponsor at least [ADDRESS_958977] of the Sponsor’s 
ability and only if Sponsor agrees to allow Investigator to submit such materials to an outside 
party.  The Investigator will withhold su ch publi cation for up to an addition al [ADDRESS_958978] the right 
to publish, present or share with any outside party study data and/or information without the 
express written consent of the Sponsor. Autho rship of  publi cations resulting  from this stu dy will 
be based on the guidelines on authorship, su ch as those  described in the Uni form Requirements 
for Manuscripts Submitt ed to Biomedical Journals, whi ch state that the named authors must h ave 
92 CONFIDENTIAL  
FluGen, Inc.     CLINICAL STUDY PROTOCOL – FLUGEN -H3N2 -V003   18May 2020 (v8.0) 
 
 
 made a significant contribution to the  design of the stu dy or analysis and interpretation of  the data, 
provided critical review of the paper, and given final approval of the final version.  
11.12.  Results  
The Sponsor  will register the existence of a clinical study and dis close its results as required by 
[CONTACT_2371]. 
11.13.  Invest igator Indemn ity  
The Sponsor  holds and will m aintain an adequate insurance policy covering damages arising  out 
of Sponso r-sponso red clinical research studi es. 
The Sponsor  will ind emnify the Investigator and hold him/h er harmless for claims related to 
damages arising from the investigation, p rovided that the study drugs were administ ered und er the 
Sponso r’s or deputy’s supervision and in st rict accordance with accepted medical practice and the  
study protocol. 
The Investigator must n otify the Sponsor  immediately upon notice of any claims or l awsuits.  
11.14.  Confident iality 
Subject confidentiality is strictly held by [CONTACT_778], their staff, and the 
Sponsor(s) and their agents. This confidentiality is extended to cover testing of biological samples 
and genetic tests in addition to the clinical information relating to participating subjects.  
The study protocol, documentation, data, and all other information generated will be held in strict 
confidence. No information concerning the study or the data will b e released to any unauthorized 
third party without prior written approval of the Sponsor.  
The study monitor or other authorized representatives of the Sponsor may inspect all documents 
and records required to be maintained by [CONTACT_093], including but not limited to, medical 
records (office, clinic, or hospi[INVESTIGATOR_307]) and pharmacy records for the subjects in this study. The clinical 
study site will permit access to such records.  
The Investigator must assure that subjects’ anonymity will be maint ained and that their identities 
are protected from unauthorized parties. Throughout this study, all data will be linked to the eCRF 
via a unique identification number. The data will be blinded correspondingly in all data analyses. 
The Investigator should k eep a subject enrollment log showing codes, names and addresses. The 
Investigator should maintain documents that are not for submission to the Sponsor (such as written 
consent forms) in strict confidence.  
However, in compliance with the ICH Guidelines and  in fulfillment of its obligations to FluGen 
to verify compliance with this protocol, FluGen Inc. or its designee requires that the Investigator 
permit FluGen designated monitors, representatives from any Regulatory Authority, FluGen 
designated auditors, o r the appropriate Independent Ethics Committee, to review the subject’s 
primary medical records (source data or documents) including, but not limited to, laboratory test 
result reports, admission and discharge summaries, and SAEs occurring during the study . Should 
access to such medical records require a waiver or authorization separate from the statement of 
informed consent, the Investigator will obtain such permission in writing from the subject before 
the subject is entered into the study.  
93 CONFIDENTIAL  
FluGen, Inc.     CLINICAL STUDY PROTOCOL – FLUGEN -H3N2 -V003   18May 2020 (v8.0) 
 
 
 12. REFERENCES  
Amb rose CS, Wua X, Jones T, Mallory RM. The role of nasal IgA in children vaccinated with 
live attenuated influenza va ccine. Vaccine 2012; 30:6794 –801. 
CDC. Prevention and control of seasonal influenza with vaccines. Recommendations of the 
Advisory Committee on Immunization Practices —[LOCATION_002], 2013 –14. MMWR Recomm 
Rep. 2013; 62 (No. RR -7):1–43. 
CDC.  Prevention and control of influenza with vaccines: Recommendations of the Advisory 
Committee on Immunization Practices ‒ [LOCATION_002], 2015 –16 Influenza Seaso n. MMWR . 
2015;64; 818 -25. 
Clements ML, Betts RF, Tierney EL, Murphy BR. Serum and nasal wash antibodies associated 
with resistance to experimental challenge with influenza A wildtype virus. J Clin Microbiol . 
1986; 24:157 –60. 
Eick AA, Wang Z, Hughes H, et al . Comparison of the trivalent live attenuated vs. inactivated 
influenza vaccines among U.S. military service members . Vaccine. 2009; 27:3568 -75. 
FluGen, Inc. M2SR Vaccine Investigator ’s Brochure, edition 4.0, [ADDRESS_958979] highly pathogenic avian influenza . Vaccine . 2017; 35:4177 –83. 
He XS, Holmes TH, Zhang C, et al. Cellular immune responses in children and adults receiving  
inactivated or live attenuated influenza vaccines. J Virol. 2006; 80:[ZIP_CODE] -66. 
Hoft DF, Lottenbach KR, Blazevic A, et al. Comparisons of the Humoral and Cellular Immune 
Responses Induced by [CONTACT_705657] (LAIV) and Inactivated Influenza  
Vaccine (IIV) in Adults. Clin Vaccine Immunol. 201 7;24: e00414 -16. 
Jin H and  Subbarao K. Live  attenuated influenza vaccine. In: Oldstone MBA, Compans RW, 
eds. Influenza pathogenesis and control, Vol II. Cham, Switzerland: Sp ringer International 
Publishing . 2015:181 –204. 
Lanthier PA, Huston GE, Moquin A, et al. Live attenuated influenza vaccine (LAIV) impacts 
innate and adaptive immune responses. Vaccine . 2011; 29:7849 –56. 
Monto  AS, Ohmit SE, Petrie JG, et al. Comparative Efficacy of Inactivated and Live Attenuated 
Influenza Vaccines. N Eng J Med . 2009;  361:1260 -7. 
Ohmit SE, Victor JC, Rotthoff JR, et al. Prevention of antigenically drifted influenza by 
[CONTACT_705658]. N Engl J Med. 2006 ;355:2513 -22. 
Osterholm MT, Kelley NS, Somme r A, Belongia EA. Eﬃcacy and eﬀectiveness of inﬂuenza 
vaccines: a systematic review and meta -analysis. Lancet Infect Dis . 2012; 12: 36 –44. 
Paules CI, Sullivan SG, Subbarao K, Fauci AS.  Chasing Seasonal Influenza — The Need for a 
Universal Influenza Vaccine . N Engl J Med . 2018;378:7 -9. 
Sarawar S, Hatta Y, Watanabe S, et al; M2SR, a novel live single replication influenza virus 
vaccine, provides effective heterosubtypic protection in mice. Vaccine . 2016;34:5090 –8. 
94 CONFIDENTIAL  
FluGen, Inc.     CLINICAL STUDY PROTOCOL – FLUGEN -H3N2 -V003   18May 2020 (v8.0) 
 
 
 Tamura  S, Tanimoto T, Kurata T. Mechanisms of broad cross -protection provided by [CONTACT_705659]. Jpn J Infect Dis . 2005;58: 195–207. 
Treanor JJ,  Talbot H K, Ohmit SE, et al. Effectiveness of Seasonal Inﬂuenza Vaccines i n the 
[LOCATION_002] During a Season with Circulation of All Three Vaccine Strains. Clin Infect Dis. 
2012;55 :951–9. 
Wang Z, Tobler S, Roayael J, et al. Live attenuated or inactivated influenza vaccines and 
medical encounters for respi[INVESTIGATOR_493785]. JAMA . 2009; 
301:945-53. 
Wilkinson TM, Li CKF, Chui CSC, et al. Preexisting influenza -specific CD4+ T cells correlate 
with disease protection against influenza challenge  in humans. Nat Med. 2012; 18:274 -80. 
Zhu W, Higgs  BW, Morehouse C, et al. A whole genome transcriptional analysis of the early 
immune response induced by [CONTACT_705660]. Vaccine . 2010; 28:2865 –76. 
95 CONFIDENTIAL  
FluGen, Inc.     CLINICAL STUDY PROTOCOL – FLUGEN -H3N2 -V003   18May 2020 (v8.0) 
 
 
 APP ENDICES  
 
FluGen, Inc.  CLINICAL STUDY PROTOCOL - FLUGEN -H3N2 -V003       18May 2020 (v8.0) 
96 CONFIDENTIAL  
 
 
 
 APPENDIX 1: VITAL SIGN AND SYSTEMIC TOXICITY ASSESSMENTS  
 
Please see n ext page.  
FluGen, Inc.  CLINICAL STUDY PROTOCOL - FLUGEN -H3N2 -V003 18May 2020 (v8.0)  
 
 
CONFIDENTIAL    97 Vital signs  
Please score items based on the following guidance (from FDA Guidance for Industry: Toxicity Grading Scale for Healthy Adult and 
Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials):  
Vital Signs *  Mild (Grade 1)  Moderate (Grade 2)  Severe (Grade 3)  Potentially Life Threatening 
(Grade 4)  
Fever (°C) **  
          (°F) **  38.0 – 38.4  
100.4 – 101.1  38.5 – 38.9  
101.2 – 102.0  39.0 – 40  
102.1 – 104  > 40  
> 104  
Tachycardia - beats per minute  101 – 115  116 – 130  > 130  ER visit or hospi[INVESTIGATOR_165073] - beats per minute***  50 – 54  45 – 49  < 45  ER visit or hospi[INVESTIGATOR_91280] (systolic) - mm Hg  141 – 150  151 – 155  > 155  ER visit or hospi[INVESTIGATOR_40670] (diastolic) - mm Hg  91 – 95  96 – 100  > 100  ER visit or hospi[INVESTIGATOR_40671] (systolic) – mm Hg  85 – 89  80 – 84  < 80  ER visit or hospi[INVESTIGATOR_149183] – breaths per minute  17 – 20  21 – 25  > 25  Intubation  
* Subject should be at rest for all vital sign measurements.  
** Oral temperature; no recent hot or cold beverages or smoking.  
*** When resting heart rate is between 60 – [ADDRESS_958980] 
populations, for example, conditioned athletes.  
 
FluGen, Inc.  CLINICAL STUDY PROTOCOL - FLUGEN -H3N2 -V003 18May 2020 (v8.0)  
 
 
CONFIDENTIAL    98  
 
Systemic Symptoms  
Please score items based on the following guidance (from FDA Guidance for Industry: Toxicity Grading Scale for Healthy Adult and 
Adolescent Volunteers Enrolled in Prev entive Vaccine Clinical Trials):  
 
Systemic (General)  Mild (Grade 1)  Moderate (Grade 2)  Severe (Grade 3)  Potentially Life 
Threatening (Grade 4)  
Nausea/vomiting  No interference with 
activity or 
1-2 epi[INVESTIGATOR_1841]/24 hours  Some interference with 
activity or 
> 2 epi[INVESTIGATOR_1841]/24  hours  Prevents daily activity, 
requires outpatient IV 
hydration  ER visit or hospi[INVESTIGATOR_705557]  2–3 loose stools or 
< 400 g/24 hours  4–5 stools or 
400-800 g/24 hours  6 or more watery stools 
or > 800g/24 hours or 
requires outpatient IV 
hydration  ER visit or hospi[INVESTIGATOR_257622] - 
narcotic pain reliever 
> 24 hours or some 
interference with activity  Significant; any use of 
narcotic pain reliever or 
prevents daily activity  ER visit or hospi[INVESTIGATOR_257623]; prevents 
daily activity  ER visit or hospi[INVESTIGATOR_257624]; prevents 
daily activity  ER visit or hospi[INVESTIGATOR_705558] (as defined 
according to applicable 
regulations)  No interference with 
activity  Some interference with 
activity not requiring 
medical intervention  Prevents daily activity 
and requires medical 
intervention  ER visit or ho spi[INVESTIGATOR_705559], Inc.  CLINICAL STUDY PROTOCOL - FLUGEN -H3N2 -V003     18May2020  (v8.0) 
CONFIDENTIAL 99 99  
 
 
 APPENDIX 2: LABORATORY ASSESSMENTS  
• Urine drug screena  
• Serologya: HIV, HCV, HbsAg  
• Urinalysis:  Dipstick: specific gravity, pH, glucose, protein, blood, ketones, 
bilirubin, urobilinogen, nitrite, leukocyte esterase  
In case of positive dipstick results, the  sediment will be examined 
microscopi[INVESTIGATOR_705560], white blood cells, and 
epi[INVESTIGATOR_1663]. Crystals, casts, and bacteria will only be reported if 
they are present.  
• Hematology:  Hemoglobin, white blood cells with differential (including 
neutro phils, lymphocytes, and eosinophils), platelets  
• Biochemistry:  Albumin, alkaline phosphatase, alanine aminotransferase, 
aspartate aminotransferase, bicarbonate  (or carbon dioxide) , 
calcium, chloride, potassium, sodium, lipid panela (total 
cholesterol, high -density lipoprotein cholesterol, low -density 
lipoprotein cholesterol, and triglycerides), total bilirubin, direct 
bilirubinb, total protein, creatinine, C -reactive protein, creatine 
kinase, blood urea nitrogen (or urea)  
• At screen ing, a urine  pregnancy test will be performed for women of childbearing potential  
• At the indicated time points, a urine pregnancy test will be performed for women of 
childbearing potential  
a. At screening only.  
b. To be assessed if total bilirubin is elevated above normal range.  
FluGen, Inc.  CLINICAL STUDY PROTOCOL - FLUGEN -H3N2 -V003       18May 2020 (v8.0)  
 
CONFIDENTIAL    100 
 Grading Scale for Laboratory AEs  
Please score items based on the following guidance (from FDA Guidance for Industry: Toxicity Grading Scale for Healthy Adult and 
Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials):  
Serum*  Mild (Grade 1)  Moderate 
(Grade  2)  Severe (Grade  3)  Potentially Life 
Threatening 
(Grade  4)**  
Sodium – Hyponatremia mEq/L  132 – 134  130 – 131  125 – 129  < 125  
Sodium – Hypernatremia mEq/L  144 – 145  146 – 147  148 – 150  > 150  
Potassium – Hyperkalemia mEq/L  5.1 – 5.2  5.3 – 5.4  5.5 – 5.6  > 5.6  
Potassium – Hypokalemia mEq/L  3.5 – 3.6  3.3 – 3.4 3.1 – 3.2  < 3.1  
Glucose – Hypoglycemia mg/dL  65 – 69  55 – 64  45 – 54  < 45  
Glucose – Hyperglycemia  
Fasting – mg/dL  
Random – mg/dL   
100 – 110  
110 – 125   
111 – 125  
126 – 200   
>125  
>200   
Insulin requirements or 
hyperosmolar coma  
Blood Urea Nitrogen  
BUN mg/dL  23 – 26  27 – 31  > 31  Requires dialysis  
Creatinine – mg/dL  1.5 – 1.7  1.8 – 2.0  2.1 – 2.5  > 2.5 or requires dialysis  
Calcium – hypocalcemia mg/dL  8.0 – 8.4  7.5 – 7.9  7.0 – 7.4   < 7.0  
Calcium – hypercalcemia mg/dL  10.5 – 11.0  11.1 – 11.5  11.6 – 12.0 > 12.0  
Magnesium – hypomagnesemia 
mg/dL  1.3 – 1.5 1.1 – 1.2 0.9 – 1.0 < 0.9  
Phosphorous – hypophosphatemia 
mg/dL  2.3 – 2.5 2.0 – 2.2 1.6 – 1.9 < 1.6  
CPK – mg/dL  1.25 – 1.[ADDRESS_958981]***  1.6 – 3.[ADDRESS_958982]  3.1 –[ADDRESS_958983]  > [ADDRESS_958984]  
Albumin – Hypoalbuminemia g/dL  2.8 – 3.4  2.5 – 2.7  < 2.5  --  
FluGen, Inc.  CLINICAL STUDY PROTOCOL - FLUGEN -H3N2 -V003       18May 2020 (v8.0)  
 
CONFIDENTIAL    101 
 Total Protein – Hypoproteinemia 
g/dL  5.5 – 6.0  5.0 – 5.4  < 5.0  --  
Alkaline phosphate – increase by 
[CONTACT_12245]  1.1 – 2.[ADDRESS_958985]  2.1 – 3.[ADDRESS_958986]  3.1 – [ADDRESS_958987]  > [ADDRESS_958988]  
Liver Function Tests –ALT, AST 
increase by [CONTACT_12245]  1.1 – 2.[ADDRESS_958989]  2.6 – 5.[ADDRESS_958990]  5.1 – [ADDRESS_958991]  > [ADDRESS_958992]  
Bilirubin – when accompanied by 
[CONTACT_434013]  1.1 – 1.[ADDRESS_958993]  1.26 – 1.[ADDRESS_958994]  1.51 – 1.[ADDRESS_958995]  > 1.[ADDRESS_958996]  
Bilirubin – when liver function test 
is normal; increase by [CONTACT_12245]  1.1 – 1.[ADDRESS_958997]  1.6 – 2.[ADDRESS_958998]  2.0 – 3.[ADDRESS_958999]  > 3.[ADDRESS_959000]  
Cholesterol  201 – 210  211 – 225  > 226  ---  
Pancreatic enzymes – amylase, 
lipase  1.1 – 1.[ADDRESS_959001]  1.6 – 2.[ADDRESS_959002]  2.1 – 5.[ADDRESS_959003]  > 5.[ADDRESS_959004]  
* The laboratory values provided in the tables serve as guidelines and are dependent upon institutional normal parameters. In stitutional normal reference ranges 
should be provided to demonstrate that they are  appropriate.  
** The clinical signs or symptoms associated with laboratory abnormalities might result in characterization of the laboratory  abnormalities as Potentially Life 
Threatening (Grade 4). For example. a low sodium value that falls within a Grade 3  parameter (125 -129 mE/L) should be recorded as a grade [ADDRESS_959005] had a new seizure associated with the low sodium value.  
***”ULN” is the upper limit of the normal range.  
FluGen, Inc.  CLINICAL STUDY PROTOCOL - FLUGEN -H3N2 -V003       18May 2020 (v8.0)  
 
CONFIDENTIAL    102 
 Hematology*  Mild (Grade 1)  Moderate (Grade 2)  Severe (Grade 3)  Potentially Life Threatening 
(Grade 4)  
Hemoglobin (Female) - gm/dL  11.0 – 12.0  9.5 – 10.9  8.0 – 9.4  < 8.0  
Hemoglobin (Female)  
change from baseline value - 
gm/dL  Any decrease – 1.5  1.6 – 2.0  2.1 – 5.0  > 5.0  
Hemoglobin (Male) - gm/dL  12.5 – 13.5  10.5 – 12.4  8.5 – 10.4  < 8.5  
Hemoglobin (Male)  
change from baseline value – 
gm/dL  Any decrease – 1.5  1.6 – 2.0  2.1 – 5.0  > 5.0  
WBC Increase - cell/mm3 10,800 – 15,000  15,001 – 20,000  20,001 – 25, 000  > 25,000  
WBC Decrease - cell/mm3 2,500 – 3,500  1,500 – 2,499  1,000 – 1,499  < 1,000  
Lymphocytes Decrease - 
cell/mm3 750 – 1,000  500 – 749  250 – 499  < 250  
Neutrophils Decrease - cell/mm3 1,500 – 2,000  1,000 – 1,499  500 – 999  < 500  
Eosinophils - cell/mm3 650 – 1500  1501 - 5000  > 5000  Hypereosinophilic  
Platelets Decreased - cell/mm3 125,000 – 140,000  100,000 – 124,000  25,000 – 99,000  < 25,000  
* The laboratory values provided in the tables serve as guidelines and are dependent upon institutional normal parameters. Institutional normal reference ranges 
should be provided to demonstrate that they are appropriate.  
 
  
FluGen, Inc.  CLINICAL STUDY PROTOCOL - FLUGEN -H3N2 -V003       18May 2020 (v8.0)  
 
CONFIDENTIAL    103 
 Grading Scale for Urinalysis AEs 
Please score items based on the follow ing guidance (from FDA Guidance for Industry: Toxicity Grading Scale for Healthy Adult and 
Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials):  
Urine *  Mild (Grade 1)  Moderate (Grade 2)  Severe (Grade 3)  Potentially Life 
Threatening (Grade  4) 
Protein  Trace  1+  2+  Hospi[INVESTIGATOR_91289]  1+ 2+ Hospi[INVESTIGATOR_257627] (microscopic) – red 
blood cells per high power 
field (rbc/hpf)  1 - 10  11 – 50  > 50 and/or gross blood  Hospi[INVESTIGATOR_705561] (PRBC) 
transfusion  
* The laboratory values provided in the tables serve as guidelines and are dependent upon institutional normal parameters. Institutional normal reference ranges 
should be provided to demonstrate that they are appropriate.
FluGen, Inc.  CLINICAL STUDY PROTOCOL - FLUGEN -H3N2 -V003 18May 2020 (v8.0) )  
CONFIDENTIAL 104 104  
 
 APPENDIX 3: REACTOGENICITY ASSESSMENT S 
 
Please see next page.
FluGen, Inc.  CLINICAL STUDY PROTOCOL - FLUGEN -H3N2 -V003 18May 2020 (v8.0)  
 
CONFIDENTIAL    105 Local Reactions (intranasal administration)  
Please score reactions as follows:  
Local 
reaction  Mild  
(Grade 1)  Moderate  
(Grade 2)  Severe  
(Grade 3)  Potentially Life 
Threatening  
(Grade 4)  
Nasal pain / 
irritation  Does not interfere  
with activity  
  Repeated use of non -
narcotic pain reliever 
> 24 hours or interferes 
with activity  Any use of narcotic pain 
reliever or prevents daily 
activity  Emergenc y room (ER) visit 
or hospi[INVESTIGATOR_705562]/  
rhinorrhea  Does not interfere  
with activity  
  Use of saline or other 
decongestant > 24 hours or 
interferes with activity  Repeated use of 
decongestants or 
significantly interferes with 
daily activity  Emergency room (ER) visit 
or hospi[INVESTIGATOR_705563]/  
Epi[INVESTIGATOR_705564] (e.g., 
squeezing of nose to 
reduce bleeding) 
> 24 hours or interferes 
with activity  Required repeated or near 
continuous intervention or 
significantly interferes with 
daily activity  Emergency room (ER) visit 
or hospi[INVESTIGATOR_705565], Inc.  FluGen, Inc.  CLINICAL STUDY PROTOCOL - FLUGEN -H3N2 -V003 118May2 020 (v8.0) 
CONFIDENTIAL 106 106  
 
 APPENDIX 4: INVESTIGATOR SIGNATURE [CONTACT_705666]:  
 
 
Study T itle: Phase 1b clinical study to investigate the safety and immunogenicity of the 
Bris10 (A/Brisbane/10/2007) M2SR and Sing2016 (A/Singapore/INFIMH -16-0019/2016) 
M2SR H3N2 monovalent influenza vaccines  
 
 
Name:  
[CONTACT_23682]:   
Address:  
 
 
 
I have read this Clinical Study Protocol and agree that it contains all information n ecessary 
for proper conduct of the study. I will carry out the  study as outlin ed herein and will 
compl ete the study within the  designated time and in accordance with the standards of Good 
Clinical Practice (as defined by [CONTACT_5787]) after 
approval by [CONTACT_3551] . 
 
 
 
 
Signature:  
[CONTACT_1782]: 
 
 
FluGen, Inc.  FluGen, Inc.  CLINICAL STUDY PROTOCOL - FLUGEN -H3N2 -V003 118May2 020 (v8.0) 
CONFIDENTIAL 107 107  
 
 APPENDIX 5: SYMPTOM MEMORY AID FOR VACCINATION PERIOD  
Please s ee next page  for sample document showing Day 1 – Day 7. A similar document will be 
provided for Day 29 – Day 35 .
FluGen, Inc.  FluGen, Inc.  CLINICAL STUDY PROTOCOL - FLUGEN -H3N2 -V003 118May2 020 (v8.0) 
CONFIDENTIAL 108 108  
 
  
 
Symptom Memory Aid  
Day 1  – Day [ADDRESS_959006] DOSE  
 
Phase 1b clinical study to investigate the safety and immunogenicity of the Bris10 
(A/Brisbane/10/2007) M2SR and Sing2016 (A/Singapore/INFIMH -16-0019/2016) M2SR 
H3N2 monovalent influenza vaccines  
 
Protocol Number:  
FLUGEN -H3N2 -V003  
 
 
 
 
 
Subject Number :   
 
 
 
 
 
 
   -    
In the event of a medical emergency , call 911 then call the S tudy Doctor as soon as 
possible  at the following telephone number [Site Emergency Number].  
 
For medical problems which are not emergencies, call the S tudy Doctor at the following 
telephone number [Site Emergency Number].  
FluGen, Inc.  FluGen, Inc.  CLINICAL STUDY PROTOCOL - FLUGEN -H3N2 -V003 118May2 020 (v8.0) 
CONFIDENTIAL [ADDRESS_959007] entry to the memory aid will be done before your vaccine dose. The clinic 
staff will train you on how to use this document by [CONTACT_705661] “Training Entry” 
column. The second entry will be on the evening of the vaccination and the remaining [ADDRESS_959008] your temperature  daily,  in degrees Celsius (°C) (Example: 3 8.2 
C), as shown on the thermometer.    
5. If you think you may have a fever at any time, take your temperature and record it as shown  on 
the thermometer.  
6. Refer to  the intensity level s from the guidelines on page [ADDRESS_959009] any visits prior to Day 8, please bring this with you to the site .  
 
PLEASE REMEMBER TO BRING THIS MEMORY AID WITH YOU TO YOUR  NEXT  
VISIT.  
 
HOW  TO TAKE  YOUR  TEMPERATURE  
• Measure your temperature at approximately the same time  each day.  If 
multiple temperatures are measured in one day, record the highest 
temperature.  Do not eat, drink, or smoke for 10 minutes prior to taking 
your temperature.   
• Push the power button on the thermometer and place it under your 
tongue toward the back of your mouth.  The tip of the thermometer 
should rest in the “correct area” as shown in the diagram to the right.  
• Keep your mouth closed and the thermometer still until the thermometer 
beeps rapi[INVESTIGATOR_375], indicating completion.  If you do not hear the beep, leave 
the thermometer in your mouth for 2 minutes.  
• Record the temperature displayed on the screen.  Press the button to turn 
the thermometer off.   
 
√= Correct Area  
X=Incorrect areas  
FluGen, Inc.  FluGen, Inc.  CLINICAL STUDY PROTOCOL - FLUGEN -H3N2 -V003 118May2 020 (v8.0) 
CONFIDENTIAL [ADDRESS_959010] the intensity level  (0, 1, 2, or 3) using the guidelines  below.  
SYMPTOM  INTENSITY 
LEVEL  DESCRIPTION  
Feverish  
Tiredness  
Body/Muscle aches  
Joint Pain  
Body Rash  0 No symptoms  
1 Mild - No interference with activity  
2 Moderate - Some interference with activity  
3 Severe - Significant interference, prevents daily activity  
Stuffy Nose/Nasal 
Congestion  0 No symptoms  
1 Mild - Noticeable but does not interfere with daily activity  
2 Moderate - Moderate discomfort/interferes with breathing from nose   
3 Severe - Not being able to breath from nose, or prevents daily activity or seeks medical 
encounter  
Runny Nose  0 No symptoms  
1 Mild - Noticeable but does not interfere with daily activity  
2 Moderate - Moderate discomfort/interferes with daily activity  
3 Severe - Significant discomfort/prevents daily activity or seeks medical encounter  
Nasal 
Pain/Irritation/Dryness  0 No symptoms  
1 Mild - Noticeable but does not interfere with daily activity  
2 Moderate - Moderate discomfort/interferes with daily activity  
3 Severe - Significant discomfort/prevents daily activity or seeks medical encounter  
Nasal Bleeding  0 No symptoms  
1 Mild - Total duration of all epi[INVESTIGATOR_11630] a 24 -hour period <30 minutes  
2 Moderate - Total duration of all epi[INVESTIGATOR_11630] a 24 -hour period > 30 minutes  
3 Severe - Any bleeding that required visit for medical encounter  
Sore/Scratchy/Itchy or 
Painful Throat  
 0 No symptoms  
1 Mild - Noticeable but does not interfere with eating and/or drinking  
2 Moderate - Moderate discomfort. Interferes with eating and/or drinking   
3 Severe - Significant discomfort/prevents eating and/or drinking or seeks medical 
encounter  
Headache  0 No symptoms  
1 Mild - No interference with daily activity  
2 Moderate - Some interference with daily activity  
3 Severe - Significant interference, prevents daily activity and/or seeks medical encounter  
Cough  0 No symptoms  
1 Mild - Noticeable but does not interfere with daily activity or sleepi[INVESTIGATOR_007]  
2 Moderate - Moderate discomfort/interferes with daily activity or sleepi[INVESTIGATOR_007]  
3 Severe - Significant discomfort/prevents daily activity or seeks medical encounter  
Nausea  0 No symptoms  
1 Mild - Transient (<24 hours) or intermittent AND No or minimal interference with oral 
intake  
2 Moderate - Persistent nausea resulting in decreased oral intake for 24 to 48 hours  
3 Severe - Persistent nausea resulting in minimal oral intake for > 48 hours OR 
Rehydration indicated (e.g., IV fluids)  
Vomiting  0 No symptoms  
1 Mild - Transient or intermittent AND no interference with daily activity; minimal 
interference with oral intake  
2 Moderate - Frequent epi[INVESTIGATOR_705566], Inc.  FluGen, Inc.  CLINICAL STUDY PROTOCOL - FLUGEN -H3N2 -V003 118May2 020 (v8.0) 
CONFIDENTIAL 111 111  
 
 3 Severe - Persistent vomiting, resulting in orthostatic hypotension ( low blood pressure 
that happens when you stand up from sitting or lying down)  or requiring rapid 
rehydration (e.g., IV fluids) or prevents normal daily activity  
 
FluGen, Inc.  CLINICAL STUDY PROTOCOL - FLUGEN -H3N2 -V003 18May 2020 (v8.0)  
 
                                112 
 
 CONFIDENTIAL Symptom  Memory Aid                                          Protocol:  FluGen -H3N2 -V003                                 Subject # : __ __ __ -__ __ __  
Date  
(dd/mmm/2019)  Training Entry  
(Pre -Dose)  
___/_____/2019  Day 1  
(Dosing Day)  
___/_____/2019  Day 2  
 
___/_____/2019  Day 3  
 
___/_____/2019  Day 4  
 
___/_____/2019  Day 5  
 
___/_____/2019  Day 6  
 
___/_____/2019  Day 7  
 
___/_____/[ADDRESS_959011] Oral 
Temperature ( C)  ___ ___.___ C  ___ ___.___ C  ___ ___.___ C  ___ ___.___ C  ___ ___.___ C  ___ ___.___ C  ___ ___.___ C  ___ ___.___ C 
Feverish  
  
  
  
  
  
  
  
  
 
Tiredness   
  
  
  
  
  
  
  
 
Body/Muscle Aches  
  
  
  
  
  
  
  
  
 
Joint Pain  
  
  
  
  
  
  
  
  
 
Body Rash   
  
  
  
  
  
  
  
 
Stuffy Nose/Nasal 
Congestion   
  
  
  
  
  
  
  
 
Runny Nose   
  
  
  
  
  
  
  
 
Nasal Irritation  
(Pain or Dryness)   
  
  
  
  
  
  
  
 
Nasal Bleeding  
  
  
  
  
  
  
  
  
 
Sore/Scratchy/Itchy  
Painful Throat   
  
  
  
  
  
  
  
 
 Headache   
  
  
  
  
  
  
  
 
Cough   
  
  
  
  
  
  
  
 
FluGen, Inc.  CLINICAL STUDY PROTOCOL - FLUGEN -H3N2 -V003 18May 2020 (v8.0)  
 
                                113 
 
 CONFIDENTIAL Nausea  
  
  
  
  
  
  
  
  
 
Vomiting  
  
  
  
  
  
  
  
  
 
 
Important:  If you experience any events of concern , contact [CONTACT_409114].  
Other Symptoms  
Other symptoms to report following vaccination:   No  Yes (Complete chart below)   
INTENSITY 
LEVEL  DESCRIPTION  
0 No symptoms  
1 Mild - events require minimal or no treatment and do not interfere with daily activities  
2 Moderate - events may cause some interference with daily activities  
3 Severe - events may require medication or other treatment.  Severe events usually prevent daily activities.  
 
 Study Day  
 
Date  
(dd/mmm/2019)  Day 1  
(Dosing Day)  
 
___/_ ____/201 9 Day 2  
 
 
___/_ ____/201 9 Day 3  
 
 
___/_ ____/201 9 Day 4  
 
 
___/_ ____/201 9 Day 5  
 
 
___/_ ____/201 9 Day 6  
 
 
___/_ ____/201 9 Day 7  
 
 
___/_ ____/201 9 
Other Symptoms  
(Describe)  
 
        
 
 
Include Intensity 
Level (0 -3)  
  
  
  
  
  
  
  
 
 